CA2563051A1 - Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications - Google Patents

Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications Download PDF

Info

Publication number
CA2563051A1
CA2563051A1 CA002563051A CA2563051A CA2563051A1 CA 2563051 A1 CA2563051 A1 CA 2563051A1 CA 002563051 A CA002563051 A CA 002563051A CA 2563051 A CA2563051 A CA 2563051A CA 2563051 A1 CA2563051 A1 CA 2563051A1
Authority
CA
Canada
Prior art keywords
substituted
compound
amount
beta
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002563051A
Other languages
French (fr)
Inventor
Teddy Kosoglou
Harry R. Davis
Gilles Jean Bernard Picard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corporation
Teddy Kosoglou
Harry R. Davis
Gilles Jean Bernard Picard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26950511&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2563051(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corporation, Teddy Kosoglou, Harry R. Davis, Gilles Jean Bernard Picard filed Critical Schering Corporation
Publication of CA2563051A1 publication Critical patent/CA2563051A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/02Halogenated hydrocarbons
    • A61K31/025Halogenated hydrocarbons carbocyclic
    • A61K31/03Halogenated hydrocarbons carbocyclic aromatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • A61K31/055Phenols the aromatic ring being substituted by halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted b-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.

Description

2 PC'T/~!SU?/O~IIInI

COMBINATIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR
(PPARy ACTIVATOR~(Sl AND STEROL ABSORPTION INHIBITOR~(S~ AND
s TREATMEi~ITS FOR VASCULAR INDICATIONS
l0 This application is a division of Canadian Application No. 2,434,682, filed January 25, 2002.
FIELD OF THE INVENTION
is The present invention relates to compositions and therapeutic combinations comprising peroxisome proliferator-activated receptor (PPAR) activators) and certain sterol absorption inhibitors) for treating vascular and lipidemic conditions such as are associated with atherosclerosis, hypercholesterolemia and other vascular conditions in mammals.
BACKGROUND OF THE INVENTION
Atherosclerotic coronary heart disease (CHD) represents the major cause for death and vascular morbidity in the western world. Risk factors for atherosclerotic coronary heart disease include hypertension, diabetes mellitus, family history, male gender, cigarette smoke and serum cholesterol. A total cholesterol level in excess of 225-250 mg/dl is associated with significant elevation of risk of CHD.
Cholesteryl esters are a major component of atherosclerotic lesions and the major storage form of cholesterol in arterial wall cells. Formation of cholesteryl esters is also a step in the intestinal absorption of dietary cholesterol. Thus, inhibition of 3o cholesteryl ester formation and reduction of serum cholesterol can inhibit the progression of atherosclerotic lesion formation, decrease the accumulation of cholesteryl esters in the arterial wall, and block the intestinal absorption of dietary cholesterol.
The regulation of whole-body cholesterol homeostasis in mammals and 3s animals involves the regulation of dietary cholesterol and modulation of cholesterol biosynthesis, bile acid biosynthesis and the catabolism of the cholesterol-containing WO 02/068732 PCT/US(12/020(19 _2_ plasma lipoproteins. The liver is the major organ responsible for cholesterol biosynthesis and catabolism and, for this reason, it is a prime determinant of plasma cholesterol levels. The liver is the site of synthesis and secretion of very low density lipoproteins (VLDL) which are subsequently metabolized to low density lipoproteins s (LDL) in the circulation. LDL are the predominant cholesterol-carrying lipoproteins in the plasma and an increase in their concentration is correlated with increased atherosclerosis. When intestinal cholesterol absorption is reduced, by whatever means, less cholesterol is delivered to the liver. The consequence of this action is decreased hepatic lipoprotein (VLDL) production and an increase in the hepatic ~o clearance of plasma cholesterol, mostly as LDL. Thus, the net effect of inhibiting intestinal cholesterol absorption is a decrease in plasma cholesterol levels.
Fibric acid derivatives ("fibrates"), such as fenofibrate, gemfibrozil and clofibrate, have been used to lower triglycerides, moderately lower LDL levels and increase HDL levels. Fibric acid derivatives are also known to be peroxisome ~s proliferator-activated receptor alpha activators.
U.S. Patents Nos. 5,767,115, 5,624,920, 5,668,990, 5,656,624 and 5,688,787, respectively, disclose hydroxy-substituted azetidinone compounds and substituted ~-lactam compounds useful for lowering cholesterol and/or in inhibiting the formation of cholesterol-containing lesions in mammalian arterial walls. U.S. Patents Nos.
?0 5,846,966 and 5,661,145, respectively, disclose hydroxy-substituted azetidinone compounds or substituted ~3-lactam compounds in combination with HMG CoA
reductase inhibitors for preventing or treating atherosclerosis and reducing plasma cholesterol levels.
PCT Patent Application No. WO 00/38725 discloses cardiovascular therapeutic 2s combinations including an ileal bile acid transport inhibitor or cholesteryl ester transport protein inhibitor in combination with a fibric acid derivative, nicotinic acid derivative, microsomal triglyceride transfer protein inhibitor, cholesterol absorption antagonist, phytosterol, stanol, antihypertensive agent or bile acid sequestrant.
U.S. Patent No. 5,698,527 discloses ergostanone derivatives substituted with 3o disaccharides as cholesterol absorption inhibitors, employed alone or in combination with certain other cholesterol lowering agents, which are useful in the treatment of hypercholesterolemia and related disorders.

WO 112/0S8732 PCT/US(12/IIZInO
Despite recent improvements in the treatment of vascular disease, there remains a need in the art for improved compositions and treatments for hyperlipidaemia, atherosclerosis and other vascular conditions.
s SUMMARY OF THE INVENTION
In one embodiment, the present invention provides a composition comprising:
(a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one sterol absorption inhibitor represented by Formula (I):

Are-Xm-(C)q-Y~-(C)~ Zp A
R' R3 N
O \Ar2 io (I) or isomers thereof, or pharmaceutically acceptable salts or solvates of the compounds of Formula (I) or of the isomers thereof, or prodrugs of the compounds of Formula (I) or of the isomers, salts or solvates thereof, wherein in Formula (I) above:
is Are and Ar2 are independently selected from the group consisting of aryl and R -substituted aryl;
Ar3 is aryl or R5-substituted aryl;
X, Y and Z are independently selected from the group consisting of -CH2-, -CH(lower alkyl)- and -C(dilower alkyl)-;
2o R and R2 are independently selected from the group consisting of -OR6, -O(CO)R6, -O(CO)OR9 and -O(CO)NR6R~;
R~ and R3 are independently selected from the group consisting of hydrogen, lower alkyl and aryl;
qis0or1;
2s ris0or1;

m, n and p are independently selected from 0, 1, 2, 3 or 4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1, 2, 3, 4, 5 or 6; and provided that when p is 0 and r is 1, the sum of m, q and n is 1, 2, 3, 4 or 5;
R4 is 1-5 substituents independently selected from the group consisting of s lower alkyl, -OR6, -0(CO)R6, -O(CO)OR9, -O(CH2)~_SOR6, -O(CO)NR6R~, -NR6R~, -NR6(CO)R~, -NR6(CO)OR9, -NR6(CO)NR~RB, -NR6S02R9, -COOR6, -CONR6R~, -CORs, -S02NR6R~, S(O)o_2R9, -O(CH2)~_~o COOR6, -O(CH2),_~oCONR6R~, -(lower alkylene)COOR6, -CH=CH-COOR6, -CF3, -CN, -N02 and halogen;
io R5 is 1-5 substituents independently selected from the group consisting of -OR6, -O(CO)R6, -O(CO)OR9, -O(CH2)~_50R6, -O(CO)NR6R~, -NR6R~, -NR6(CO)R~, -NR6(CO)OR9, -NR6(CO)NR~RB, -NR6S02R9, -COOR6, -CONR6R~, -CORE, -S02NR6R~, S(O)o_ZR9, -O(CH2)~_~o-COOR6, -O(CH2)~_~oCONR6R~, -(lower alkylene)COOR6 and -CH=CH-COOR6;
~s R6, R~ and R8 are independently selected from the group consisting of hydrogen, lower alkyl, aryl and aryl-substituted lower alkyl; and R9 is lower alkyl, aryl or aryl-substituted lower alkyl.
In another embodiment, there is provided a composition comprising: (a) at least one fibric acid derivative; and (b) a compound represented by Formula (II) below:
F
F (1l) or pharmaceutically acceptable salt or solvate thereof, or prodrug of the compound of Formula (II) or of the salt or solvate thereof.

WO 02/0S8732 PCT/US112/02011~) In another embodiment, the present invention provides a composition comprising: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one sterol absorption inhibitor represented by Formula (III):
R' Ar'-A-Yq ~ -Zp Ar3 N~Arz s or isomers thereof, or pharmaceutically acceptable salts or solvates of the compounds of Formula (III) or of the isomers thereof, or prodrugs of the compounds of Formula io (III) or of the isomers, salts or solvates thereof, wherein, in Formula (III) above:
Ar' is R3-substituted aryl; Ar2 is R4-substituted aryl; Ar3 is R5-substituted aryl;
Y and Z are independently selected from the group consisting of -CHZ , -CH(lower alkyl)- and -C(dilower alkyl)-;
A is selected from -O-, -S-, -S(O)- or -S(O)2 ;
Is R~ is selected from the group consisting of -OR6, -O(CO)R6, -O(CO)OR9 and -O(CO)NR6R7; R2 is selected from the group consisting of hydrogen, lower alkyl and aryl; or R~ and R2 together are =O;
qis1,2or3;
p is 0, 1, 2, 3 or 4;
2o R5 is 1-3 substituents independently selected from the group consisting of -OR6, -O(CO)R6, -O(CO)OR9, -O(CH2)~_SOR9, -O(CO)NR6R~, -NR6R~, -NR6(CO)R~, -NR6(CO)OR9, -NR6(CO)NR~RB, -NRsS02-lower alkyl, -NR6S02 aryl, -CONR6R~, -CORE, -S02NR6R~, S(O)o_2-alkyl, S(O)o_2 aryl, -O(CH2)~.~o-COOR6, -O(CH2)~_~oCONR6R~, o-halogeno, m-halogeno, 2s o-lower alkyl, m-lower alkyl, -(lower alkylene)-COOR6, and -CH=CH-COOR6;
R3 and R4 are independently 1-3 substituents independently selected from the group consisting of R5, hydrogen, p-lower alkyl, aryl, -N02, -CF3 and WO 02/058732 PCT/US(12/(1211119 p-halogeno;
R6, R~ and Re are independently selected from the group consisting of hydrogen, lower alkyl, aryl and aryl-substituted lower alkyl; and R9 is lower alkyl, aryl or aryl-substituted lower alkyl.
s In another embodiment, the present invention provides a composition comprising: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one sterol absorption inhibitor represented by Formula (IV):
R' 9 ~ ~A
Ar'-R'-Q
N
O ~Arz io (IV) or isomers thereof, or pharmaceutically acceptable salts or solvates of the compounds of Formula (IV) or of the isomers thereof, or prodrugs of the compounds of Formula (IV) or of the isomers, salts or solvates thereof, wherein, in Formula (IV) above:
is A is selected from the group consisting of R2-substituted heterocycloalkyl, substituted heteroaryl, R2-substituted benzofused heterocycloalkyl, and R2-substituted benzofused heteroaryl;
Are is aryl or R3-substituted aryl;
Ar2 is aryl or R4-substituted aryl;
2o Q is a bond or, with the 3-position ring carbon of the azetidinone, forms the R5 (Rs)a (RO~
spiro group b ; and R~ is selected from the group consisting of:
-(CH2)q-, wherein q is 2-6, provided that when Q forms a spiro ring, q can also be zero or 1;
2s -(CH2)e-G-(CHZ)~-, wherein G is -O-, -C(O)-, phenylene, -NR8- or WO 02/U58732 PCT/US1)2/02(1119 -S(O)o_2-, a is 0-5 and r is 0-5, provided that the sum of a and r is 1-6;
-(C2 C6 alkenylene)-; and -(CH2)fV-(CH2)9-, wherein V is C3 C6 cycloalkylene, f is 1-5 and g is 0-5, provided that the sum of f and g is 1-6;
s R5 is selected from:
I I I I I I I
-CH-, -C(C~-C6 alkyl)-, -CF-, -C(OH)-, -C(C6H4-R9)-, -N-, or -+NO- ;
R6 and R~ are independently selected from the group consisting of -CH2-, -CH(C~-C6 alkyl)-, -C(di-(C~-C6) alkyl), -CH=CH- and -C(C~-C6 alkyl)=CH-; or RS together with an adjacent R6, or RS together with an to adjacent R~, form a -CH=CH- or a -CH=C(C~-C6 alkyl)- group;
a and b are independently 0, 1, 2 or 3, provided both are not zero; provided that when R6 is -CH=CH- or -C(C~-C6 alkyl)=CH-, a is 1; provided that when R~
is -CH=CH- or -C(C~-C6 alkyl)=CH-, b is 1; provided that when a is 2 or 3, the R6's can be the same or different; and provided that when b is 2 or 3, the Re's can be the same is or different;
and when Q is a bond, R also can be selected from:
Rio R~2 Rio Rio I ~ , -M-Yd-C-Zt,- , -Xm-(C)S-Y~ (C)t-Zp- or -X-(C)~-Yk-S(O)o_2-;
» R~s R~>
where M is -O-, -S-, -S(O)- or -S(O)z-;
X, Y and Z are independently selected from the group consisting of 20 -CH2-, -CH(C~-C6 alkyl)- and -C(di-(C~-C6) alkyl);
R~~ and R~2 are independently selected from the group consisting of -OR~4, -O(CO)R~4, -O(CO)OR~6 and -O(CO)NR~4R~5;
R~~ and R13 are independently selected from the group consisting of hydrogen, (C~-C6)alkyl and aryl; or R~~ and R~~ together are =O, or R~2 and R~3 together are =O;
2s d is 1, 2 or 3;
h is 0, 1, 2, 3 or 4;

WO 02/0S8732 PCT/US(12/02t1t19 _$_ s is 0 or 1; t is 0 or 1; m, n and p are independently 0-4; provided that at least one of s and t is 1, and the sum of m, n, p, s and t is 1-6; provided that when p is 0 and t is 1, the sum of m, s and n is 1-5; and provided that when p is 0 and s is 1, the sum of m, t and n is 1-5;
s vis0or1;
j and k are independently 1-5, provided that the sum of j, k and v is 1-5;
R2 is 1-3 substituents on the ring carbon atoms selected from the group consisting of hydrogen, (C1-C1o)alkyl, (C2 C1o)alkenyl, (C2-C1o)alkynyl, (C3-C6)cycloalkyl, (C3 C6)cycloalkenyl, R17-substituted aryl, R1~-substituted benzyl, io R1'-substituted benzyloxy, R1~-substituted aryloxy, halogeno, -NR14R15, NR14R15(C1-C6 alkylene)-, NR14R15C(O)(C1-C6 alkylene)-,-NHC(O)R16, OH, C1-C6 alkoxy, -OC(0)R16, -COR14, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkyl, N02, -S(0)o_2R16, -S02NR14R15 and -(C1-C6 alkylene)COOR14; when R2 is a substituent on a heterocycloalkyl ring, R2 is o~
(CHz)1-z is as defined, or is =O or ~o ; and, where R2 is a substituent on a substitutable ring nitrogen, it is hydrogen, (C1-C6)alkyl, aryl, (C1-C6)alkoxy, aryloxy, (C1-C6)alkylcarbonyl, arylcarbonyl, hydroxy, -(CH2)1_6CONR~8R18, R1s or (~Hz)o-a ~ .
wherein J is -O-, -NH-, -NR18- or -CH2-;
2o R3 and R4 are independently selected from the group consisting of 1-3 substituents independently selected from the group consisting of (C1-C6)alkyl, -OR14, -O CO R14, -O CO OR16 -O CH OR'4, -O CO NR14R15, -NR14R1s, ( ) ( ) , ( 2)1_5 ( ) -NR14(CO)R15, -NR14(CO)OR16, -NR14(CO)NR15R1s, -NR14S02R16, -COOR14, -CONR R , -COR , -S02NR R , S(O)o_2R , -O(CH2)~.~o-COOR , WO 02/058732 PCT/US02/020t19 _g_ -O(CH2),_,oCONR'4R'S, -(C~-C6 alkylene)-COOR'4, -CH=CH-COOR'4, -CF3, -CN, -N02 and halogen;
R8 is hydrogen, (C~-C6)alkyl, aryl (C,-C6)alkyl, -C(O)R'4 or -COOR'4;
R9 and R'~ are independently 1-3 groups independently selected from the s group consisting of hydrogen, (C~-C6)alkyl, (C,-C6)alkoxy, -COOH, N02, -NR'4R'S, OH and halogeno;
R'4 and R'S are independently selected from the group consisting of hydrogen, (C~-C6)alkyl, aryl and aryl-substituted (C~-C6)alkyl;
R's is (C~-C6)alkyl, aryl or R'~-substituted aryl;
1o R'8 is hydrogen or (C~-C6)alkyl; and R'9 is hydrogen, hydroxy or (C~-C6)alkoxy.
In another embodiment; the present invention provides a composition comprising: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one sterol absorption inhibitor represented by Formula (V):
is R
ArsX ~(C)q~Y S(O)S Arz m R~ n N
O ~Ar3 (V) or isomers thereof, or pharmaceutically acceptable salts or solvates of the compounds of Formula (V) or of the isomers thereof, or prod rugs of the compounds of Formula (V) 20 or of the isomers, salts or solvates thereof, wherein, in Formula (V) above:
Ar' is aryl, R'~-substituted aryl or heteroaryl;
ArZ is aryl or R4-substituted aryl;
Ar3 is aryl or R5-substituted aryl;
X and Y are independently selected from the group consisting of -CH2 , 2s -CH(lower alkyl)- and -C(dilower alkyl)-;

WO 02/US8732 PCT/USO2/02()09 R is -OR6, -0(CO)R6, -O(CO)OR9 or -O(CO)NR6R~; R~ is hydrogen, lower alkyl or aryl; or R and R~ together are =O;
qis0or1;
r is 0, 1 or 2;
s m and n are independently 0, 1, 2, 3, 4 or 5; provided that the sum of m, n and qis1,2,3,4or5;
R4 is 1-5 substituents independently selected from the group consisting of lower alkyl, -OR6, -O(CO)R6, -O(CO)OR9, -O(CH2)~_SOR6, -O(CO)NR6R~, -NR6R~, -NR6(CO)R7, -NR6(CO)OR9, -NR6(CO)NR~RB, -NR6S02R9, -COOR6, to -CONR6R7, -COR6, -S02NR6R~, S(0)o_2R9, -O(CHZ)~_~o-COOR6, -O(CH2)~_,oCONR6R~, -(lower alkylene)COOR6 and -CH=CH-COOR6;
R5 is 1-5 substituents independently selected from the group consisting of -OR6, -O(CO)R6, -O(CO)OR9, -O(CH2)~_50R6, -O(CO)NR6R~, -NR6R~, -NR (CO)R , -NR (CO)OR , -NR (CO)NR R , -NR S02R , -COOK , -CONK R , is -COR6, -S02NR6R~, S(O)o_2R9, -O(CH2)~_~o-COOR6, -0(CHZ)~_~oCONR6R', -CF3, -CN, -NOZ, halogen, -(lower alkylene)COOR6 and -CH=CH-COOR6;
R6, R~ and R6 are independently selected from the group consisting of hydrogen, lower alkyl, aryl and aryl-substituted lower alkyl;
R9 is lower alkyl, aryl or aryl-substituted lower alkyl; and 2o R~~ is 1-5 substituents independently selected from the group consisting of lower alkyl, -OR6, -O(CO)R6, -O(CO)OR9, -O(CH2)~_50R6, -O(CO)NR6R~, -NR R , -NR (CO)R , -NR (CO)OR , -NR (CO)NR R , -NR S02R , -COOR , -CONR6R~, -CORE, -S02NR6R~, -S(O)o_2R9, -O(CHz)~_~o-COOR6, -O(CH2)~_~oCONR6R~, -CF3, -CN, -N02 and halogen.
2s In another embodiment, the present invention provides a composition comprising: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one sterol absorption inhibitor represented by Formula (VI):

VVO 02/0;8732 PCT/US112/t12(1119 \R~-(R2)v A/R2o (R3)u N~
0 R2~
(VI) or isomers thereof, or pharmaceutically acceptable salts or solvates of the compounds of Formula (VI) or of the isomers thereof, or prodrugs of the compounds of Formula s (VI) or of the isomers, salts or solvates thereof, wherein in Formula (VI) above:
R~ is -CH-, -C(lower alkyl)-, -~F-, -~(OH)-, -~(C6H~)-, -~(C6H4-R~s)-, - N- or ~N 0 ;
R2 and R3 are independently selected from the group consisting of:
io -CH2-, -CH(lower alkyl)-, -C(di-lower alkyl)-, -CH=CH- and -C(lower alkyl)=CH-; or R1 together with an adjacent R2, or R1 together with an adjacent R3, form a -CH=CH- or a -CH=C(lower alkyl)- group;
a and v are independently 0, 1, 2 or 3, provided both are not zero; provided that when R2 is -CH=CH- or -C(lower alkyl)=CH-, v is 1; provided that when R3 is is CH=CH- or -C(lower alkyl)=CH-, a is 1; provided that when v is 2 or 3, the R2's can be the same or different; and provided that when a is 2 or 3, the R3's can be the same or different;
R4 is selected from B-(CH2)mC(O)-, wherein m is 0, 1, 2, 3, 4 or 5; B-(CH2)q-, wherein q is 0, 1, 2, 3, 4, 5 or 6; B-(CH2)e-Z-(CH2)~, wherein Z is -O-, -C(O)-, 2o phenylene, -N(Rg)- or -S(O)0_2-, a is 0, 1, 2, 3, 4 or 5 and r is 0, 1, 2, 3, 4 or 5, provided that the sum of a and r is 0, 1, 2, 3, 4, 5 or 6; B-(CZ-Cg alkenylene)-;
B-(C4-C6 alkadienylene~; B-(CH2~-Z-(C2-Cg alkenyiene)-, wherein Z is as defined above, and wherein t is 0, 1, 2 or 3, provided that the sum of t and the number of carbon atoms in the alkenylene chain is 2, 3, 4, 5 or 6; B-(CH2)~V-(CH2)g-, wherein V
2s is C3-Cg cycloalkylene, f is 1, 2, 3, 4 or 5 and g is 0, 1, 2, 3, 4 or 5, provided that the WO 02/0,8732 PCT/US02/0211119 sum of f and g is 1, 2, 3, 4, 5 or 6; B-(CH2~-V-(C2-Cg alkenylene)- or B-(C2-alkenylene)-V-(CH2)t-, wherein V and t are as defined above, provided that the sum of t and the number of carbon atoms in the alkenylene chain is 2, 3, 4, 5 or 6;
B-(CH2)a-Z-(CH2)b-V-(CH2)d-, wherein Z and V are as defined above and a, b and d s are independently 0, 1, 2, 3, 4, 5 or 6, provided that the sum of a, b and d is 0, 1, 2, 3, 4, 5 or 6; or T-(CH2)s-, wherein T is cycloalkyl of 3-6 carbon atoms and s is 0, 1, 2, 3, 4, 5 or 6; or i R1 and R4 together form the group B-CH=C- ;
B is selected from indanyl, indenyl, naphthyl, tetrahydronaphthyl, heteroaryl or io W-substituted heteroaryl, wherein heteroaryl is selected from the group consisting of pyrrolyl, pyridinyl, pyrimidinyl, pyrazinyl, triazinyl, imidazolyl, thiazolyl, pyrazolyl, thienyl, oxazolyl and furanyl, and for nitrogen-containing heteroaryls, the N-oxides thereof, or R~s ~~'% R~6 Rig is W is 1 to 3 substituents independently selected from the group consisting of lower alkyl, hydroxy lower alkyl, lower alkoxy, alkoxyalkyl, alkoxyalkoxy, alkoxycarbonylalkoxy, (lower alkoxyimino)-lower alkyl, lower alkanedioyl, lower alkyl lower alkanedioyl, allyioxy, -CF3, -OCF3, benzyl, R7-benzyl, benzyloxy, R7-benzyloxy, phenoxy, R7-phenoxy, dioxolanyl, N02, 20 -N(Rg)(Rg), N(Rg)(Rg)-lower alkylene-, N(Rg)(Rg)-lower alkylenyloxy-, OH, halogeno, -CN, -N3, -NHC(O)OR10, -NHC(O)Rlp, R1102SNH-. (R1102S)2N-.
-S(O)2NH2, -S(O)p_2Rg, tert-butyldimethyl-silyloxymethyl, -C(O)R12, -COORIg, -CON(Rg)(Rg), -CH=CHC(O)R12, -lower alkyiene-C(O)R12, RIpC(O)(lower alkyienyloxy)-, n 2s N(Rg)(Rg)C(O)(lower alkylenyloxy)- and CH2 '--~R~3 for substitution on ring carbon atoms, and the substituents on the substituted heteroaryl ring nitrogen atoms, when present, are selected from the group consisting of lower alkyl, lower alkoxy, WO 02/058732 PCT/US02/11211(19 -C(O)ORIp, -C(O)Rlp, OH, N(Rg)(Rg)-lower alkylene-, N(Rg)(Rg)-lower alkylenyloxy, -S(O)2NH2 and 2-(trimethylsilyl)-ethoxymethyl;
R7 is 1-3 groups independently selected from the group consisting of lower alkyl, lower alkoxy, -COOH, N02, -N(Rg)(Rg), OH, and halogeno;
s Rg and Rg are independently selected from H or lower alkyl;
R1p is selected from lower alkyl, phenyl, R7-phenyl, benzyl or R7-benzyl;
R11 is selected from OH, lower alkyl, phenyl, benzyl, R7-phenyl or R7-benzyl;
R12 is selected from H, OH, alkoxy, phenoxy, benzyloxy, n -N(Rg)(Rg), lower alkyl, phenyl or R7-phenyl;
R13 is selected from -O-, -CH2-, -NH-, -N(lower alkyl)- or -NC(O)R1 g;
~o R15, R16 and R17 are independently selected from the group consisting of H
and the groups defined for W; or R15 is hydrogen and R16 and R17, together with adjacent carbon atoms to which they are attached, form a dioxolanyl ring;
R1 g is H, lower alkyl, phenyl or phenyl lower alkyl; and R2p and R21 are independently selected from the group consisting of phenyl, is W-substituted phenyl, naphthyl, W-substituted naphthyl, indanyl, indenyl, tetrahydronaphthyl, benzodioxolyl, heteroaryl, W-substituted heteroaryl, benzofused heteroaryl, W-substituted benzofused heteroaryl and cyclopropyl, wherein heteroaryl is as defined above.
In another embodiment, the present invention provides a composition 2o comprising: (a) at least one peroxisome proliferator-activated receptor activator;
and(b) at least one sterol absorption inhibitor represented by Formula (VII):
a R
A
E
N\
p \R4 (VII) WO 02/0,8732 PCT/US(12/02(1119 or isomers thereof, or pharmaceutically acceptable salts or solvates of the compounds of Formula (VII) or of the isomers thereof, or prodrugs of the compounds of Formula (VII) or of the isomers, salts or solvates thereof, wherein in Formula (VII) above:
A is -CH=CH-, -C=C- or -(CH2)p- wherein p is 0, 1 or 2;
s B is R~
I~ Rz ~R

E is C1p to C20 alkyl or -C(O)-(Cg to C1g)-alkyl, wherein the alkyl is straight or io branched, saturated or containing one or more double bonds;
R is hydrogen, C1-C15 alkyl, straight or branched, saturated or containing one or more double bonds, or B-(CH2)r -, wherein r is 0, 1, 2, or 3;
R1, R2, and R3 are independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, carboxy, NO2, NH2, OH, halogeno, lower is alkylamino, dilower alkylamino, -NHC(O)ORS, Rg02SNH- and -S(O)2NH2;
R4 is ~ ~ (OR5)n wherein n is 0, 1, 2 or 3;
R5 is lower alkyl; and 2o Rg is OH, lower alkyl, phenyl, benzyl or substituted phenyl wherein the substituents are 1-3 groups independently selected from the group consisting of lower alkyl, lower alkoxy, carboxy, N02, NH2, OH, halogeno, lower alkylamino and dilower alkylamino.
In another embodiment, the present invention provides a composition comprising: (a) at least one peroxisome proliferator-activated receptor activator; and 2s (b) at least one sterol absorption inhibitor represented by Formula (VIII):

R2s ry0-G
Are-R~-Q
I
O N~Arz (VIII) or isomers thereof, or pharmaceutically acceptable salts or solvates of the compounds of Formula (VIII) or of the isomers thereof, or prodrugs of the compounds of Formula s (VIII) or of the isomers, salts or solvates thereof, wherein, in Formula (VIII) above, R26 is H or OG1;
G and G~ are independently selected from the group consisting of OR4 ~5 OR4 O OR
.nIOR3 v~lOR3 , -CH2 ~nIORS
H, 0 ~ O
C02R2 CH20Rs OR3 OR4 O R3a R4aQ, yR
OR3 ~ CH Rb and O 2 R40/i O provided that when R26 is H or O'~CH2Ra OH, G is not H;
R, Ra and Rb are independently selected from the group consisting of H, -OH, ~o halogeno, -NH2, azido, (C1-Cg)alkoxy(C1-Cg}-alkoxy or-W-R30;
W is independently selected from the group consisting of -NH-C(O)-, -O-C(O)-, -O-C(O)-N(R31 )-, -NH-C(O)-N(R31 )- and -O-C(S)-N(R31 )_;
R2 and R6 are independently selected from the group consisting of H, (C1-Cg)alkyl, aryl and aryl(C1-C6)alkyl;
~s R3, R4, R5, R7, R3a and R4a are independently selected from the group consisting of H, (C1-C6)alkyl, aryl(C~-Cg)alkyl, -C(O)(C1-Cg)alkyl and -C(O)aryl;
R3~ is selected from the group consisting of R32-substituted T, WO 02/0S8732 PCT/US02/02(1(19 R32-substituted-T-(C1-C6)alkyl, R32-substituted-(C2-C4)alkenyl, R32-substituted-(C1-C6)alkyl, R32-substituted-(C3-C7)cycloalkyl and R32-substituted-(C3-C7)cycloalkyl(C1-C6)alkyl;
R31 is selected from the group consisting of H and (C1-C4)alkyl;
s T is selected from the group consisting of phenyl, furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, iosthiazolyl, benzothiazolyl, thiadiazolyl, pyrazolyl, imidazolyl and pyridyl;
R32 is independently selected from 1-3 substituents independently selected from the group consisting of halogeno, (C1-C4)alkyl, -OH, phenoxy, to -CF3, -N02, (C1-C4)alkoxy, methylenedioxy, oxo, (C1-C4)alkylsulfanyl, (C1-C4)alkylsulfinyl, (C1-C4)alkylsulfonyl, -N(CH3)2, -C(O)-NH(C1-C4)alkyl, -C(O)-N((C1-C4)alkyl)2, -C(O)-(C1-C4)alkyl, -C(O)-(C1-C4)alkoxy and pyrrolidinylcarbonyl; or R32 is a covalent bond and R31, the nitrogen to which it is attached and R32 form a pyrrolidinyl, piperidinyl, N-methyl-piperazinyl, indolinyl or is morpholinyl group, or a (C1-C4)alkoxycarbonyl-substituted pyrrolidinyl, piperidinyl, N-methylpiperazinyl, indolinyl or morpholinyl group;
Ar1 is aryl or R10-substituted aryl;
Ar2 is aryl or R11-substituted aryl;
Q is a bond or, with the 3-position ring carbon of the azetidinone, ~R~2-~R~3)a zo forms the spiro group (R~a) I~ ; and R1 is selected from the group consisting of -(CH2)q-, wherein q is 2-6, provided that when Q forms a spiro ring, q can also be zero or 1;
-(CH2)e-E-{CH2)r, wherein E is -O-, -C(O)-, phenylene, -NR22- or 2s -S(O)0-2-, a is 0-5 and r is 0-5, provided that the sum of a and r is 1-6;
-(C2-C6)alkenylene-; and -(CH2~V-(CH2)g-, wherein V is C3-C6 cycloalkylene, f is 1-5 and g is 0-5, provided that the sum of f and g is 1-6;

R12 is I I
-CH-, -C(C~-C6 alkyl)-, -CF-, -C(OH)-, -C(C6H4-R23)-, -N-, or -+NO- ;
R13 and R14 are independently selected from the group consisting of -CH2-, -CH(C1-Cg alkyl)-, -C(di-(C1-Cg) alkyl), -CH=CH- and -C(C1-Cg alkyl}=CH-; or s together with an adjacent R13, or R12 together with an adjacent R14, form a -CH=CH- or a -CH=C(C1-Cg alkyl}- group;
a and b are independently 0, 1, 2 or 3, provided both are not zero;
provided that when R13 is -CH=CH- or -C(C1-Cg alkyl)=CH-, a is 1;
provided that when R14 is -CH=CH- or -C(C1-Cg alkyl)=CH-, b is 1;
to provided that when a is 2 or 3, the R13's can be the same or different; and provided that when b is 2 or 3, the R14's can be the same or different;
and when Q is a bond, R1 also can be:
R~5 R17 R~s R~s -M-Yd-C-Zt,- , -Xm'(C)s-~'~ (C)t-zp- or -X)-(C)v-Yk S(O)o-2-;
R~s Rya R~s Ris M is -O-, -S-, -S(O}- or -S(O)2-;
is X, Y and Z are independently selected from the group consisting of -CH2-, -CH(C1-C6)alkyl- and -C(di-(C1-Cg)alkyl);
R10 and R11 are independently selected from the group consisting of 1-3 substituents independently selected from the group consisting of (C1-Cg)alkyl, -OR19, -O(CO)Rlg, -O(CO)OR21, -O(CH2)1_50R19, zo -O(CO)NR19R20, _NR19R20, _NR19(CO)R20, -NR19(CO)OR21, -NR19(CO)NR20R25, _NR19S02R21, _COOR19, -CONR1 9R20, _COR19, -S02NR19R20, S(p)0-2821, _O(CH2)1-10-COOR19, -O(CH2)1_IpCONR19R20, -(C1-Cg alkylene)-COORIg, -CH=CH-COOR19, -CF3, -CN, -N02 and halogen;
zs R15 and R17 are independently selected from the group consisting of WO 02/US8732 PCT/USU2/(1211119 _1g_ -OR19, -O(CO)R19, -0(CO)OR21 and -O(CO)NR19R20;
R16 and R1$ are independently selected from the group consisting of H, (C1-Cg)alkyl and aryl; or R15 and R16 together are =O, or R17 and R1$ together are =0;
s d is 1, 2 or 3;
h is 0, 1, 2, 3 or 4;
s is 0 or 1; t is 0 or 1; m, n and p are independently 0-4;
provided that at least one of s and t is 1, and the sum of m, n, p, s and t is 1-6;
provided that when p is 0 and t is 1, the sum of m, s and n is 1-5; and provided o that when p is 0 and s is 1, the sum of m, t and n is 1-5;
vis0or1;
j and k are independently 1-5, provided that the sum of j, k and v is 1-5;
R~5 _Xi_(C)V_Yk S(p)o_2_ and when Q is a bond and R1 is R'6 , Ar1 can also be pyridyl, isoxazolyl, furanyl, pyrrolyl, thienyl, imidazolyl, pyrazolyl, thiazolyl, pyrazinyl, is pyrimidinyl or pyridazinyl;
R19 and R20 are independently selected from the group consisting of H, (C1-Cg)alkyl, aryl and aryl-substituted (C1-Cg)alkyl;
R21 is (C1-Cg)alkyl, aryl or R24-substituted aryl;
R22 is H, (C1-Cg)alkyl, aryl (C1-C6)alkyl, -C(O)R19 or-COOR19;
2o R23 and R24 are independently 1-3 groups independently selected from the group consisting of H, (C1-Cg)alkyl, (C1-Cg)alkoxy, -COOH, N02, -NR19R20, -OH and halogeno; and R25 is H, -OH or (C1-Cg)alkoxy.
In another embodiment, the present invention provides a composition 2s comprising: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one sterol absorption inhibitor represented by Formula (IX):

WO 02/058732 PCT/US(12/0211119 O R' r.
Ar'-CH-Q ~ ' R2s O N Ar2 (IX) or isomers thereof, or pharmaceutically acceptable salts or solvates of the compounds of Formula (IX) or of the isomers thereof, or prodrugs of the compounds of Formula s (lX) or of the isomers, salts or solvates thereof, wherein, in Formula (IX) above, R26 is selected from the group consisting of:
a) OH;
b) OCH3;
c) fluorine and to d) chlorine.
R' is selected from the group consisting of OR5 OR4 ORS OR4 OR' O
wIOR3 ~nIOR3 , -CH2 ~nfORS
H, ' O CO2R2 O CH20Rs OR3 OR4 O R3a 4a R O/ ~R -S03H; natural and unnatural OR3 O~CH2Rb . amino acids.
O
R4O/i O~CHZRa R, Ra and Rb are independently selected from the group consisting of H, -OH, halogeno, -NH2, azido, (C1-Cg)alkoxy(C1-Cg)-alkoxy and -W-R30;
W is independently selected from the group consisting of is -NH-C(O)-, -O-C(O)-, -O-C(O)-N(R31 )-, -NH-C(O)-N(R31 )- and -O-C(S)-N(R31 )_;
R2 and R6 are independently selected from the group consisting of H, (C1-C6)alkyl, aryl and aryl(C1-C6)alkyl;

WO 02/058732 PCT/US02/(120119 R3, R4, R5, R7, R3a and R4a are independently selected from the group consisting of H, (C1-Cg)alkyl, aryl(C1-Cg)alkyl, -C(O)(C1-Cg)alkyl and -C(O)aryl;
R30 is independently selected form the group consisting of R32-substituted T, R32-substituted-T-(C1-C6)alkyl, R32-substituted-(C2-C4)alkenyl, R32-substituted-s (C1-Cg)alkyl, R32-substituted-(C3-C7)cycloalkyl and R32-substituted-(C3-C7)cycloalkyl(C1-Cg)alkyl;
R31 is independently selected from the group consisting of H and (C 1-C4)alkyl;
T is independently selected from the group consisting of phenyl, furyl, thienyl, io pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, iosthiazolyl, benzothiazolyl, thiadiazolyl, pyrazolyl, imidazolyl and pyridyl;
R32 is independently selected from 1-3 substituents independently selected from the group consisting of H, halogeno, (C1-C4)alkyl, -OH, phenoxy, -CF3, -N02, (C1-C4)alkoxy, methylenedioxy, oxo, (C1-C4)alkylsulfanyl, (C1-C4)alkylsulfinyl, is (C1-C4)alkylsulfonyl, -N(CH3)2, -C(O)-NH(C1-C4)alkyl, -C(O)-N((C1-C4)alkyl)2, -C(O)-(C1-C4)alkyl, -C(O)-(C1-C4)alkoxy and pyrrolidinylcarbonyl; or R32 is a covalent bond and R31, the nitrogen to which it is attached and R32 form a pyrrolidinyl, piperidinyl, N-methyl-piperazinyl, indolinyl or morpholinyl group, or a (C1-C4)alkoxycarbonyl-substituted pyrrolidinyl, piperidinyl, N-methylpiperazinyl, indolinyl or 2o morpholinyl group;
Ar1 is aryl or R10-substituted aryl;
Ar2 is aryl or R11-substituted aryl;
Q is -(CH2)q-, wherein q is 2-6, or, with the 3-position ring carbon of the azetidinone, ~R~2-(R~3)a 2s forms the spiro group (R'a) ~~ ;
R12 is i ~ ~ i ~ I I
-CH-, -C(C~-C6 alkyl)-, -CF-, -C(OH)-, -C(C6H4-R23)-, -N-, or -+NO- ;

R13 and R14 are independently selected from the group consisting of -CH2-, -CH(C1-C6 alkyl)-, -C(di-(C1-Cg) alkyl), -CH=CH- and -C(C1-Cg alkyl)=CH-; or together with an adjacent R13, or R12 together with an adjacent R14, form a -CH=CH- or a -CH=C(C1-Cg alkyl)- group;
s a and b are independently 0, 1, 2 or 3, provided both are not zero; provided that when R13 is -CH=CH- or -C(C1-Cg alkyl)=CH-, a is 1; provided that when R14 is -CH=CH- or-C(C1-Cg alkyl)=CH-, b is 1; provided that when a is 2 or 3, the R13's can be the same or different; and provided that when b is 2 or 3, the R14's can be the same or different;
io R10 and R11 are independently selected from the group consisting of 1-3 substituents independently selected from the group consisting of (C1-Cg)alkyl, -OR19,-O(CO)R19. -O(CO)OR21, -O(CH2)1-5081 g. -O(CO)NR1 gR20, _NR19R20, -NR19(CO)R20, -NR19(CO)OR21, -NR19(CO)NR20R25, _NR19gO2R21, _COOR19, -CONR19R20, -COR19, -S02NR19R20, S(O)0-2821, _O(CH2)1-10-COOR19, is -O(CH2)1-10CONR19R20, -(C1-Cg alkylene)-COOR1 g, -CH=CH-COOR19, -CF3, -CN, -N02 and halogen;
Ar1 can also be pyridyl, isoxazolyl, furanyl, pyrrolyl, thienyl, imidazolyl, pyrazolyl, thiazolyl, pyrazinyl, pyrimidinyl or pyridazinyl;
R19 and R20 are independently selected from the group consisting of H, 20 (C~-Cg)alkyl, aryl and aryl-substituted (C~-Cg)alkyl;
R21 is (C1-Cg)alkyl, aryl or R24-substituted aryl;
R22 is H, (C1-Cg)alkyl, aryl (C1-Cg)alkyl, -C(O)R19 or -COOR19;
R23 and R24 are independently 1-3 groups independently selected from the group consisting of H, (C1-Cg)alkyl, (C~-Cg)alkoxy, -COOH, N02, -NR19R20, -OH
2s and halogeno; and R25 is H, -OH or (C1-Cg)alkoxy.
Therapeutic combinations also are provided comprising: (a) a first amount of at least one peroxisome proliferator-activated receptor activator; and (b) a second WO U2/US8732 PCT/USU2/IIZU(IJ

amount of at least one sterol absorption inhibitor represented by Formulae (I-XI) above or isomers thereof, or pharmaceutically acceptable salts or solvates of the compounds of Formula (I-XI) or of the isomers thereof, or prodrugs of the compounds of Formula (I-XI) or of the isomers, salts or solvates thereof, wherein the first amount s and the second amount together comprise a therapeutically effective amount for the treatment or prevention of a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal.
Pharmaceutical compositions for the treatment or prevention of a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a io mammal, comprising a therapeutically effective amount of the above compositions or therapeutic combinations and a pharmaceutically acceptable carrier also are provided.
Methods of treating or preventing a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal, comprising the step of administering to a mammal in need of such treatment an effective amount of the ~5 above compositions or therapeutic combinations also are provided.
Other than in the operating examples, or where otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term "about."
DETAILED DESCRIPTION
The compositions and therapeutic combinations of the present invention comprise at least one (one or more) activators for peroxisome proliferator-activated receptors (PPAR). These activators act as agonists for the peroxisome proliferator-2s activated receptors. Three subtypes of PPAR have been identified, and these are designated as peroxisome proliferator-activated receptor alpha (PPARa), peroxisvme proliferator-activated receptor gamma (PPARy) and peroxisome proliferator-activated receptor delta (PPARS). It should be noted that PPARb is also referred to in the literature as PPAR(3 and as NUC1, and each of these names refers to the same 3o receptor.
PPARa regulates the metabolism of lipids. PPARa is activated by fibrates and a number of medium and long-chain fatty acids, and it is involved in stimulating (3-WO (12/Ua8732 PCT/L!SI)2!(12U11!~

oxidation of fatty acids. The PPARy receptor subtypes are involved in activating the program of adipocyte differentiation and are not involved in stimulating peroxisome proliferation in the liver. PPARb has been identified as being useful in increasing high density lipoprotein (HDL) levels in humans. See, e_g., WO 97/28149.
s PPARa activator compounds are useful for, among other things, lowering triglycerides, moderately lowering LDL levels and increasing HDL levels.
Examples of PPARa activators useful in the compositions of the present invention include fibrates.
Non-limiting examples of suitable fabric acid derivatives ("fibrates") include clofibrate (such as ethyl 2-(p-chlorophenoxy)-2-methyl-propionate, for example io ATROMID-S~ Capsules which are commercially available from Wyeth-Ayerst);
gemfibrozil (such as 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid, for example LOPID~ tablets which are commercially available from Parke Davis);
ciprofibrate (C.A.S. Registry No. 52214-84-3, see U.S. Patent No. 3,948,973;
bezafibrate (C.A.S. Registry No. 41859-67-0, see U.S. Patent Is No. 3,781,328; clinofibrate (C.A.S. Registry No. 30299-08-2, see U.S. Patent No. 3,716,583;
binifibrate (C.A.S. Registry No. 69047-39-8, see BE 884722;
lifibrol (C.A.S. Registry No. 96609-16-4);
fenofibrate (such as TRICOR~ micronized fenofibrate (2-[4-(4-chlorobenzoyl) 2o phenoxyJ-2-methyl-propanoic acid, 1-methylethyl ester) which is commercially available from Abbott Laboratories or LIPANTHYLO micronized fenofibrate which is commercially available from Labortoire Founier, France) and mixtures thereof.
These compounds can be used in a variety of forms, including but not limited to acid form, salt form, racemates, enantiomers, zwitterions and tautomers.
zs Other examples of PPARa activators useful with the practice of the present invention include suitable fluorophenyl compounds as disclosed in U.S. No.
6,028,109;
certain substituted phenylpropionic compounds as disclosed in WO 00/75103;
and PPARa activator compounds as disclosed in WO 98/43081.
Non-limiting examples of suitable PPARy activators useful in the compositions of the present invention include suitable derivatives of glitazones or thiazolidinediones, such WO 02/(1;8732 PCT/l!Stl2/(12(NIo as, troglitazone (such as REZULIN~ troglitazone (-5-[[4-[3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl] methyl]-2,4-thiazolidinedione) commercially available from Parke-Davis); rosiglitazone (such as AVANDIA~ rosiglitazone maleate (-5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]
phenyl]
s methyl]-2,4-thiazolidinedione, (Z)-2-butenedioate) (1:1 ) commercially available from SmithKline Beecham) and pioglitazone (such as ACTOST"' pioglitazone hydrochloride (5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-) thiazolidinedione monohydrochloride) commercially available from Takeda Pharmaceuticals). Other useful thiazolidinediones include ciglitazone, englitazone, darglitazone and BRL
l0 49653 as disclosed in WO 98/05331;
PPARy activator compounds disclosed in WO 00/76488;
and PPARy activator compounds disclosed in U.S. Patent No.
5,994,554.
Other useful PPARy activator compounds include certain acetylphenols as ~s disclosed in U.S. Patent No. 5,859,051;
certain quinoline phenyl compounds as disclosed in WO 99/20275;
aryl compounds as disclosed by WO 99/38845;
certain 1,4-disubstituted phenyl compounds as disclosed in WO 00/63161; certain aryl compounds as disclosed in WO
01/00579;
2o benzoic acid compounds as disclosed in WO 01/12612 and WO 01/12187; and substituted 4-hydroxy-phenylalconic acid compounds as disclosed in WO
97/31907.
PPARS compounds are useful for, among other things, lowering triglyceride 2s levels or raising HDL levels. Non-limiting examples of suitable PPARb activators useful in the compositions of the present invention include suitable thiazole and oxazole derivates, such as C.A.S. Registry No. 317318-32-4, as disclosed in WO
01 /00603; certain fluoro, chloro or thio phenoxy phenylacetic acids as disclosed in WO 97/28149;
3o suitable non-f3-oxidizable fatty acid analogues as disclosed in U.S. Patent No. 5,093,365; and PPARiS

WO (12/(168732 PCT/L'SU2/I)2111n.1 activator compounds disclosed in WO 99/04815.
Moreover, compounds that have multiple functionality for activating various combinations of PPARa, PPARy and PPARb also are useful in compositions of the s present invention. Non-limiting examples include certain substituted aryl compounds as disclosed in U.S. Patent No. 6,248,781; WO 00/23416; WO 00/23415; WO
00/23425; WO 00/23445; WO 00/23451; and WO 00/63153, which are described as being useful PPARa and/or PPARy activator compounds. Other non-limiting examples of useful PPARa and/or ~o PPARy activator compounds include activator compounds as disclosed in WO
97/25042; activator compounds as disclosed in WO 00163190; activator compounds as disclosed in WO 01/21181;
biaryl-oxa(thia)zole compounds as disclosed in WO 01/16120;
1 s activator compounds as disclosed in WO 00/63196 and WO
00/63209; substituted 5-aryl-2,4-thiazolidinediones compounds as disclosed in U.S. Patent No. 6,008,237;
arylthiazolidinedione and aryloxazolidinedione compounds as disclosed in WO 00/78312 and WO 00/783136 ;
2o GW2331 or (2-(4-[difluorophenyl]-1 heptylureido)ethyl]phenoxy)-2-methylbutyric compounds as disclosed in WO 98/05331;
aryl compounds as disclosed in U.S. Patent No. 6,166,049;
oxazole compounds as disclosed in WO 01 /17994 ;
and dithiolane compounds as disclosed in Zs WO 01/25225 and WO 01/25226.
Other useful PPAR activator compounds include substituted benzylthiazolidine-2,4-dione compounds as disclosed in WO 01/14349. WO 01/14350 and WO/01/04351;
mercaptocarboxylic compounds as disclosed in WO 00/50392; ascofuranone 3o compounds as disclosed in WO 00/53563;
carboxylic compounds as disclosed in WO 99/46232;
compounds as disclosed in WO 99/12534;

WO 02/(1;8732 PCT!L'SI)2/112~Nn1 benzene compounds as disclosed in WO 99/15520;
o-anisamide compounds as disclosed in WO 01/21578 and PPAR activator compounds as disclosed in WO
01 /40192.
s The peroxisome proliferator-activated receptors) activators) are administered in a therapeutically effective amount to treat the specified condition, for example in a daily dose can range from about 0.1 to about 1000 mg per day, preferably about 0.25 to about 50 mg/day, and more preferably about 10 mg per day, given in a single dose or 2-4 divided doses. The exact dose, however, is determined by the attending ~o clinician and is dependent on such factors as the potency of the compound administered, the age, weight, condition and response of the patient.
The term "therapeutically effective amount" means that amount of a therapeutic agent of the composition, such as the peroxisome proliferator-activated receptor activator(s), sterol absorption inhibitors) and other pharmacological or therapeutic Is agents described below, that will elicit a biological or medical response of a tissue, system, animal or mammal that is being sought by the administrator (such as a researcher, doctor or veterinarian) which includes alleviation of the symptoms of the condition or disease being treated and the prevention, slowing or halting of progression of one or more conditions, for example vascular conditions, such as 2o hyperlipidaemia (for example atherosclerosis, hypercholesterolemia or sitosterolemia), vascular inflammation, stroke, diabetes, obesity andlor to reduce the level of sterols) (such as cholesterol) in the plasma.
As used herein, "combination therapy" or "therapeutic combination" means the administration of two or more therapeutic agents, such as peroxisome proliferator-2s activated receptor activators) and sterol absorption inhibitor(s), to prevent or treat a condition, for example a vascular condition, such as hyperlipidaemia (for example atherosclerosis, hypercholesterolemia or sitosterolemia), vascular inflammation, stroke, diabetes, obesity and/or reduce the level of sterols) (such as cholesterol) in the plasma. As used herein, "vascular" comprises cardiovascular, cerebrovascular 3o and combinations thereof. The compositions, combinations and treatments of the present invention can be administered by any suitable means which produce contact of these compounds with the site of action in the body, for example in the plasma, liver WO 02/0S8732 PCT/US021112(109 or small intestine of a mammal or human. Such administration includes coadministration of these therapeutic agents in a substantially simultaneous manner, such as in a single tablet or capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each therapeutic agent. Also, such administration s includes use of each type of therapeutic agent in a sequential manner. In either case, the treatment using the combination therapy will provide beneficial effects in treating the condition. A potential advantage of the combination therapy disclosed herein may be a reduction in the required amount of an individual therapeutic compound or the overall total amount of therapeutic compounds that are effective in treating the io condition. By using a combination of therapeutic agents, the side effects of the individual compounds can be reduced as compared to a monotherapy, which can ........
improve patient compliance. Also, therapeutic agents can be selected to provlti~"a broader range of complimentary effects or complimentary modes of action.
As discussed above, the compositions, pharmaceutical compositions and is therapeutic combinations of the present invention comprise one or more substituted azetidinone or substituted ~i-lactam sterol absorption inhibitors discussed in detail below. As used herein, "sterol absorption inhibitor" means a compound capable of inhibiting the absorption of one or more sterols, including but not limited to cholesterol, phytosterols (such as sitosterol, campesterol, stigmasterol and avenosterol), 5a-zn stanols (such as cholestanol, 5a-campestanol, 5a-sitostanol), and mixtures thereof, when administered in a therapeutically effective (sterol absorption inhibiting) amount to a mammal or human.
In a preferred embodiment, sterol absorption inhibitors useful in the compositions, therapeutic combinations and methods of the present invention are zs represented by Formula (I) below:
R RZ
Art-Xm-(C)q-Y~-(C)~ Zp R' R3 N
~Ar2 WO 02/0i8732 PCT/US02/(120119 _2$_ or isomers of the compounds of Formula (I), or pharmaceutically acceptable salts or solvates of the compounds of Formula (I) or of the isomers of the compounds of s Formula (I), or prodrugs of the compounds of Formula (I) or of the isomers, salts or solvates of the compounds of Formula (I), wherein, in Formula (I) above:
Are and Ar2 are independently selected from the group consisting of aryl and R4-substituted aryl;
Ar3 is aryl or R5-substituted aryl;
to X, Y and Z are independently selected from the group consisting of -CH2-, -CH(lower alkyl)- and -C(dilower alkyl}-;
R and R2 are independently selected from the group consisting of -OR6, -O(CO)R6, -O(CO)OR9 and -O(CO)NR6R';
R~ and R3 are independently selected from the group consisting of hydrogen, is lower alkyl and aryl;
q is 0 or 1; r is 0 or 1; m, n and p are independently selected from 0, 1, 2, 3 or 4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1, 2, 3, 4, 5 or 6; and provided that when p is 0 and r is 1, the sum of m, q and n is 1, 2, 3, 4 or 5;
2o R4 is 1-5 substituents independently selected from the group consisting of lower alkyl, -OR6, -O(CO)R6, -O(CO)OR9, -O(CH2)~,50R6, -O(CO)NR6R~, -NR R , -NR (CO)R , -NR (CO)OR , -NR (CO)NR R , -NR S02R , -COOK , -CONR6R~, -CORE, -S02NR6R~, S(O)o_2R9, -O(CH2)~_~o COOR6, -O(CH2)~_~oCONR6R', -(lower alkylene)COOR6, -CH=CH-COOR6, -CF3, -CN, 25 -N02 and halogen;
R5 is 1-5 substituents independently selected from the group consisting of -OR6, -O(CO)R6, -0(CO)OR9, -O(CH2)~_SOR6, -0(CO)NR6R~, -NR6R~, -NR6(CO)R7, -NR (CO)OR , -NR (CO)NR R , -NR S02R , -COOR , -CONR R , -COR , -S02NR6R', S(O)~2R9, -O(CH2)~_~a COOR6, -0(CHZ)~_~oCONR6R', -(lower alkylene)COOR6 and -CH=CH-COOR6;
s R6, R7 and R8 are independently selected from the group consisting of hydrogen, lower alkyl, aryl and aryl-substituted lower alkyl; and R9 is lower alkyl, aryl or aryl-substituted lower alkyl.
Preferably, R4 is 1-3 independently selected substituents, and R5 is preferably 1-3 independently selected substituents.
to As used herein, the term "alkyl" or "lower alkyl" means straight or branched alkyl chains having from 1 to 6 carbon atoms and "alkoxy" means alkoxy groups having 1 to 6 carbon atoms. Non-limiting examples of lower alkyl groups include, for example methyl, ethyl, propyl, and butyl groups.
"Alkenyl" means straight or branched carbon chains having one or more double ~s bonds in the chain, conjugated or unconjugated. Similarly, "alkynyl" means straight or branched carbon chains having one or more triple bonds in the chain. Where an alkyl, alkenyl or alkynyl chain joins two other variables and is therefore bivalent, the terms alkylene, alkenylene and alkynylene are used.
"Cycloalkyl" means a saturated carbon ring of 3 to 6 carbon atoms, while 20 "cycloalkylene" refers to a corresponding bivalent ring, wherein the points of attachment to other groups include all positional isomers.
"Halogeno" refers to fluorine, chlorine, bromine or iodine radicals.
"Aryl" means phenyl, naphthyl, indenyl, tetrahydronaphthyl or indanyl.
"Phenylene" means a bivalent phenyl group, including ortho, meta and para-2s substitution.
The statements wherein, for example, R, R~, R2 and R3. are said to be independently selected from a group of substituents, mean that R, R~, R2 and R3 are independently selected, but also that where an R, R~, R2 and R3 variable occurs more than once in a molecule, each occurrence is independently selected (e.g., if R
is WO 02!0S8732 PCT/US(12/(12(1(19 -OR6, wherein R6 is hydrogen, R2 can be -OR6 wherein R6 is tower alkyl). Those skilled in the art will recognize that the size and nature of the substituent(s) will affect the number of substituents that can be present.
Compounds of the invention have at least one asymmetrical carbon atom and s therefore all isomers, including enantiomers, stereoisomers, rotamers, tautomers and racemates of the compounds of Formula (I-XI) (where they exist) are contemplated as being part of this invention. The invention includes d and I isomers in both pure form and in admixture, including racemic mixtures. Isomers can be prepared using conventional techniques, either by reacting optically pure or optically enriched starting io materials or by separating isomers of a compound of the Formulae I-XI.
Isomers may also include geometric isomers, e.g., when a double bond is present.
Those skilled in the art will appreciate that for some of the compounds of the Formulae I-XI, one isomer will show greater pharmacological activity than other isomers.
is Compounds of the invention with an amino group can form pharmaceutically acceptable salts with organic and inorganic acids. Examples of suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, fumaric, succinic, ascorbic, malefic, methanesulfonic and other mineral and carboxylic acids well known to those in the art. The salt is prepared by contacting the zo free base form with a sufficient amount of the desired acid to produce a salt. The free base form may be regenerated by treating the salt with a suitable dilute aqueous base solution such as dilute aqueous sodium bicarbonate. The free base form differs from its respective salt form somewhat in certain physical properties, such as solubility in polar solvents, but the salt is otherwise equivalent to its respective free base forms for 2s purposes of the invention.
Certain compounds of the invention are acidic (e.g., those compounds which possess a carboxyl group). These compounds form pharmaceutically acceptable salts with inorganic and organic bases. Examples of such salts are the sodium, potassium, calcium, aluminum, gold and silver salts. Also included are salts formed 3o with pharmaceutically acceptable amines such as ammonia, alkyl amines, hydroxyalkylamines, N-methylglucamine and the like.

WO 02/0S8732 PCT/US112/U2Ut19 As used herein, "solvate" means a molecular or ionic complex of molecules or ions of solvent with those of solute (for example, one or more compounds of Formulae I-XI, isomers of the compounds of Formulae I-XI, or prodrugs of the compounds of Formulae I-XI). Non-limiting examples of useful solvents include polar, protic solvents s such as water and/or alcohols (for example methanol).
As used herein, "prodrug" means compounds that are drug precursors which, following administration to a patient, release the drug in vivo via some chemical or physiological process (e.g., a prodrug on being brought to the physiological pH or through enzyme action is converted to the desired drug form).
to Preferred compounds of Formula (I) are those in which Are is phenyl or R4-substituted phenyl, more preferably (4-R4)-substituted phenyl. Ar2 is preferably phenyl or R4-substituted phenyl, more preferably (4-R4)-substituted phenyl.
Ar3 is preferably R5-substituted phenyl, more preferably (4-R5)-substituted phenyl.
When Are is (4-R4)-substituted phenyl, R4 is preferably a halogen. When Ar2 and Ar3 are R4- and is R5-substituted phenyl, respectively, R4 is preferably halogen or -OR6 and R5 is preferably -OR6, wherein R6 is lower alkyl or hydrogen. Especially preferred are compounds wherein each of Are and Ar2 is 4-fluorophenyl and Ar3 is 4-hydroxyphenyl or 4-methoxyphenyl.
X, Y and Z are each preferably -CHZ-. R~ and R3 are each preferably 2o hydrogen. R and R2 are preferably -OR6 wherein R6 is hydrogen, or a group readily metabolizable to a hydroxyl (such as -O(CO)R6, -O(CO)OR9 and -O(CO)NR6R~, defined above).
The sum of m, n, p, q and r is preferably 2, 3 or 4, more preferably 3.
Preferred are compounds wherein m, n and r are each zero, q is 1 and p is 2.
zs Also preferred are compounds of Formula (I) in which p, q and n are each zero, r is 9 and m is 2 or 3. More preferred are compounds wherein m, n and r are each zero, q is 1, p is 2, Z is -CH2- and R is -OR6, especially when R6 is hydrogen.
Also more preferred are compounds of Formula (I) wherein p, q and n are each zero, r is 1, m is 2, X is -CHZ and RZ is -OR6, especially when R6 is hydrogen.

WO 02/1168732 PCT/US112111211n~1 Another group of preferred compounds of Formula (I) is that in which Are is phenyl or R4-substituted phenyl, Ar2 is phenyl or R4-substituted phenyl and Ar3 is RS-substituted phenyl. Also preferred are compounds in which Are is phenyl or R4-substituted phenyl, Ar2 is phenyl or R4-substituted phenyl, Ar3 is R5-substituted phenyl, s and the sum of m, n, p, q and r is 2, 3 or 4, more preferably 3. More preferred are compounds wherein Are is phenyl or R4-substituted phenyl, Ar2 is phenyl or R4-substituted phenyl, Ar3 is RS-substituted phenyl, and wherein m, n and r are each zero, q is 1 and p is 2, or wherein p, q and n are each zero, r is 1 and m is 2 or 3.
In a preferred embodiment, a sterol inhibitor of Formula (I) useful in the compositions, therapeutic combinations and methods of the present invention is represented by Formula (II) (ezetimibe) below:
OH F
W
O
F
is or pharmaceutically acceptable salts or solvates of the compound of Formula (II), or prodrugs of the compound of Formula (II) or of the salts or solvates of the compound of Formula (II).
Compounds of Formula I can be prepared by a variety of methods well know to those skilled in the art, for example such as are disclosed in U.S. Patents Nos.
20 5,631,365, 5,767,115, 5,846,966, 6,207,822, U.S. Pat. 110. 6, 627, 757, and PCT Patent Application WO 93/02048, and in the Example below. For example, suitable compounds of Formula I can be prepared by a method comprising the steps of:
Zs (a) treating with a strong base a lactone of the Formula A or B:

WO 02/I1s8732 PCT/US112/0211(19 R2, Rs R3 Zp p ~ZP
Yn p Yn 1 or 1 (CR'R1 )q R
O
1o'Xm 1o Xm O
Ar A Ar B
wherein R' and R2~ are R and R2, respectively, or are suitably protected hydroxy groups; Arl~ is Arl, a suitably protected hydroxy-substituted aryl or a suitably protected amino-substituted aryl; and the remaining variables are as defined above s for Formula I, provided that in lactone of formula B, when n and r are each zero, p is 1-4;
(b) reacting the product of step (a) with an imine of the formula Ar3o N
vAr2o wherein Ar2~ is Ar2, a suitably protected hydroxy-substituted aryl or a suitably io protected amino-substituted aryl; and Ar3~ is Ar3, a suitably protected hydroxy-substituted aryl or a suitably protected amino-substituted aryl;
c) quenching the reaction with an acid;
d) optionally removing the protecting groups from R', R2~, Ark ~, Ar2~ and Ar30, when present; and Is e) optionally functionalizing hydroxy or amino substituents at R, R2, Arl, Ar2 and Ar3.
Using the lactones shown above, compounds of Formula IA and IB are obtained as follows:
R3 ZP p Ado 1 R OH
Ar -X - C -Y -C-Z A
Y p + ~ -f- m ( I 14 n I 3 P

n N R R
(CR'R1 )q ~Ar2° N
I IA O ~Ar-2 Arlo Xm A

WO 02/0S8732 PCT/US02/(12(I(19 wherein the variables are as defrned above; and R~ ~R H R2 C~~ Ar3o , ~ I
Y Ar -Xm-C'Y~- C)~ Zp Ar.3 R~ N R Rs o N
O O ~Arz IB O
~Xm Ar2 Ar~° B
wherein the variables are as defined above.
Alternative sterol absorption inhibitors useful in the compositions, therapeutic s combinations and methods of the present invention are represented by Formula (III) below:
R' Ari-A-Yq C-Zp Ar3 O N~Arz ro or isomers of the compounds of Formula (III), or pharmaceutically acceptable salts or solvates of the compounds of Formula (III) or of the isomers of the compounds of Formula (III), or prodrugs of the compounds of Formula (III) or of the isomers, salts or solvates of the compounds of Formula (III), wherein, in Formula (III) above:
rs Ar' is R3-substituted aryl;
Ar2 is R4-substituted aryl;
Ar3 is R5-substituted aryl;
Y and Z are independently selected from the group consisting of -CH2-, -CH(lower alkyl)- and -C(dilower alkyl)-;
2o A is selected from -O-, -S-, -S(O)- or -S(O)2-;
R' is selected from the group consisting of -OR6, -O(CO)R6, -0(CO)OR9 and WO 02/058732 PCT/USI12/1121111~) -O(CO)NR6R~; R2 is selected from the group consisting of hydrogen, lower alkyl and aryl; or R~ and R2 together are =O;
q is 1, 2 or 3;
p is 0, 1, 2, 3 or 4;
s R5 is 1-3 substituents independently selected from the group consisting of -OR6, -O(CO)R6, -O(CO)OR9, -0(CH2)~_50R9, -O(CO)NR6R~, -NR6R~, -NR6(CO)R~, -NR6(CO)OR9, -NR6(CO)NR~R8, -NR6S02-lower alkyl, -NR6S02-aryl, -CONR6R~, -CORE, -S02NR6R~, S(O)o_2-alkyl, S(O)o_2-aryl, -O(CH2)~_~o COOR6, -O(CH2)~_ ~oCONR6R~, o-halogeno, m-halogeno, o-lower alkyl, m-lower alkyl, -(lower alkylene)-to COOR6, and -CH=CH-COOR6;
R3 and R4 are independently 1-3 substituents independently selected from the group consisting of R5, hydrogen, p-lower alkyl, aryl, -N02, -CF3 and p-halogeno;
R6, R~ and R$ are independently selected from the group consisting of is hydrogen, lower alkyl, aryl and aryl-substituted lower alkyl; and R9 is lower alkyl, aryl or aryl-substituted lower alkyl.
Preferred compounds of Formula I include those in which Ar is R3-substituted phenyl, especially (4-R3)-substituted phenyl. Ar2 is preferably substituted phenyl, especially (4-R4)-substituted phenyl. Ar3 is preferably R5-2o substituted phenyl, especially (4-R5)-substituted phenyl. Mono-substitution of each of Are, Ar2 and Ar3 is preferred.
Y and Z are each preferably -CHZ-. R2 is preferably hydrogen. R~ is preferably -OR6 wherein R6 is hydrogen, or a group readily metabolizable to a hydroxyl (such as -0(CO)R6, -O(CO)OR9 and -O(CO)NR6R~, defined above). Also preferred are 2s compounds wherein R~ and R2 together are =O.
The sum of q and p is preferably 1 or 2, more preferably 1. Preferred are compounds wherein p is zero and q is 1. More preferred are compounds wherein p is zero, q is 1, Y is -CH2 and R~ is -OR6, especially when R6 is hydrogen.

WO 02/0;8732 PCT/l!S(12/(12009 Another group of preferred compounds is that in which Are is R3-substituted phenyl, Ar2 is R4-substituted phenyl and Ar3 is RS-substituted phenyl.
Also preferred are compounds wherein Are is R3-substituted phenyl, Ar2 is R4-substituted phenyl, Ar3 is RS-substituted phenyl, and the sum of p and q is 1 or 2, s especially 1. More preferred are compounds wherein Are is R3-substituted phenyl, Ar2 is R4-substituted phenyl, Ar3 is R5-substituted phenyl, p is zero and q is 1.
A is preferably -O-.
R3 is preferably -COOR6, -CONR6R7, -CORE, -S02NR6R~, S(O)o_2-alkyl, S(0)0.2-aryl, N02 or halogeno. A more preferred definition for R3 is halogeno, especially fluoro io or chloro.
R4 is preferably hydrogen, lower alkyl, -OR6, -O(CO)R6, -O(CO)OR9, -O(CO)NR6R~, -NR6R~, CORE or halogeno, wherein R6 and R~ are preferably independently hydrogen or lower alkyl, and R9 is preferably lower alkyl. A
more preferred definition for R4 is hydrogen or halogeno, especially fluoro or chloro.
~s RS is preferably -OR6, -O(CO)R6, -O(CO)OR9, -O(CO)NR6R~, -NR6R7, -(lower alkylene)-COOR6 or -CH=CH-COOR6, wherein R6 and R~ are preferably independently hydrogen or lower alkyl, and R9 is preferably lower alkyl. A
more preferred definition for R5 is -OR6, -(lower alkylene)-COOR6 or -CH=CH-COOR6, wherein R6 is preferably hydrogen or lower alkyl.
2o Methods for making compounds of Formula III are well known to those skilled in the art. Non-limiting examples of suitable methods are disclosed in U.S.
Patent No.
5,688,990, In another embodiment, sterol absorption inhibitors useful in the compositions, therapeutic combinations and methods of the present invention are represented by 2s Formula (IV):

WO U2/OS8732 PCT/USll2/02(1119 R' 9 ~ ~. A
Ar'-R'-Q
O N~Arz (IV) or isomers of the compounds of Formula (IV), or pharmaceutically acceptable salts or s solvates of the compounds of Formula (IV) or of the isomers of the compounds of Formula (IV), or prodrugs of the compounds of Formula (iV) or of the isomers, salts or solvates of the compounds of Formula (IV), wherein, in Formula (IV) above:
A is selected from the group consisting of R2-substituted heterocycloalkyl, R2-substituted heteroaryl, R2-substituted benzofused heterocycloalkyl, and R2-substituted to benzofused heteroaryl;
Ar' is aryl or R3-substituted aryl;
Ar2 is aryl or R4-substituted aryl;
Q is a bond or, with the 3-position ring carbon of the azetidinone, forms the \R i-- R6)a spiro group ( )b , and is R1 is selected from the group consisting of:
-(CH2)q-, wherein q is 2-6, provided that when Q forms a spiro ring, q can also be zero or 1;
-(CH2)e-G-(CH2)~-, wherein G is -O-, -C(O)-, phenylene, -NR8- or -S(O)o,2_, a is 0-5 and r is 0-5, provided that the sum of a and r is 1-6;
20 -(C2-C6 alkenylene)-; and -(CHz)~V-(CHZ)9-, wherein V is C3-C6 cycloalkylene, f is 1-5 and g is 0-5, provided that the sum of f and g is 1-6;
RS is selected from:
I ~ ~ I I I
-CH-, -C(C~-C6 alkyl)-, -CF-, -C(OH)-, -C(C6H4-R9)-, -N-, or -+NO- ;

WO 02/08732 PCT/US02/1120(19 R6 and R' are independently selected from the group consisting of -CH2-, -CH(C~-C6 alkyl)-, -C(di-(C~-C6) alkyl), -CH=CH- and -C(C~-C6 alkyl)=CH-; or RS together with an adjacent R6, or R5 together with an adjacent R~, form a -CH=CH- or a -CH=C(C~-C6 alkyl)- group;
s a and b are independently 0, 1, 2 or 3, provided both are not zero; provided that when R6 is -CH=CH- or -C(C~-C6 alkyl)=CH-, a is 1; provided that when R~
is s -CH=CH- or -C(C~-C6 alkyl)=CH-, b is 1; provided that when a is 2 or 3, the R
's can be the same or different; and provided that when b is 2 or 3, the Re's can be the same or different; ' ~o and when Q is a bond, R~ also can be selected from:
Rio R~2 Rio Rio I i -M-Yd-C-Zh-, -Xm-(C)S-Y~ (C)t-Zp- or -X~-(C)~-Yk S(O)o_2-;
R~s Rig R~i where M is -O-, -S-, -S(O)- or -S(O)2-;
X, Y and Z are independently selected from the group consisting of -CH2-, -CH(C~-C6 alkyl)- and -C(di-(C~-C6) alkyl);
is R~~ and R~2 are independently selected from the group consisting of -OR~4, -0(CO)R~4, -O(CO)OR~6 and -O(CO)NR~4R~5;
R~~ and R~3 are independently selected from the group consisting of hydrogen, (C,-C6)alkyl and aryl; or R~~ and R~~ together are =O, or R~2 and R~3 together are =O;
d is 1, 2 or 3;
2o h is 0, 1, 2, 3 or 4;
s is 0 or 1; t is 0 or 1; m, n and p are independently 0-4; provided that at least one of s and t is 1, and the sum of m, n, p, s and t is 1-6; provided that when p is 0 and t is 1, the sum of m, s and n is 1-5; and provided that when p is 0 and s is 1, the sum of m, t and n is 1-5;
2s vis0or1;
j and k are independently 1-5, provided that the sum of j, k and v is 1-5;

WO 02/0S8732 PCT/US1)2/11201H1 R2 is 1-3 substituents on the ring carbon atoms selected from the group consisting of hydrogen, (C1-C1o)alkyl, (C2 C~o)alkenyl, (CZ C1o)alkynyl, (C3 C6)cycloalkyl, (C3 C6)cycloalkenyl, R1~-substituted aryl, R1~-substituted benzyl, R17-substituted benzyloxy, R1~-substituted aryloxy, halogeno, -NR14R15, NR14R15(C1-s C6 alkylene)-, NR14R15C(O)(C1-C6 alkylene)-,-NHC(O)R16, OH, C1-C6 alkoxy, -OC(O)R16, -COR14, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkyl, N02, -S(O)o_2R16, -S02NR14R15 and -(C1-C6 alkylene)COOR14; when R2 is a substituent on a o~
(Chi2)1-2 heterocycloalkyl ring, R2 is as defined, or is =O or o ; and, where R2 is a ~o substituent on a substitutable ring nitrogen, it is hydrogen, (C1-C6)alkyl, aryl, (C1-C6)alkoxy, aryloxy, (C1-C6)alkylcarbonyl, arylcarbonyl, hydroxy, -(CH2)1-6CONR18R1e, o R1s or (CH2)o-4 ~

wherein J is -O-, -NH-, -NR - or -CH2-;
R3 and R4 are independently selected from the group consisting of 1-3 is substituents independently selected from the group consisting of (C1-C6)alkyl, -OR , -O(CO)R , -O(CO)OR , -O(CHZ)1_SOR , -O(CO)NR R , -NR R , -NR (CO)R , -NR (CO)OR , -NR (CO)NR R , -NR S02R , -COOR , -CONR R , -COR , -S02NR R , S(O)o_2R , -O(CH2)1_1o COOR , -O(CH2)1_IOCONR14R15, -(C1-C6 alkylene)-COOR14, -CH=CH-COOR14, -CF3, -CN, -zo N02 and halogen;
Re is hydrogen, (C1-C6)alkyl, aryl (C1-C6)alkyl, -C(O)R14 or -COOR14;
R9 and R1~ are independently 1-3 groups independently selected from the group consisting of hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, -COOH, N02, -NR14R15, OH and halogeno;

WO 02/(1,8732 PCT/US02/020119 R~4 and R'S are independently selected from the group consisting of hydrogen, (C~-C6)alkyl, aryl and aryl-substituted (C~-C6)alkyl;
R~6 is (C~-C6)alkyl, aryl or R~~-substituted aryl;
R~$ is hydrogen or (C~-C6)alkyl; and s R~9 is hydrogen, hydroxy or (C~-C6)alkoxy.
As used in Formula (IV) above, "A" is preferably an Rz-substituted, 6-membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms. Preferred heterocycloalkyl rings are piperidinyl, piperazinyl and morpholinyl groups.
The ring z "A" is preferably joined to the phenyl ring through a ring nitrogen. Preferred R
to substituents are hydrogen and lower alkyl. R~9 is preferably hydrogen.
Arz is preferably phenyl or R4-phenyl, especially (4-R4)-substituted phenyl.
Preferred definitions of R4 are lower alkoxy, especially methoxy, and halogeno, especially fluoro.
Are is preferably phenyl or R3-substituted phenyl, especially is (4-R3)-substituted phenyl.
There are several preferred definitions for the -R~-Q- combination of variables:
Q is a bond and R~ is lower alkylene, preferably propylene;
Q is a spiro group as defined above, wherein preferably R6 and R~ are each ethylene and R5 is -CH- or -C(OH)- ;
Rio Q is a bond and R~ is -M-Yd-C - Zh- wherein the variables R"
2o are chosen such that R is -O-CHz-CH(OH)-;
Ri2 Rio Q is a bond and R~is -Xm-(C)S-Y~ ( i)t-~- wherein the Rig variables are chosen such that R~is -CH(OH)-(CHz)z-; and VVO (12/1168732 PCT/1JS112/11211119 Rio wherein the Q is a bond and R~ is -Xi-(C)~-Yk-S(O)~2-R»
variables are chosen such that R is -CH(OH)-CH2-S(O)o_2-.
Methods for making compounds of Formula IV are well known to those skilled in the art. Non-limiting examples of suitable methods are disclosed in U.S.
Patent No.
5,656,624.
s In another embodiment, sterol absorption inhibitors useful in the compositions, therapeutic combinations and methods of the present invention are represented by Formula (V):
R
i Ar~~X ,(C)q~Y S(~)r Ate m R, n N
~A r3 ~o (V) or isomers of the compounds of Formula (V), or pharmaceutically acceptable salts or solvates of the compounds of Formula (V) or of the isomers of the compounds of Formula (V), or prodrugs of the compounds of Formula (V) or of the isomers, salts or Is solvates of the compounds of Formula (V), wherein, in Formula (V) above:
,o Ar is aryl, R -substituted aryl or heteroaryl;

Ar is aryl or R -substituted aryl;
Ar3 is aryl or RS-substituted aryl;
X and Y are independently selected from the group consisting of -CH2-, 20 -CH(lower alkyl)- and -C(dilower alkyl)-;
R is -OR6, -O(CO)R6, -O(CO)OR9 or -O(CO)NR6R~; R~ is hydrogen, lower alkyl or aryl; or R and R together are =O;
qis0or1;
r is 0, 1 or 2;

m and n are independently 0, 1, 2, 3, 4 or 5; provided that the sum of m, n and q is 1, 2, 3, 4 or 5;
R4 is 1-5 substituents independently selected from the group consisting of lower alkyl, -OR6, -0(CO)R6, -O(CO)OR9, -O(CH2)~_50R6, -O(CO)NR6R', s -NR6R', -NR6(CO)R', -NR6(CO)OR9, -NR6(CO)NR'Ra, -NR6S02R9, -COOR6, -CONR6R', -CORE, -S02NR6R', S(O)o_2R9, -O(CHZ)~_~o COOR6, -O(CH2)~_,oCONR6R~, -(lower alkylene)COOR6 and -CH=CH-COOR6;
R5 is 1-5 substituents independently selected from the group consisting of -OR6, -O(GO)R6, -O(CO)OR9, -O(CH2)~_50R6, -O(CO)NR6R', -NR6R', -NR6(CO)R', ~o -NR6(CO)OR9, -NR6(CO)NR'R6, -NR6S02R9, -COOR6, -CONR6R', -CORE, -SOZNR6R', S(O)o_2R9, -O(CH2)~_~o COOR6, -O(CH2)~_~oCONRsR', -CF3, -CN, -N02, halogen, -(lower alkylene)COOR6 and -CH=CH-COOR6;
R6, R' and R8 are independently selected from the group consisting of is hydrogen, lower alkyl, aryl and aryl-substituted lower alkyl;
R9 is lower alkyl, aryl or aryl-substituted lower alkyl; and R~~ is 1-5 substituents independently selected from the group consisting of lower alkyl, -OR6, -O(CO)R6, -O(CO)OR9, -O(CH2)~_50R6, -O(CO)NR6R', -NR R , -NR (CO)R , -NR (CO)OR , -NR (CO)NR R , -NR S02R , -COOR , 20 -CONR6R7, -CORE, -S02NR6R', -S(O)o_2R9, -O(CH2)~_~o-COOR6, -O(CHZ)~_ ~oCONR6R', -CF3, -CN, -N02 and halogen.
Within the scope of Formula V, there are included two preferred structures. In Formula VA, q is zero and the remaining variables are as defined above, and in zs Formula VB, q is 1 and the remaining variables are as defined above:

WO 02/0S8732 PCT/USl)2/02l1U9 R
Art~Xr"' S(O)r A~ Arv ~Cw $(0)r At'2 Yn Xm R~ Yn N N
4 ~Ar3 0 ~Ar3 VA
R4, R5 and R'~ are each preferably 1-3 independently selected substituents as set forth above. Preferred are compounds of Formula (V) wherein Ar' is phenyl, R'~-substituted phenyl or thienyl, especially (4-R'~)-substituted phenyl or thienyl. Ar2 is s preferably R4-substituted phenyl, especially (4-R4)-substituted phenyl. Ar3 is preferably phenyl or RS-substituted phenyl, especially (4-RS)-substituted phenyl.
When Ar' is R'~-substituted phenyl, R'~ is preferably halogeno, especially fluoro.
When Ar2 is R4-substituted phenyl, R4 is preferably -OR6, especially wherein R6 is hydrogen or lower alkyl. When Ar3 is R5-substituted phenyl, R$ is preferably halogeno, to especially fluoro. Especially preferred are compounds of Formula (V) wherein Ar' is phenyl, 4-fluorophenyl or thienyl, Ar2 is 4-(alkoxy or hydroxy)phenyl, and Ar3 is phenyl or 4-fluorophenyl.
X and Y are each preferably -CH2-. The sum of m, n and q is preferably 2, 3 or 4, more preferably 2. When q is 1, n is preferably 1 to 5.
~s Preferences for X, Y, Ar', Ar2 and Ar3 are the same in each of Formulae (VA) and (VB).
In compounds of Formula (VA), the sum of m and n is preferably 2, 3 or 4, more preferably 2. Also preferred are compounds wherein the sum of m and n is 2, and r is 0 or 1.
zo In compounds of Formula (VB), the sum of m and n is preferably 1, 2 or 3, more preferably 1. Especially preferred are compounds wherein m is zero and n is 1.
R' is preferably hydrogen and R is preferably -OR6 wherein R6 is hydrogen, or a group readily metabolizable to a hydroxyl (such as -O(CO)R6, -0(CO)OR9 and -0(CO)NR6R~, defined above), or R and R' together form a =O
2s group.

WO 02/0S8732 PCT/1;502/12m9 Methods for making compounds of Formula V are well known to those skilled in the art. Non-limiting examples of suitable methods are disclosed in U.S.
Patent No.
5,624,920.
In another embodiment, sterol absorption inhibitors useful in the compositions, s therapeutic combinations and methods of the present invention are represented by Formula (VI):
Ra \R~-(R2)v /R2o A
(Rs)u N
O R2~
(VI) ~o or isomers of the compounds of Formula (VI), or pharmaceutically acceptable salts or solvates of the compounds of Formula (VI) or of the isomers of the compounds of Formula (VI), or prodrugs of the compounds of Formula (VI) or of the isomers, salts or solvates of the compounds of Formula (VI), wherein:
R1 is i L j, ~ ~
is -CH-, -C(lower alkyl)-, -c;F-, -l.(OH)-, -c:(C6H5)-, -c:(C6H4-R~5)-, - N- or ~N O-R2 and R3 are independently selected from the group consisting of:
-CH2-, -CH(lower alkyl)-, -C(di-lower alkyl)-, -CH=CH- and -C(lower alkyl)=CH-; or R1 together with an adjacent R2, or R1 together with an adjacent R3, form a 20 -CH=CH- or a -CH=C(lower alkyl)- group;
a and v are independently 0, 1, 2 or 3, provided both are not zero; provided that when R2 is -CH=CH- or -C(lower alkyl)=CH-, v is 1; provided that when R3 is -CH=CH- or -C(lower alkyl)=CH-, a is 1; provided that when v is 2 or 3, the R2's can be the same or different; and provided that when a is 2 or 3, the R3's can be the same or 2s different;
R4 is selected from B-(CH2)mC(O)-, wherein m is 0, 1, 2, 3, 4 or 5;

WO 02/0S8732 PCT/US02/11211(19 B-(CH2)q-, wherein q is 0, 1, 2, 3, 4, 5 or 6; B-(CH2)e-Z-(CH2)r-, wherein Z
is -O-, -C(O)-, phenylene, -N(Rg)- or -S(O)p-2-, e. is 0, 1, 2, 3, 4 or 5 and r is 0, 1, 2, 3, 4 or 5, provided that the sum of a and r is 0, 1, 2, 3, 4, 5 or 6; B-(C~-Cg alkenylene)-; B-(C4-Cg alkadienylene)-; B-(CH2)t-Z-(C2-Cg alkenylene)-, wherein Z is as defined above, s and wherein t is 0, 1, 2 or 3, provided that the sum of t and the number of carbon atoms in the alkenylene chain is 2, 3, 4, 5 or 6; B-(CH2)~V-(CH2)g-, wherein V
is C3-Cg cycloalkylene, f is 1, 2, 3, 4 or 5 and g is 0, 1, 2, 3, 4 or 5, provided that the sum of f and g is 1, 2, 3, 4, 5 or 6; B-(CH2)t-V-(C2-Cg alkenylene)- or B-(C2-Cg alkenylene)-V-(CH2~-, wherein V and t are as defined above, provided that the sum of t and the io number of carbon atoms in the alkenylene chain is 2, 3, 4, 5 or 6;
B-(CH2)a-Z-(CH2)b-V-(CH2)d-, wherein Z and V are as defined above and a, b and d are independently 0, 1, 2, 3, 4, 5 or 6, provided that the sum of a, b and d is 0, 1, 2, 3, 4, 5 or 6; or T-(CH2)s-, wherein T is cycloalkyl of 3-6 carbon atoms and s is 0, 1, 2, 3, 4, 5 or 6; or is R1 and R4 together form the group B-CH=C- ;
B is selected from indanyl, indenyl, naphthyl, tetrahydronaphthyl, heteroaryl or W-substituted heteroaryl, wherein heteroaryl is selected from the group consisting of pyrrolyl, pyridinyl, pyrimidinyl, pyrazinyl, triazinyl, imidazolyl, thiazolyl, pyrazolyl, thienyl, oxazolyl and furanyl, and for nitrogen-containing heteroaryls, the N-oxides 2o thereof, or R~s ~~'% R~6 R»
W is 1 to 3 substituents independently selected from the group consisting of lower alkyl, hydroxy lower alkyl, lower alkoxy, alkoxyalkyl, alkoxyalkoxy, alkoxycarbonylalkoxy, (lower alkoxyimino)-lower alkyl, lower alkanedioyl, lower alkyl 2s lower alkanedioyi, allyloxy, -CF3, -OCF3, benzyl, R7-benzyl, benzyloxy, R7-benzyloxy, phenoxy, R7-phenoxy, dioxolanyl, N02, -N(Rg)(Rg), N(Rg)(Rg)-lower alkylene-, N(Rg)(Rg)-lower alkylenyloxy-, OH, halogeno, -CN, -N3, -NHC(O)OR10, WO 02/0S8732 PCT/US02/(12(1119 -NHC(0)R10, R' 102SNH-, (R1102S)2N-, -S(0)zNH2, -S(O)0-2Rg, tert-butyldimethyl-silyloxymethyl, -C(0)R12, -COOR1 g, -CON(Rg)(Rg), -CH=CHC(O)R' 2, -lower alkylene-C(O)R12, R10C(O)(lower alkylenyloxy)-, N(Rg)(Rg)C(0)(lower n CH2- N R~3 alkylenyloxy)- and ~ for substitution on ring carbon atoms, s and the substituents on the substituted heteroaryl ring nitrogen atoms, when present, are selected from the group consisting of lower alkyl, lower alkoxy, -C(0)OR10, -C(O)R10, OH, N(Rg)(Rg)-lower alkylene-, N(Rg)(Rg)-lower alkylenyloxy-, -S(O)2NH2 and 2-(trimethylsilyl)-ethoxymethyl;
R7 is 1-3 groups independently selected from the group consisting of lower io alkyl, lower alkoxy, -COOH, N02, -N(Rg)(Rg), OH, and halogeno;
Rg and Rg are independently selected from H or lower alkyl;
R1p is selected from lower alkyl, phenyl, R7-phenyl, benzyl or R7-benzyl;
R11 is selected from OH, lower alkyl, phenyl, benzyl, R7-phenyl or ~ s R7-benzyl;
R12 is selected from H, OH, alkoxy, phenoxy, benzyloxy, ~R~3 -N(Rg)(Rg), lower alkyl, phenyl or R7-phenyl;
R13 is selected from -O-, -CH2-, -NH-, -N(lower alkyl)- or -NC(0)R1 g;
R15, Rig and R~7 are independently selected from the group consisting of H
and the groups defined for W; or R~5 is hydrogen and Rig and R17, together with 2o adjacent carbon atoms to which they are attached, form a dioxolanyl ring;
R1 g is H, lower alkyl, phenyl or phenyl lower alkyl; and R20 and R21 are independently selected from the group consisting of phenyl, W-substituted phenyl, naphthyl, W-substituted naphthyl, indanyl, indenyl, tetrahydronaphthyf, benzodioxolyl, heteroaryl, W-substituted heteroaryl, benzofused 2s heteroaryl, W-substituted benzofused heteroaryl and cyclopropyl, wherein heteroaryl is as defined above.

WO 02/US8732 PCT/US02/020(19 One group of preferred compounds of Formula VI is that in which R21 is selected from phenyl, W-substituted phenyl, indanyl, benzofuranyl, benzodioxolyl, tetrahydronaphthyl, pyridyl, pyrazinyl, pyrimidinyl, quinolyl or cyclopropyl, wherein W is lower alkyl, lower alkoxy, OH, halogeno, -N(Rg)(Rg), s -NHC(0)ORIp, -NHC(O)Rlp, N02, -CN, -N3, -SH, -S(O)p-2-(lower alkyl), -COORIg, -CON(Rg)(Rg), -COR12, phenoxy, benzyloxy, -OCF3, -CH=C(O)RD 2 or tert-butyidimethylsilyioxy, wherein Rg, Rg, R1 p, R12 and R1 g are as defined for Formula IV. When W is 2 or 3 substituents, the substituents can be the same or different.
io Another group of preferred compounds of Formula VI is that in which R2p is phenyl or W-substituted phenyl, wherein preferred meanings of W are as defined above for preferred definitions of R21.
More preferred are compounds of Formula VI wherein R2p is phenyl or W-substituted phenyl and Rz1 is phenyl, W-substituted phenyl, indanyl, benzofuranyl, is benzodioxolyl, tetrahydronaphthyl, pyridyl, pyrazinyl, pyrimidinyl, quinolyl or cyclopropyl; W is lower alkyl, lower aikoxy, OH, halogeno, -N(Rg)(Rg), -NHC(O)OR1 p, -NHC(O)R1 p, N02, -CN, -N3, -SH, -S(O)p-2-(lower alkyl), -COOR1 g, -CON(Rg)(Rg), -COR12, phenoxy, benzyloxy, -CH=CHC(O)R12, -OCF3 or tent-butyl-dimethyl-silyloxy, wherein when W is 2 or 3 substituents, the substituents can be the zo same or different, and wherein Rg, Rg, Rlp, R12 and R1g are as defined in Formula VI.
I I
Also preferred are compounds of Formula VI wherein R1 is -CH- or -C(ON)- .
Another group of preferred compounds of Formula VI is in which R2 and R3 are each -CH2- and the sum of a and v is 2, 3 or 4, with u=v=2 being more preferred.
zs R4 is preferably B-(CH2)q- or B-(CH2)e-Z-(CH2)~, wherein B, Z, q, a and r are Rt5 as defined above. B is preferably R» , wherein R1g and R17 are each hydrogen and wherein R15 is preferably H, OH, lower alkoxy, especially methoxy, or halogeno, especially chloro.

WO 02/fhg732 PCT/US(12/0211i19 Preferably Z is -O-, a is 0, and r is 0.
Preferably q is 0-2.
R2p is preferably phenyl or W-substituted phenyl.
Preferred W substituents for R20 are lower alkoxy, especially s methoxy and ethoxy, OH, and -C(O)R~2, wherein R~2 is preferably lower alkoxy.
Preferably R2~ is selected from phenyl, lower alkoxy-substituted phenyl and F-phenyl.
i Especially preferred are compounds of Formula VI wherein R~ is -CH-, or -l.(OH)- , R2 and R3 are each -CH2-, u=v=2, R4 is B-(CH2)q-, wherein B is phenyl or to phenyl substituted by lower alkoxy or chloro, q is 0-2, R20 is phenyl, OH-phenyl, lower alkoxy-substituted phenyl or lower alkoxycarbonyl-substituted phenyl, and R2~
is phenyl, lower alkoxy-substituted phenyl or F-phenyl.
Methods for making compounds of Formula VI are well known to those skilled Is in the art. Non-limiting examples of suitable methods are disclosed in U.S.
Patent No.
5,698,548.
In another embodiment, sterol inhibitors useful in the compositions, therapeutic combinations and methods of the present invention are represented by Formula (VII):
s E
J' Zp \ R4 (VII) or isomers of the compounds of Formula (VII), or pharmaceutically acceptable salts or solvates of the compounds of Formula (VII) or of the isomers of the compounds of Formula (VII), or prod rugs of the compounds of Formula (VII) or of the isomers, salts 2s or solvates of the compounds of Formula (VII), wherein in Formula (VII) above:

WO 02/0S8732 PCT/US02/02111)9 A is -CH=CH-, -C=C- or -(CH2)p- wherein p is 0, 1 or 2;
B is R~
~ ~~ Rz E is C10 to C20 alkyl or-C(O)-(Cg to C1g)-alkyl, wherein the alkyl is straight or branched, saturated or containing one or more double bonds;
R is hydrogen, C1-C15 alkyl, straight or branched, saturated or containing one or more double bonds, or B-(CH2)r -, wherein r is 0, 1, 2, or 3;
io R1, R2, and R3 are independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, carboxy, N02, NH2, OH, halogeno, lower alkylamino, dilower alkylamino, -NHC(O)ORS, RgO2SNH- and -S(O)2NH2;
R4 is / ~ (OR5)n ~ s wherein n is 0, 1, 2 or 3;
R5 is lower alkyl; and Rg is OH, lower alkyl, phenyl, benzyl or substituted phenyl wherein the substituents are 1-3 groups independently selected from the group consisting of lower alkyl, lower alkoxy, carboxy, N02, NH2, OH, halogeno, lower alkylamino and dilower 2o alkylamino.
Preferred compounds of Formula (Vli) are those wherein R is hydrogen, methyl, ethyl, phenyl or phenylpropyl. Another group of preferred compounds of Formula (VII) is that wherein R4 is p-methoxyphenyl or 2,4,6-trimethoxyphenyl.
Still another group of preferred compounds of Formula (VII) is that wherein A is ethylene zs or a bond. Yet another group of preferred compounds of Formula (VII) is that wherein E is decyl, oleoyl or 7-Z-hexadecenyl. Preferably R1, R2 and R3 are each hydrogen.

WO 02/0S8732 PCT/US02/02(IU9 More preferred compounds of Formula (VII) are those wherein R is hydrogen, methyl, ethyl, phenyl or phenylpropyl; R4 is p-methoxyphenyl or 2,4,6-trimethoxyphenyl; A is ethylene or a bond; E is decyl, oleoyl or 7-Z-hexadecenyl; and R~ , R2 and R3 are each hydrogen.
s A preferred compound of Formula (VII) is that wherein E is decyl, R is hydrogen, B-A is phenyl and R4 is p-methoxyphenyl.
In another embodiment, sterol inhibitors useful in the compositions and methods of the present invention are represented by Formula (VIII):
R2s r~0-G
Ar'-R'-Q
io O N~Arz (VIII) or isomers of the compounds of Formula (VIII), or pharmaceutically acceptable salts or solvates of the compounds of Formula (VIII) or of the isomers of the compounds of Formula (VIII), or prodrugs of the compounds of Formula (VIII) or of the isomers, salts is or solvates of the compounds of Formula (VIII), wherein, in Formula (VIII) above, R26 is H or OG ~ ;
G and G~ are independently selected from the group consisting of O
.nIpR3 .nIOR3 , -CH2 ~nIORS
H, O ~ O

OR3a R4a~ yR
and OR3 O O~ CHzRb >
R40/i provided that when R26 is H or O~CH2Ra OH, G is not H;

R, Ra and Rb are independently selected from the group consisting of H, -OH, halogeno, -NH2, azido, (C1-Cg)alkoxy(C1-Cg)-alkoxy or-W-R30;
W is independently selected from the group consisting of -NH-C(O)-, -O-C(O)-, -O-C(O)-N(R31 )-, -NH-C(O)-N(R31 )- and -O-C(S)-N(R31 )-;
s R2 and R6 are independently selected from the group consisting of H, (C1-Cg)alkyl, aryl and aryl(C1-Cg)alkyl;
R3, R4, R5, R~, R3a and R4a are independently selected from the group consisting of H, (C1-Cg)alkyl, aryl(C1-Cg)alkyl, -C(O)(C1-Cg)alkyl and -C(O)aryl;
io R3~ is selected from the group consisting of R32-substituted T, R32-substituted-T-(C1-Cg)alkyl, R32-substituted-(C2-C4)alkenyl, R32-substituted-(C1-Cg)alkyl, R32-substituted-(C3-C7)cycloalkyl and R32-substituted-(C3-C7)cycloalkyl (C ~ -Cg)alkyl;
R31 is selected from the group consisting of H and (C1-C4)alkyl;
is T is selected from the group consisting of phenyl, fury!, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, iosthiazolyl, benzothiazolyl, thiadiazolyl, pyrazolyl, imidazolyl and pyridyl;
R32 is independently selected from 1-3 substituents independently selected from the group consisting of halogeno, (C1-C4)alkyl, -OH, phenoxy, zo -CF3, -N02, (C1-C4)alkoxy, methylenedioxy, oxo, (C1-C4)alkylsulfanyl, (C1-C4)alkylsulfinyl, (C1-C4)alkylsulfonyl, -N(CH3)2, -C(O)-NH(C1-C4)alkyl, -C(O)-N((C1-C4)alkyl)2, -C(O)-(C1-C4)alkyl, -C(O)-(C1-C4)alkoxy and pyrrolidinylcarbonyl; or R32 is a covalent bond and R31, the nitrogen to which it is attached and R32 form a pyrrolidinyl, piperidinyl, N-methyl-piperazinyl, indolinyl or zs morpholinyl group, or a (C1-C4)alkoxycarbonyl-substituted pyrrolidinyl, piperidinyl, N-methylpiperazinyl, indolinyl or morpholinyl group;
Ar1 is aryl or R1~-substituted aryl;
Ar2 is aryl or R11-substituted aryl;
Q is a bond or, with the 3-position ring carbon of the azetidinone, WO 02/058732 PCT/US112/ll2(1119 ~R~2-(R~s) a forms the spiro group (R~a) ~~ ; and R1 is selected from the group consisting of -(CH2)q-, wherein q is 2-6, provided that when Q forms a spiro ring, q can also be zero or 1;
s -(CH2)e-E-(CH2)~, wherein E is -O-, -C(O)-, phenylene, -NR22- or -S(O)0-2-, a is 0-5 and r is 0-5, provided that the sum of a and r is 1-6;
-(C2-Cg)alkenylene-; and -(CH2~-V-(CH2)g-, wherein V is C3-C6 cycloalkylene, f is 1-5 and g is y 0-5, provided that the sum of f and g is 1-6;
io R12 is 1 1 ~ 1 1 ! I
-CH-, -C(Ci-Cs alkyl)-, -CF-, -C(OH)-, -C(C6H4-R23)-, -N-, or -+NO~ ;
I
R13 and R14 are independently selected from the group consisting of -CH2-, -CH(C1-Cg alkyl)-, -C(di-(C1-Cg) alkyl), -CH=CH- and -C(C1-Cg alkyl)=CH-; or R12 together with an adjacent R13, or R12 together with an is adjacent R14, form a -CH=CH- or a -CH=C(C1-Cg alkyl)- group;
a and b are independently 0, 1, 2 or 3, provided both are not zero;
provided that when R13 is -CH=CH- or -C(C1-Cg alkyl)=CH-, a is 1;
provided that when R14 is -CH=CH- or -C(C1-Cg alkyl)=CH-, b is 1;
provided that when a is 2 or 3, the R13's can be the same or different; and 2o provided that when b is 2 or 3, the R14's can be the same or different;
and when Q is a bond, R1 also can be:
Ris R» R~s R~s 1 ~
--N1-Yd_C-Zt,-, -Xm-(C)s-Y~ (C)c-Zp- °r -X~-(C)~-Yk S(O)o-2-;
R~8 R~s R~s M is -O-, -S-, -S(O)- or -S(O)2-;
X, Y and Z are independently selected from the group consisting of WO 02/0S8732 PCT/US112/(120(19 -CH2-, -CH(C1-Cg)alkyl- and -C(di-(C1-Cg)alkyl);
R10 and R11 are independently selected from the group consisting of 1-3 substituents independently selected from the group consisting of (C1-Cg)alkyl, -OR19, -O(CO)R19, -O(CO)OR21, -O(CH2)1_50R19, s -O(CO)NR19R20, _NR19R20, _NR19(CO)R20, -NR19(CO)OR21, -NR19(CO)NR20R25, _NR19S02R21, -COOR19, -CONR19R20, -COR19, -S02NR19R20, S(p)0-2821, -p(CH2)1-10-COOR19, -O(CH2)1-10CONR19R20, -(C1-Cg alkylene)-COOR19, -CH=CH-COOR19, -CF3, -CN, -N02 and halogen;
to R15 and R17 are independently selected from the group consisting of -OR19, -O(CO)R19, -O(CO)OR21 and -O(CO)NR19R20;
R16 and R1$ are independently selected from the group consisting of H, (C1-Cg)alkyl and aryl; or R15 and R16 together are =O, or R17 and R1$ together are =O;
is d is 1, 2 or 3;
h is 0, 1, 2, 3 or 4;
s is 0 or 1; t is 0 or 1; m, n and p are independently 0-4;
provided that at least one of s and t is 1, and the sum of m, n, p, s and t is 1-6;
provided that when p is 0 and t is 1, the sum of m, s and n is 1-5; and provided 2o that when p is 0 and s is 1, the sum of m, t and n is 1-5;
vis0orl;
j and k are independently 1-5, provided that the sum of j, k and v is 1-5;
Ri5 -Xj-(C)v-Yk S(0)p_2-and when Q is a bond and R1 is R'6 , Ar1 can also be pyridyl, isoxazolyl, furanyl, pyrrolyl, thienyl, imidazolyl, pyrazolyl, thiazolyl, pyrazinyl, 2s pyrimidinyl or pyridazinyl;
R19 and R20 are independently selected from the group consisting of H, (C1-Cg)alkyl, aryl and aryl-substituted (C1-Cg)alkyl;
R21 is (C1-Cg)alkyl, aryl or R24-substituted aryl;

WO 02/0;8732 PCT/US112/0211(19 R22 is H, (C~-C6)alkyl, aryl (C~-Cg)alkyl, -C(O)R~9 or-COOR~9;
R23 and R24 are independently 1-3 groups independently selected from the group consisting of H, (C~-Cg)alkyl, (C~-Cg)alkoxy, -COOH, N02, -NR~ 9R20, -OH and halogeno: and s R25 is H, -OH or (C~-C6)alkoxy.
Ar2 is preferably phenyl or R~ ~-phenyl, especially (4-R~ ~ )-substituted phenyl.
Preferred definitions of R~ ~ are lower alkoxy, especially methoxy, and halogeno, especially fluoro.
to Ark is preferably phenyl or R~0-substituted phenyl, especially (4-R~0)_ substituted phenyl. Preferably R~ 0 is halogeno, and more preferably fluoro.
There are several preferred definitions for the -R~-Q- combination of variables:
Q is a bond and R~ is lower alkylene, preferably propylene;
Q is a spiro group as defined above, wherein preferably R~3 and R~4 are each ( 1 is ethylene and R~2 is -CH- or -C(OH)- , and R~ is -(CH2)q wherein q is 0-6;
Ri5 Q is a bond and R~ is "~'Yd-C-Zri wherein the variables Ris are chosen such that R~ is -O-CH2-CH(OH)-;
Q is a bond and R~ -Xm-(C)S-Y~ (C)t-ZP- wherein the Is R~$ R~s variables are chosen such that R~ is -CH(OH)-(CH2)2-; and R~5 Q is a bond and R~ is -Xi-(C)~-Yk S(O)o_2- wherein the Ris variables are chosen such that R~ is -CH(OH)-CH2-S(O)0-2-.

WO 02/0;8732 PCT/US02/02l)09 A preferred compound of Formula (Vlll) therefore, is one wherein G and G~ are as defined above and in which the remaining variables have the following definitions:
Ar1 is phenyl or R1 ~-substituted phenyl, wherein R1 ~ is halogeno;
Ar2 is phenyl or R11-phenyl, wherein R11 is 1 to 3 substituents independently s selected from the group consisting of C1-Cg alkoxy and halogeno;
Q is a bond and R1 is lower alkylene; Q, with the 3-position R~2-(R~s) a ring carbon of the azetidinone, forms the group (R~4) ~ ~ wherein preferably R13 and R14 are each ethylene and a and b are each 1, and wherein R12 is i i -CH- or -C(OH)- ; Q is a bond and R~ is -O-CH2-CH(OH)-; Q is a bond and R1 is io -CH(OH)-(CH2)2-; or Q is a bond and R~ is -CH(OH)-CH2-S(O)p-2-.
Preferred variables for G and G~ groups of the formulae O
O~-~nOR3. O~~"~OR3 and -CHZ .."ORs are as follows:
R2, R3, R4, R5, R6 and R7 are independently selected from the group is consisting of H, (C1-Cg)alkyl, benzyl and acetyl.
Preferred variables for group G or G~ of the formula:
R4ap R
OR3 O~CH2Rb R° O..
O CH2Ra are as follows:
R3, R3a, R4 and R4a are selected from the group consisting of H, (C1-2o Cg)alkyl, benzyl and acetyl;
R, Ra and Rb are independently selected from the group consisting of H, WO ()2/058732 PCT/US112/0211(19 -OH, halogeno, -NH2, azido, (C1-C6)alkoxy(C1-C6)alkoxy and -W-R30, wherein W is -0-C(0)- or -O-C(O)-NR31-, R31 is H and R36 is (C1-Cg)alkyl, -C(O)-(C1-C4)alkoxy-(C1-C6)alkyl, T , T-(C1-C6)alkyl, or T or T-(C1-C6)alkyl wherein T is substituted by one or two halogeno or s (C1-C6)alkyl groups.
Preferred R3~ substituents are selected from the group consisting of: 2-fluorophenyl, 2,4-difluoro-phenyl, 2,6-dichlorophenyl, 2-methylphenyl, 2-thienylmethyl, 2-methoxy-carbonylethyl, thiazol-2-yl-methyl, 2-furyl, 2-methoxycarbonylbutyl and phenyl.
~o Preferred combinations of R, Ra and Rb are as follows:
1 ) R, Ra and Rb are independently -OH or -O-C(O)-NH-R3o, especially wherein Ra is -OH and R and Rb are -O-C(O)-NH-R3~ and R3~ is selected from the preferred substituents identified above, or wherein R and Ra are each -OH and Rb is-O-C(O)-NH-R3~ wherein R3~ is 2-fluorophenyl, 2,4-difluoro-is phenyl, 2,6-dichlorophenyl;
2) Ra is -OH, halogeno, azido or (C1-C6)-alkoxy(C~-C6)alkoxy, Rb is H, halogeno, azido or (C~-C6)alkoxy(C1-C6)-alkoxy, and R is -O-C(O)-NH-R3~, especially compounds wherein Ra is -OH, Rb is H and R30 is 2-fluorophenyl;
20 3) R, Ra and Rb are independently -OH or -O-C(O)-R3~ and R30 is (C~-C6)alkyl, T , or T substituted by one or two halogeno or (C~-C6)alkyl groups, especially compounds wherein R is -OH and Ra and Rb are -O-C(O)-R3~ wherein R30 is 2-furyl; and 4) R, Ra and Rb are independently -OH or halogeno. Three additional 25 classes of preferred compounds are those wherein the C1~ anomeric oxy is beta, wherein the C2~ anomeric oxy is beta, and wherein the R group is alpha.
G and G1 are preferably selected from:

WO 02/0S8732 PCT/US02/1120(19 OH OH O, OH OH O~c OAc O
O~nIOH ~ O~'~IOH , -CH2 nIOH ~ ~'~IpAc O --PhCH2Q. OCH2Ph PhCH2~ OCH Ph OCH3 2 '~ 2 ~~ IOCH2Ph , n IOCH2Ph , CH IOCH Ph --~ OCH2Ph O~CO2CH2Ph~ O 'CH20CH2Ph OCH2Ph OA~ OAc OH OH OCH3 O
O~~IIOAc , O~~iIOH , -CH2 , '~IOH
~/'CH20Ac .J~CO2CH3 OH OH
OH OAc H(~~ ~~~OH Ac0/ ~~OAc HO~, OH \O O ~CH20H ~ Ac0/~. OA \O O CH20Ac ~ ~CH OH p CH OAc O H _~ _ F
H~i~'~O C H \ /
and OH ~O~CH20H
HO~
'~CH20H
wherein Ac is acetyl and Ph is phenyl.
to Preferably, R26 is H or OH, more preferably H. The -O-G substituent is preferably in the 4-position of the phenyl ring to which it is attached.
In another embodiment, sterol inhibitors useful in the compositions and methods of the present invention are represented by Formula (IX) below:
OR' r.
Are-CH-Q ~ ' R2s O A~ (IX) WO 02/0;8732 PCT/US02/0211(1~l or isomers of the compounds of Formula (IX), or pharmaceutically acceptable salts or solvates of the compounds of Formula (IX) or of the isomers of the compounds of Formula (IX), or prodrugs of the compounds of Formula (IX) or of the isomers, salts or solvates of the compounds of Formula (1X), wherein in Formula (IX) above:
R26 is selected from the group consisting of:
a) OH;
b) OCH3;
c) fluorine and to d) chlorine.
R' is selected from the group consisting of OR5 OR4 OR5 OR4 OR' - O
wIOR3 ~nlOR3 , -'CH2 wIOR
H, ' O CO2Rz O CH20R6 OR3 OR4 OR3a R4a0/, ~R -S03H; natural and unnatural OR3 OJ'''CH2Rb , amino acids.
O
R40/i O~CH2Ra R, Ra and Rb are independently selected from the group consisting of H, -OH, halogeno, -NH2, azido, (C~-Cg)afkoxy(C~-Cg)-alkoxy and -W-R30;
W is independently selected from the group consisting of is -NH-C(O)-, -O-C(O)-, -O-C(O)-N(R31 )-, -NH-C(O)-N(R31 )- and -O-C(S)-N(R31 )_;
R2 and R6 are independently selected from the group consisting of H, (C1-C6)alkyl, aryl and aryl(C1-Cg)alkyl;
R3, R4, R5, R7, R3a and R4a are independently selected from the group 2o consisting of H, (C1-C6)alkyl, aryl(C1-C6)alkyl, -C(O)(C1-Cg)alkyi and -C(O)aryl;

R3~ is independently selected form the group consisting of R32-substituted T, R32-substituted-T-(C~-Cg)alkyl, R32-substituted-(C2-C4)alkenyl, R32-substituted-(C~-Cg)alkyl, R32-substituted-(C3-C7)cycloalkyl and R32-substituted-(C3-C7)cycloalkyl(C~-Cg)alkyl;
s R3~ is independently selected from the group consisting of H and (C~-C4)alkyl;
T is independently selected from the group consisting of phenyl, furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, iosthiazolyl, benzothiazolyl, thiadiazolyl, pyrazolyl, imidazolyl and pyridyl;
R32 is independently selected from 1-3 substituents independently selected io from the group consisting of H, halogeno, (C~-C4)alkyl, -OH, phenoxy, -CF3, -N02, (C~-C4)alkoxy, methylenedioxy, oxo, (C~-C4)alkylsulfanyl, (C~-C4)alkylsulfinyl, (C~-C4)alkylsulfonyl, -N(CH3)2, -C(O)-NH(C~-C4)alkyl, -C(O)-N((C~-C4)alkyl)2, -C(O)-(C~-C4)alkyl, -C(O)-(C~-C4)alkoxy and pyrrolidinylcarbonyl; or R32 is a covalent bond and R3~, the nitrogen to which it is attached and R32 form a pyrrolidinyl, ~s piperidinyl, N-methyl-piperazinyl, indolinyl or morpholinyl group, or a (C~-C4)alkoxycarbonyl-substituted pyrrolidinyl, piperidinyl, N-methylpiperazinyl, indolinyl or morpholinyl group;
Ark is aryl or R~~-substituted aryl;
Ar2 is aryl or R~ ~-substituted aryl;
2o Q is -(CH2)q-, wherein q is 2-6, or, with the 3-position ring carbon of the azetidinone, ~R~2~ R13)a Ria ~~
forms the spiro group ( )b , R~2 is i i i ~ I 1 -CH-, -C(C~-C6 alkyl)-, -CF-, -C(OH)-, -C(C6H4-R23)-, -N-, or -+NO- ;
2s R~ 3 and R~4 are independently selected from the group consisting of -CH2-, CH(C~-C6 alkyl)-, -C(di-(C~-C6) alkyl), -CH=CH- and -C(C~-Cg alkyl)=CH-; or R~2 WO 02/0S8732 PCT/UStl2/(1211~19 together with an adjacent R13, or R12 together with an adjacent R14, form a -CH=CH-or a -CH=C(C1-Cg alkyl)- group;
a and b are independently 0, 1, 2 or 3, provided both are not zero; provided that when R13 is -CH=CH- or-C(C1-Cg alkyl)=CH-, a is 1; provided that when R14 is s -CH=CH- or -C(C1-Cg alkyl)=CH-, b is 1; provided that when a is 2 or 3, the R13's can be the same or different; and provided that when b is 2 or 3, the R14's can be the same or different;
R10 and R11 are independently selected from the group consisting of 1-3 substituents independently selected from the group consisting of (C1-Cg)alkyl, -OR19, to -O(CO)R19, -O(CO)OR21, -O(CH2)1_50R~9, -O(CO)NR19R20, -NR19R20, -NR19(CO)R20, -NR19(CO)OR21, -NR19(CO)NR20R25, _NR19g02R21, -COOR19, -CONR19R20, _COR19, -S02NR19R20, S(O)0-2821, _O(CH2)1-10-COOR19, -O(CH2)1-10CONR19R20, -(C1-Cg alkylene)-COOR19, -CH=CH-COOR19, -CF3, -CN, is -N02 and halogen;
Ar1 can also be pyridyl, isoxazolyl, furanyl, pyrrolyl, thienyl, imidazolyl, pyrazolyl, thiazolyl, pyrazinyl, pyrimidinyl or pyridazinyl;
R19 and R20 are independently selected from the group consisting of H, (C1-Cg)alkyl, aryl and aryl-substituted (C1-Cg)alkyl;
2o Rzt is (C~-Cg}alkyl, aryl or R24-substituted aryl;
R22 is H, (C1-Cg)alkyl, aryl (C1-Cg)alkyl, -C(O)R~9 or-COOR19;
R23 and R24 are independently 1-3 groups independently selected from the group consisting of H, (C~-C6)alkyl, (C1-Cg)alkoxy, -COOH, N02, -NR19R20, -OH
and halogeno; and 2s R25 is H, -OH or (C1-Cg)alkoxy.
Ar2 is preferably phenyl or R11-phenyl, especially (4-R11 )-substituted phenyl.
Preferred definitions of R1 ~ are lower alkoxy, WO 02/0S8732 PCT/USll2/11211119 especially methoxy, and halogeno, especially fluoro.
Ar1 is preferably phenyl or R1g-substituted phenyl, especially (4-R1Q)-substituted phenyl. A preferred definition of R~ ~ is halogeno, especially fluoro.
Preferably Q is a lower alkyl or a spiro group as defined above, wherein s preferably R~ 3 and R~ 4 are each ethylene and R~ 2 is -CH- or -C(OH)- , A preferred compound of formula IX, therefore, is one wherein R' is as defined above and in which the remaining variables have the following definitions:
Ar1 is phenyl or R1 ~-substituted phenyl, wherein R1 ~ is halogeno;
Ar2 is phenyl or R1 ~-phenyl, wherein R1 ~ is 1 to 3 substituents independently to selected from the group consisting of C~-Cg alkoxy and halogeno;
Q is a lower alkyl (i.e. C-1 to C-2) with Q = C-2 being preferred, or Q, with the Ri2~R~s) a 3-position ring carbon of the azetidinone, forms the group (R'4) wherein preferably R13 and R14 are each ethylene and a and b are each 1, and l i wherein R12 is -CH- or -C(OH)- ;
is Preferred variables for R' groups of the formula O
Oy~nOR3, ~v~~OR3 and -CH2 .."ORs --~C02R2 --~CH20R6 OR3 OR4 are as follows:
R2, R3, R4, R5, R6 and R7 are independently selected from the group consisting of H, (C1-C6)alkyl, benzyl and acetyl.
2o Preferred variables for group R' of the formula OR3a R4ap R
OR3 O~CHZRb R4C~..
O CH2Ra WO 02/058732 PCT/USU2/ll2(1119 are as follows:
R3, R3a, R4 and R4a are selected from the group consisting of H, (C1-C6)alkyl, benzyl and acetyl;
R, Ra and Rb are independently selected from the group consisting of H, -OH, s halogeno, -NH2, azido, (C1-C6)alkoxy(C1-C6)alkoxy and -W-R3~, wherein W is -O-C(O)- or-O-C(O}-NR31-, R31 is H and R3~ is (C1-C6)alkyl, -C(O)-(C1-C4)alkoxy-(C1-C6)alkyl, T , T-(C1-C6)alkyl, or T or T-(C1-C6)alkyl wherein T is substituted by one or two halogeno or (C1-C6)alkyl groups.
Preferred R3~ substituents are 2-fluorophenyl, 2,4-difluoro-phenyl, 2,6-io dichlorophenyl, 2-methylphenyl, 2-thienylmethyl, 2-methoxy-carbonylethyl, thiazol-2-yl-methyl, 2-furyl, 2-methoxycarbonylbutyl and phenyl. Preferred combinations of R, Ra and Rb are as follows: 1 ) R, Ra and Rb are independently -OH or -O-C(O}-NH-R3~, especially wherein Ra is -OH and R and Rb are -O-C(O)-NH-R3~ and R3~ is selected from the preferred substituents identified above, or wherein R and Ra are -ls OH and Rb is-O-C(O)-NH-R3~ wherein R3~ is 2-fluorophenyl, 2,4-difluoro-phenyl, 2,6-dichlorophenyl; 2) Ra is -OH, halogeno, azido or (C1-C6)-alkoxy(C1-C6)alkoxy, Rb is H, halogeno, azido or (C1-C6)alkoxy(C1-C6)-alkoxy, and R is -O-C(O)-NH-R30, especially compounds wherein Ra is -OH, Rb is H and R3~ is 2-fluorophenyl; 3) R, Ra and Rb are independently -OH or -O-C(O)-R30 and R3~ is (C1-C6)alkyl, T , or T
2o substituted by one or two halogeno or (C1-C6)alkyl groups, especially compounds wherein R is -OH and Ra and Rb are -O-C(O)-R30 wherein R3~ is 2-furyl; and 4) R, Ra and Rb are independently -OH or halogeno. Three additional classes of preferred are compounds are those wherein the C1~ anomeric oxy is beta, wherein the C2~
anomeric oxy is beta, and wherein the R group is alpha.
2s R' is preferably selected from:
OH OH O~ OH OH OAc pAc O
nIOH , -CH2 ~~IOH , ~~~IOAc Q~~~IOH , --~ O , ' C02H CHZOH ~H OH COzCH3 PhCH2C,L OCH2Ph PhCH~. OCH2Ph O
'~IOCH2Ph , ~ilOCH2Ph , CH2 ~~IOCHZPh O , O~ ~ OCH2Ph C02CH2Ph CH20CH2Ph OCH2Ph OA OAc OH OH OCH3 O~nIOAc , O~nIOH -CH2 , '~IOH
.-.~ ~ OH
CH20Ac C02CH3 OH
OH OAc Hg.~~ ~~~OH AcO~~ ,~~OAc H~/ OH'\O O~CHZOH ~ Ac0/i. 0A;0 0 CHzOAc H H CH OAc p C yO ~~ 2 O F
OH
HC)'~~'~O C H \ /
and OH ~.O~CH20H
HO ~ y0 'oCHZOH
wherein Ac is acetyl and Ph is phenyl.
An example of a useful compound of this invention is one represented by the io formula X:
OR' i OH
F I ~ p~N i F
X
wherein R' is defined as above, or pharmaceutically acceptable salts or solvates of ~s the compound of Formula (X), or prodrugs of the compound of Formula (X) or of the pharmaceutically acceptable salts or solvates of the compound of Formula (X).

A more preferred compound is one represented by formula XI:
O
HO, OH

HO
O , .OH
HO
F I ~ O~N
F (XI) or pharmaceutically acceptable salts or solvates of the compound of Formula (XI), or prodrugs of the compound of Formula (XI) or of the pharmaceutically acceptable salts or solvates of the compound of Formula (XI).
In another embodiment, compositions, pharmaceutical compositions, therapeutic combinations, kits and methods of treatment as described above are provided which comprise: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone compound or at least one io substituted ~3-lactam compound, or isomers of the at least one substituted azetidinone compound or the at least one substituted ~3-lactam compound, or pharmaceutically acceptable salts or solvates of the at least one substituted azetidinone compound or the at feast one substituted ~i-lactam compound or of the isomers of the at least one substituted azetidinone compound or the at least one substituted ~-lactam compound, is or prod rugs of the at least one substituted azetidinone compound or the at least one substituted (3-lactam compound or of the isomers, salts or solvates of the at least one substituted azetidinone compound or the at least one substituted ~3-lactam compound, wherein the first amount and the second amount together in their totality (whether administered concurrently or consecutively) comprise a therapeutically effective 2o amount for the treatment or prevention of a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal.
Suitable substituted azetidinone compounds or substituted ~3-lactam compounds can be selected from any of the compounds discussed above in Formulae I-XI. Other useful substituted azetidinone compounds include N-sulfonyl-2-25 azetidinones such as are disclosed in U.S. Patent No. 4,983,597 and ethyl 4-(2-WO 02/0;$732 PCT/l'S112/112n119 oxoazetidin-4-yl)phenoxy-alkanoates such as are disclosed in Ram et al., Indian J.
Ghem. Sect. B. 298, 12 (1990), p. 1134-7.
The compounds of Formulae I-XI can be prepared by known methods, s including the methods discussed above and, for example, WO 93/02048 describes the preparation of compounds wherein -R1-Q- is alkylene, alkenylene or alkylene interrupted by a hetero atom, phenylene or cycloalkylene; WO 94/17038 describes the preparation of compounds wherein Q is a spirocyclic group; WO 95/08532 describes the preparation of compounds wherein -R1-Q- is a hydroxy-substituted ~o alkylene group; w0 95/026334 describes compounds wherein -R~-Q- is a hydroxy-substituted alkylene attached to the Ark moiety through an -0- or S(O)p-2-group; and U.S. Pat. rto. 5, 633, 246 describes the preparation of compounds wherein ~R1-C~- is a hydr~oxy-substituted alkylene group attached the azetidinone ring by a -S(O)0..2- group.
is The daily dose of the sterol absorption inhibitors) can range from about 0.1 to about 1000 mg per day, preferably about 0.25 to about 50 mglday, and more preferably about 10 mg per day, given in a single dose or 2-4 divided doses.
The exact dose, however, is determined by the attending clinician and is dependent on the potency of the compound administered, the age, weight, condition and response of 2o the patient.
For administration of pharmaceutically acceptable salts of the above compounds, the weights indicated above refer to the weight of the acid equivalent or the base equivalent of the therapeutic compound derived from the salt.
In one embodiment of the present invention, the compositions or therapeutic Zs combinations can further comprise one or more pharmacological or therapeutic agents or drugs such as cholesterol biosynthesis inhibitors and/or lipid-lowering agents discussed below.
In another embodiment, the composition or treatment can further comprise one or more cholesterol biosynthesis inhibitors coadministered with or in combination with 3o the peroxisome proliferator-activated receptor activators) and sterol absorption inhibitors) discussed above.

WO 02/0S8732 PCT/US(12/U2U119 Non-limiting examples of cholesterol biosynthesis inhibitors for use in the compositions, therapeutic combinations and methods of the present invention include competitive inhibitors of HMG CoA reductase, the rate-limiting step in cholesterol biosynthesis, squalene synthase inhibitors, squalene epoxidase inhibitors and s mixtures thereof. Non-limiting examples of suitable HMG CoA reductase inhibitors include statins such as lovastatin (for example MEVACOR~ which is available from Merck & Co.), pravastatin (for example PRAVACHOL~ which is available from Bristol Meyers Squibb), fluvastatin, simvastatin (for example ZOCOR~ which is available from Merck & Co.), atorvastatin, cerivastatin, CI-981, rivastatin (sodium 7-(4-Io fluorophenyi)-2,6-diisopropyl-5-methoxymethylpyridin-3-yl)-3,5-dihydroxy-6-heptanoate), rosuvastatin, pitavastatin (such as NK-104 of Negma Kowa of Japan);
HMG CoA synthetase inhibitors, for example L-659,699 ((E,E)-11-(3'R-(hydroxy-methyl)-4'-oxo-2'R-oxetanyl]-3,5,7R-trimethyl-2,4-undecadienoic acid);
squalene synthesis inhibitors, for example squalestatin 1; and squalene epoxidase inhibitors, is for example, NB-598 ((E)-N-ethyl-N-(6,6-dimethyl-2-hepten-4-ynyl)-3-((3,3'-bithiophen-5-yi)methoxy]benzene-methanamine hydrochloride) and other sterol biosynthesis inhibitors such as DMP-565. Preferred HMG CoA reductase inhibitors include lovastatin, pravastatin and simvastatin. The most preferred HMG CoA reductase inhibitor is simvastatin.
zo Generally, a total daily dosage of cholesterol biosynthesis inhibitors) can range from about 0.1 to about 160 mg per day, and preferably about 0.2 to about 80 mg/day in single or 2-3 divided doses.
In another preferred embodiment, the composition or treatment comprises the compound of Formula (II) in combination with one or more peroxisome proliferator-2s activated receptors) activators) and one or more cholesterol biosynthesis inhibitors.
In this embodiment, preferably the peroxisome proliferator-activated receptor activators) is a fibric acid derivative selected from gemfibrozil, clofibrate andlor fenofibrate. Preferably the cholesterol biosynthesis inhibitor comprises one or more HMG CoA reductase inhibitors, such as, for example, lovastatin, pravastatin and/or 3o simvastatin. More preferably, the composition or treatment comprises the compound of Formula (II) in combination with simvastatin and gemfibrozil or fenofibrate.

VI'O 02/Ihg732 PCT/l'S(121112111N) In another alternative embodiment, the compositions, therapeutic combinations or methods of the present invention can further comprise one or more bile acid sequestrants (insoluble anion exchange resins), coadministered with or in combination with the PPAR activators(s) and sterol absorption inhibitors) discussed above.
s Bile acid sequestrants bind bile acids in the intestine, interrupting the enterohepatic circulation of bile acids and causing an increase in the faecal excretion of steroids. Use of bile acid sequestrants is desirable because of their non-systemic mode of action. Bile acid sequestrants can lower intrahepatic cholesterol and promote the synthesis of apo B/E (LDL) receptors that bind LDL from plasma to further reduce ~ o cholesterol levels in the blood.
Non-limiting examples of suitable bile acid sequestrants include cholestyramine (a styrene-divinylbenzene copolymer containing quaternary ammonium cationic groups capable of binding bile acids, such as QUESTRAN~ or QUESTRAN LIGHT~
cholestyramine which are available from Bristol-Myers Squibb), colestipol (a Is copolymer of diethylenetriamine and 1-chloro-2,3-epoxypropane, such as COLESTID~ tablets which are available from Pharmacia), colesevelam hydrochloride (such as WeICholO Tablets (poly(allylamine hydrochloride) cross-linked with epichlorohydrin and alkylated with 1-bromodecane and (6-bromohexyl)-trimethylammonium bromide) which are available from Sankyo), water soluble 2o derivatives such as 3,3-ioene, N-(cycloalky!) alkylamines and poliglusam, insoluble quaternized polystyrenes, saponins and mixtures thereof. Other useful bile acid sequestrants are disclosed in PCT Patent Applications Nos. WO 97/11345 and WO
98/57652, and U.S. Patents Nos. 3,692,895 and 5,703,188.
Suitable inorganic cholesterol sequestrants include bismuth zs salicylate plus montmorillonite clay, aluminum hydroxide and calcium carbonate antacids.
Generally, a total daily dosage of bile acid sequestrant(s) can range from about 1 to about 50 grams per day, and preferably about 2 to about 16 grams per day in single or 2-4 divided doses.
3o In an alternative embodiment, the compositions or treatments of the present invention can further comprise one or more ileal bile acid transport ("IBAT") inhibitors (or apical sodium co-dependent bile acid transport ("ASBT") inhibitors) coadministered WO 02/US8732 PCT/l.'S()2/11211110 with or in combination with the peroxisome proliferator-activated receptor activators) and sterol absorption inhibitors) discussed above. The IBAT inhibitors can inhibit bile acid transport to reduce LDL cholesterol levels. Non-limiting examples of suitable IBAT inhibitors include benzothiepines such as therapeutic compounds comprising a s 2,3,4,5-tetrahydro-1-benzothiepine 1,1-dioxide structure such as are disclosed in PCT
Patent Application WO 00/38727.
Generally, a total daily dosage of IBAT inhibitors) can range from about 0.01 to about 1000 mg/day, and preferably about 0.1 to about 50 mg/day in single or 2-divided doses.
io In another alternative embodiment, the compositions or treatments of the present invention can further comprise nicotinic acid (niacin) and/or derivatives thereof coadministered with or in combination with the peroxisome proliferator-activated receptor activators) and sterol absorption inhibitors) discussed above.
As used herein, "nicotinic acid derivative" means a compound comprising a ~ s pyridine-3-carboxylate structure or a pyrazine-2-carboxylate structure, including acid forms, salts, esters, zwitterions and tautomers, where available. Examples of nicotinic acid derivatives include niceritrol, nicofuranose and acipimox (5-methyl pyrazine-2-carboxylic acid 4-oxide). Nicotinic acid and its derivatives inhibit hepatic production of VLDL and its metabolite LDL and increases HDL and apo A-1 levels. An example of a 2o suitable nicotinic acid product is NIASPAN~ (niacin extended-release tablets) which are available from Kos.
Generally, a total daily dosage of nicotinic acid or a derivative thereof can range from about 500 to about 10,000 mg/day, preferably about 1000 to about mg/day, and more preferably about 3000 to about 6000 mg/day in single or divided 2s doses.
In another alternative embodiment, the compositions or treatments of the present invention can further comprise one or more AcyICoA:Cholesterol O-acyltransferase ("ACAT") Inhibitors, which can reduce LDL and VLDL levels, coadministered with or in combination with the peroxisome proliferator-activated 3o receptor activators) and sterol absorption inhibitors) discussed above.
ACAT is an enzyme responsible for esterifying excess intracellular cholesterol and may reduce the WO 02/OSR732 PCT/L'S(I?/1~21n~) synthesis of VLDL, which is a product of cholesterol esterification, and overproduction of apo B-100-containing lipoproteins.
Non-limiting examples of useful ACAT inhibitors include avasimibe ([[2,4,6-tris(1-methylethyl)phenylJacetylJsulfamic acid, 2,6-bis(1-methylethyl)phenyl ester, s formerly known as CI-1011 ), HL-004, lecimibide (DuP-128) and CL-277082 (N-(2,4-difluorophenyl)-N-[[4-(2,2-dimethylpropyl)phenylJmethylJ-N-heptylurea). See P.
Chang et al., "Current, New and Future Treatments in Dyslipidaemia and Atherosclerosis", DfU4S 2000 Ju(;60(1 ); 55-93.
Generally, a total daily dosage of ACAT inhibitors) can range from about 0.1 to io about 1000 mg/day in single or 2-4 divided doses.
In another alternative embodiment, the compositions or treatments of the present invention can further comprise one or more Cholesteryl Ester Transfer Protein ("CETP") Inhibitors coadministered with or in combination with the peroxisome proliferator-activated receptor activators) and sterol absorption inhibitors) discussed is above. CETP is responsible for the exchange or transfer of cholesteryl ester carrying HDL and triglycerides in VLDL.
Non-limiting examples of suitable CETP inhibitors are disclosed in PCT Patent Application No. WO 00/38721 and U.S. Patent No. 6.147,090.
Pancreatic cholesteryl ester hydrolase (pCEH) inhibitors such as ?o WAY-121898 also can be coadministered with or in combination with the peroxisorne proliferator-activated receptors) activator and sterol absorption inhibitors) discussed above.
Generally, a total daily dosage of CETP inhibitors) can range from about 0.01 to about 1000 mg/day, and preferably about 0.5 to about 20 mg/kg body weight/day in ?s single or divided doses.
In another alternative embodiment, the compositions or treatments of the present invention can further comprise probucol or derivatives thereof (such as AGI-1067 and other derivatives disclosed in U.S. Patents Nos. 6,121,319 and 6,147,250), which can reduce LDL levels, coadministered with or in combination with the 3o peroxisome proliferator-activated receptor activators) and sterol absorption inhibitors) discussed above.

WO 02/(H8732 PCT/US(12/(l2llll) Generally, a total daily dosage of probucol or derivatives thereof can range from about 10 to about 2000 mg/day, and preferably about 500 to about 1500 mg/day in single or 2-4 divided doses.
In another alternative embodiment, the compositions or treatments of the s present invention can further comprise low-density lipoprotein (LDL) receptor activators, coadministered with or in combination with the peroxisome proliferator-activated receptor activators) and sterol absorption inhibitors) discussed above.
Non-limiting examples of suitable LDL-receptor activators include HOE-402, an imidazolidinyl-pyrimidine derivative that directly stimulates LDL receptor activity. See to M. Huettinger et al., "Hypolipidemic activity of HOE-402 is Mediated by Stimulation of the LDL Receptor Pathway", Arterioscler. Thromb. 1993; 13:1005-12.
Generally, a total daily dosage of LDL receptor activators) can range from about 1 to about 1000 mg/day in single or 2-4 divided doses.
In another alternative embodiment, the compositions or treatments of the is present invention can further comprise fish oil, which contains Omega 3 fatty adds (3-PUFA), which can reduce VLDL and triglyceride levels, coadministered with or in combination with the peroxisome proliferator-activated receptor activators) and sterol absorption inhibitors) discussed above. Generally, a total daily dosage of fish oil or Omega 3 fatty acids can range from about 1 to about 30 grams per day in single or 2-20 4 divided doses.
In another alternative embodiment, the compositions or treatments of the present invention can further comprise natural water soluble fibers, such as psyllium, guar, oat and pectin, which can reduce cholesterol levels, coadministered with or in combination with the peroxisome proliferator-activated receptor activators) and sterol 25 absorption inhibitors) discussed above. Generally, a total daily dosage of natural water soluble fibers can range from about 0.1 to about 10 grams per day in single or 2-4 divided doses.
In another alternative embodiment, the compositions or treatments of the present invention can further comprise plant sterols, plant stanols and/or fatty acid 3o esters of plant stanols, such as sitostanol ester used in BENECOL~
margarine, which can reduce cholesterol levels, coadministered with or in combination with the peroxisome proliferator-activated receptor activators) and sterol absorption WO 02/0S8732 PCT/lJSll2/11211U) inhibitors) discussed above. Generally, a total daily dosage of plant sterols, plant stanois and/or fatty acid esters of plant stanols can range from about 0.5 to about 20 grams per day in single or 2-4 divided doses.
In another alternative embodiment, the compositions or treatments of the s present invention can further comprise antioxidants, such as probucol, tocopherol, ascorbic acid, ~-carotene and selenium, or vitamins such as vitamin B6 or vitamin B,2, coadministered with or in combination with the peroxisome proliferator-activated receptor activators} and sterol absorption inhibitors) discussed above.
Generally, a total daily dosage of antioxidants or vitamins can range from about 0.05 to about 10 io grams per day in single or 2-4 divided doses.
In another alternative embodiment, the compositions or treatments of the present invention can further comprise monocyte and macrophage inhibitors such as polyunsaturated fatty acids (PUFA), thyroid hormones including throxine analogues such as CGS-26214 (a thyroxine compound with a fluorinated ring), gene therapy and is use of recombinant proteins such as recombinant apo E, coadministered with or in combination with the peroxisome proiiferator-activated receptor activators) and sterol absorption inhibitors) discussed above. Generally, a total daily dosage of these agents can range from about 0.01 to about 1000 mg/day in single or 2-4 divided doses.
2o Also useful with the present invention are compositions or therapeutic combinations which further comprise hormone replacement agents and compositions.
Useful hormone agents and compositions for hormone replacement therapy of the present invention include androgens, estrogens, progestins, their pharmaceutically acceptable salts and derivatives thereof. Combinations of these agents and 2s compositions are also useful.
The dosage of androgen and estrogen combinations vary, desirably from about 1 mg to about 4 mg androgen and from about 1 mg to about 3 mg estrogen.
Examples include, but are not limited to, androgen and estrogen combinations such as the combination of esterified estrogens (sodium estrone sulfate and sodium equilin 3o sulfate) and methyltestosterone (17-hydroxy-17-methyl-, (17B)- androst-4-en-3-one) available from Solvay Pharmaceuticals, Inc., Marietta, GA, under the tradename Estratest.

WO 02/0S8732 PCT/US112/(12(I(19 Estrogens and estrogen combinations may vary in dosage from about 0.01 mg up to 8 mg, desirably from about 0.3 mg to about 3.0 mg. Examples of useful estrogens and estrogen combinations include:
(a) the blend of nine (9) synthetic estrogenic substances including sodium s estrone sulfate, sodium equilin sulfate, sodium 17 a -dihydroequilin sulfate, sodium 17 a -estradiol sulfate, sodium 17 ~i -dihydroequilin sulfate, sodium 17 a -dihydroequilenin sulfate, sodium 17 ~i -dihydroequilenin sulfate, sodium equilenin sulfate and sodium 17 ~i -estradiol sulfate; available from Duramed Pharmaceuticals, Inc., Cincinnati, OH, under the tradename Cenestin;
to (b) ethinyl estradiol (19-nor-17 a -pregna-1,3,5(10)-trien-20-yne-3,17-diol;
available by Schering Plough Corporation, Kenilworth, NJ, under the tradename Estinyl;
(c) esterified estrogen combinations such as sodium estrone sulfate and sodium equilin sulfate; available from Solvay under the tradename Estratab and from is Monarch Pharmaceuticals, Bristol, TN, under the tradename Menest;
(d) estropipate (piperaZine estra-1,3,5(10)-men-17-one, 3-(sulfooxy)-estrone sulfate); available from Pharmacia & Upjohn, Peapack, NJ, under the tradename Ogen and from Women First Health Care, Inc., San Diego, CA, under the tradename Ortho-Est; and 20 (e) conjugated estrogens (17 a-dihydroequilin, 17 a-estradiol, and 17 ~i-dihydroequilin); available from Wyeth-Ayerst Pharmaceuticals, Philadelphia, PA, under the tradename Premarin.
Progestins and estrogens may also be administered with a variety of dosages, generally from about 0.05 to about 2.0 mg progestin and about 0.001 mg to about 2 2s mg estrogen, desirably from about 0.1 mg to about 1 mg progestin and about 0.01 mg to about 0.5 mg estrogen. Examples of progestin and estrogen combinations that may vary in dosage and regimen include:
(a) the combination of estradioi (estra-1, 3, 5 (10)-triene-3, 17 (3-diol hemihydrate) and norethindrone (17 ~i-acetoxy-19-nor-17 a-pregn-4-en-20-yn-3-one);
3o which is available from Pharmacia 8 Upjohn, Peapack, NJ, under the tradename Activella;

WO 02/0,8732 PCT/US112/l)2lllNl (b) the combination of levonorgestrel (d(-)-13 (3-ethyl-17 o-ethinyl-17 (3-hydroxygon- 4-en-3-one) and ethinyl estradi.al; available from Wyeth-Ayerst under the tradename Alesse, from Watson Laboratories, Inc., Corona, CA, under the tradenames Levora and Trivora, Monarch Pharmaceuticals, under the tradename s Nordette, and from Wyeth-Ayerst under the tradename Triphasil;
(c) the combination of ethynodiol diacetate (19-nor-17 a-pregn-4-en-20-yne-3 ~3, 17-diol diacetate) and ethinyl estradiol; available from G.D. Searle &
Co., Chicago, IL, under the tradename Demulen and from Watson under the tradename Zovia;
~o (d) the combination of desogestrel (13-ethyl-11- methylene-18,19-dinor-17 a-pregn- 4-en- 20-yn-17-ol) and ethinyl estradiol; available from Organon under the tradenames Desogen and Mircette, and from Ortho-McNeil Pharmaceutical, Raritan, NJ, under the tradename Ortho-Cept;
(e) the combination of norethindrone and ethinyl estradiol; available from is Parke-Davis, Morris Plains, NJ, under the tradenames Estrostep and femhrt, from Watson under the tradenames Microgestin, Necon, and Tri-Norinyl, from Ortho-McNeil under the tradenames Modicon and Ortho-Novum, and from Warner Chilcott Laboratories, Rockaway, NJ, under the tradename Ovcon;
(f) the combination of norgestrel ( (~)-13-ethyl-17-hydroxy-18, 19-dinor-17 2o a-preg-4-en-20-yn-3-one) and ethinyl estradiol; available from Wyeth-Ayerst under the tradenames Ovral and Lo/Ovral, and from Watson under the tradenames Ogestrel and Low-Ogestrel;
(g) the combination of norethindrone, ethinyl estradiol, and mestranol (3-methoxy-19-nor-17 a-pregna-1,3,5(10)-trien-20-yn-17-ol); available from Watson 2s under the tradenames Brevicon and Norinyl;
(h) the combination of 17 ~i-estradiol (estra-1,3,5(10)-triene-3,17 (3-diol) and micronized norgestimate (17 a-17-(Acetyloxyl)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one3-oxime); available from Ortho-McNeil under the tradename Ortho-Prefest;
(i) the combination of norgestimate (18,19-dinor-17-pregn-4-en-20-yn-3-30 one, 17--(acetyloxy)-13-ethyl-,oxime, (17(o)-(+)-) and ethinyl estradiol;
available from Ortho-McNeil under the tradenames Ortho Cyclen and Ortho Tri-Cyclen; and WO 02/tIS8732 PCT/UStl2/t12t1119 (j) the combination of conjugated estrogens (sodium estrone sulfate and sodium equilin sulfate) and medroxyprogesterone acetate (20-dione, 17-(acetyloxy)-6-methyl-, (6(u))- pregn-4-ene-3); available from Wyeth-Ayerst under the tradenames Premphase and Prempro.
s In general, a dosage of progestins may vary from about .05 mg to about 10 mg or up to about 200 mg if microsized progesterone is administered. Examples of progestins include norethindrone; available from ESI Lederle, Inc., Philadelphia, PA, under the tradename Aygestin, from Ortho-McNeil under the tradename Micronor, and from Watson under the tradename Nor-QD; norgestrel; available from Wyeth-Ayerst to under the tradename Ovrette; micronized progesterone (pregn-4-ene-3, 20-dione);
available from Solvay under the tradename Prometrium; and medroxyprogesterone acetate; available from Pharmacia & Upjohn under the tradename Provera.
The compositions, therapeutic combinations or methods of the present invention can further comprise one or more obesity control medications. Useful is obesity control medications include, but are not limited to, drugs that reduce energy intake or suppress appetite, drugs that increase energy expenditure and nutrient-partitioning agents. Suitable obesity control medications include, but are not limited to, noradrenergic agents (such as diethylpropion, mazindol, phenylpropanolamine, phentermine, phendimetrazine, phendamine tartrate, methamphetamine, 2o phendimetrazine and tartrate); serotonergic agents (such as sibutramine, fenfluramine, dexfenfluramine, tluoxetine, fluvoxamine and paroxtine);
thermogenic agents (such as ephedrine, caffeine, theophylline, and selective (33-adrenergic agonists); alpha-blocking agents; kainite or AMPA receptor antagonists; leptin-lipolysis stimulated receptors; phosphodiesterase enzyme inhibitors; compounds having 2s nucleotide sequences of the mahogany gene; fibroblast growth factor-10 polypeptides;
monoamine oxidase inhibitors (such as befloxatone, moclobemide, brofaromine, phenoxathine, esuprone, befol, toloxatone, pirlindol, amiflamine, sercloremine, bazinaprine, lazabemide, milacemide and caroxazone); compounds for increasing lipid metabolism (such as evodiamine compounds); and lipase inhibitors (such as 30 orlistat). Generally, a total dosage of the above-described obesity control medications can range from 1 to 3,000 mglday, desirably from about 1 to 1,000 mg/day and more desirably from about 1 to 200 mglday in single or 2-4 divided doses.

WO U2/US8732 PCT/USl>2/U2UU9 The compositions, therapeutic combinations or methods of the present invention can further comprise one or more blood modifiers which are chemically different from the substituted azetidinone and substituted j3-lactam compounds (such as compounds I-XI above) and the PPAR receptor activators discussed above, for s example, they contain one or more different atoms, have a different arrangement of atoms or a different number of one or mare atoms than the sterol absorption inhibitors) or PPAR receptor activators discussed above. Useful blood modifiers include but are not limited to anti-coagulants (argatroban, bivalirudin, dalteparin sodium, desirudin, dicumarol, lyapolate sodium, nafamostat mesylate, ~o phenprocoumon, tinzaparin sodium, warfarin sodium); antithrombotic (anagrelide hydrochloride, bivalirudin, cilostazol, dalteparin sodium, danaparoid sodium, dazoxiben hydrochloride, efegatran sulfate, enoxaparin sodium, fluretofen, ifetroban, ifetroban sodium, lamifiban, lotrafiban hydrochloride, napsagatran, orbofiban acetate, roxifiban acetate, sibrafiban, tinzaparin sodium, trifenagrel, abciximab, zolimomab Is aritox); fibrinogen receptor antagonists (roxifiban acetate, fradafiban, orbofiban, lotrafiban hydrochloride, tirofrban, xemilofiban, monoclonal antibody 7E3, sibrafiban);
platelet inhibitors (cilostazol, clopidogrel bisulfate, epoprostenol, epoprostenol sodium, ticlopidine hydrochloride, aspirin, ibuprofen, naproxen, sulindae, idomethacin, mefenamate, droxicam, diclofenac, sulfinpyrazone, piroxicam, dipyridamole);
platelet 2o aggregation inhibitors (acadesine, beraprost, beraprost sodium, ciprostene calcium, itazigrel, lifarizine, lotrafiban hydrochloride, orbofiban acetate, oxagrelate, fradafiban, orbofiban, tirofiban, xemilofiban); hemorrheologic agents (pentoxifylline);
lipoprotein associated coagulation inhibitors; Factor Vlla inhibitors (4H-31-benzoxazin-4-ones, 4H-3,1-benzoxazin-4-thiones, quinazolin-4-ones, quinazolin-4-thiones, benzothiazin-4-25 ones, imidazolyl-boronic acid-derived peptide analogues TFPI-derived peptides, naphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)-benzyl]-2-oxo-pyrrolidin-3-(S)-yl} amide trifluoroacetate, dibenzofuran-2-sulfonic acid {1-[3-(aminomethyl)-benzyl]-5-oxo-pyrrolidin-3-yl}-amide, tolulene-4-sulfonic acid {1-[3-(aminoiminomethyl)-benzyl]-2-oxo-pyrrolidin-3-(S)-yl}-amide trifluoroacetate, 3,4-dihydro-1 H-isoquinoline-2-sulfonic 3o acid {1-[3-(aminoiminomethyl)-benzyl]-2-oxo-pyrrolin-3-(S)-yl}-amide trifluoroacetate);
Factor Xa inhibitors (disubstituted pyrazolines, disubstituted triazolines, substituted n-j(aminoiminomethyl)phenyl] propylamides, substituted n-j(aminomethyl)phenylJ

WO 02/0,8732 PCT/US(12/(120(19 propylamides, tissue factor pathway inhibitor (TFPI), low molecular weight heparins, heparinoids, benzimidazolines, benzoxazolinones, benzopiperazinones, indanones, dibasic (amidinoaryl) propanoic acid derivatives, amidinophenyl-pyrrolidines, amidinophenyl-pyrrolines, amidinophenyl-isoxazolidines, amidinoindoles, s amidinoazoles, bis-arlysulfonylaminobenzamide derivatives, peptidic Factor Xa inhibitors).
The compositions, therapeutic combinations or methods of the present invention can further comprise one or more cardiovascular agents which are chemically different from the substituted azetidinone and substituted ~-lactam io compounds (such as compounds I-XI above) and the PPAR receptor activators discussed above, for example, they contain one or more different atoms, have a different arrangement of atoms or a different number of one or more atoms than the sterol absorption inhibitors) or PPAR receptor activators discussed above.
Useful cardiovascular agents include but are not limited to calcium channel blockers Is (clentiazem maleate, amlodipine besylate, isradipine, nimodipine, felodipine, nilvadipine, nifedipine, teludipine hydrochloride, diltiazem hydrochloride, belfosdil, verapamil hydrochloride, fostedil); adrenergic blockers (fenspiride hydrochloride, labetalol hydrochloride, proroxan, alfuzosin hydrochloride, acebutolol, acebutolol hydrochloride, alprenolol hydrochloride, atenolol, bunolol hydrochloride, carteolol 2o hydrochloride, celiprolol hydrochloride, cetamolol hydrochloride, cicloprolol hydrochloride, dexpropranolol hydrochloride, diacetolol hydrochloride, dilevalol hydrochloride, esmolol hydrochloride, exaprolol hydrochloride, flestolol sulfate, labetalol hydrochloride, levobetaxolol hydrochloride, levobunolol hydrochloride, metalol hydrochloride, metoprolol, metoprolol tartrate, nadolol, pamatolol sulfate, 2s penbutolol sulfate, practolol, propranolol hydrochloride, sotalol hydrochloride, timolol, timolol maleate, tiprenolol hydrochloride, tolamolol, bisoprolol, bisoprolol fumarate, nebivolol); adrenergic stimulants; angiotensin converting enzyme (ACE) inhibitors (benazepril hydrochloride, benazeprilat, captopril, delapril hydrochloride, fosinopril sodium, libenzapril, moexipril hydrochloride, pentopril, perindopril, quinapril 3o hydrochloride, quinaprilat, ramipril, spirapril hydrochloride, spiraprilat, teprotide, enalapril maleate, lisinopril, zofenopril calcium, perindopril erbumine);
antihypertensive agents (althiazide, benzthiazide, captopril, carvedilol, chlorothiazide sodium, clonidine hydrochloride, cyclothiazide, delapril hydrochloride, dilevalol hydrochloride, doxazosin mesylate, fosinopril sodium, guanfacine hydrochloride, methyldopa, metoprolol succinate, moexipril hydrochloride, monatepil maleate, pelanserin hydrochloride, phenoxybenzamine hydrochloride, prazosin hydrochloride, primidolol, quinapril s hydrochloride, quinaprilat, ramipril, terazosin hydrochloride, candesartan, candesartan cilexetil, telmisartan, amlodipine besylate, amlodipine maleate, bevantolol hydrochloride); angiotensin II receptor antagonists (candesartan, irbesartan, losartan potassium, candesartan cilexetil, telmisartan); anti-angina) agents (amlodipine besylate, amlodipine maleate, betaxolol hydrochloride, bevantolol hydrochloride, io butoprozine hydrochloride, carvedilol, cinepazet maleate, metoprolol succinate, molsidomine, monatepi) maleate, primidolol, ranolazine hydrochoride, tosifen, verapamil hydrochloride); coronary vasodilators (fostedil, azaclorzine hydrochloride, chrornonar hydrochloride, clonitrate, diltiazem hydrochloride, dipyridamole, droprenilamine, erythrityl tetranitrate, isosorbide dinitrate, isosorbide mononitrate, is lidoflazine, mioflazine hydrochloride, mixidine, moisidomine, nicorandil, nifedipine, nisoldipine, nitroglycerine, oxprenolol hydrochloride, pentrinitrol, perhexiline maleate, prenylamine, propatyl nitrate, terodiline hydrochloride, tolamolol, verapamil); diuretics (the combination product of hydrochlorothiazide and spironolactone and the combination product of hydrochlorothiazide and triamterene).
2o The compositions, therapeutic combinations or methods of the present invention can further comprise one or more antidiabetic medications for reducing blood glucose levels in a human. Useful antidiabetic medications include, but are not limited to, drugs that reduce energy intake or suppress appetite, drugs that increase energy expenditure and nutrient-partitioning agents. Suitable antidiabetic medications ?s include, but are not limited to, sulfonylurea (such as acetohexamide, chlorpropamide, gliamilide, gliclazide, glimepiride, glipizide, glyburide, glibenclamide, tolazamide, and tolbutamide), meglitinide (such as repaglinide and nateglinide), biguanide (such as metformin and buformin), alpha-gfucosidase inhibitor (such as acarbose, miglitol, camiglibose, and voglibose), certain peptides (such as amlintide; pramlintide, exendin, 3o and GLP-1 agonistic peptides), and orally administrable insulin or insulin composition for intestinal delivery thereof. Generally, a total dosage of the above-described WO 02/(158732 PCT/US02/02(I(i9 antidiabetic medications can range from 0.1 to 1,000 mg/day in single or 2-4 divided doses.
Mixtures of any of the pharmacological or therapeutic agents described above can be used in the compositions and therapeutic combinations of the present s invention.
In another embodiment, the present invention provides a composition or therapeutic combination comprising (a) at least one AcyICoA:Cholesterol O-acyltransferase Inhibitor and (b) at least one substituted azetidinone compound or at least one substituted (3-lactam compound, or isomers of the at least one substituted io azetidinone compound or the at least one substituted (3-lactam compound, or pharmaceutically acceptable salts or solvates of the at least one substituted azetidinone compound or the at feast one substituted (3-lactam compound or of the isomers of the at least one substituted azetidinone compound or the at least one substituted ~3-lactam compound, or prodrugs of the at least one substituted t5 azetidinone compound or the at least one substituted ~3-lactam compound or of the isomers, salts or solvates of the at least one substituted azetidinone compound or at least one substituted (3-lactam compound.
In another embodiment, the present invention provides a composition or therapeutic combination comprising (a) probucol or a derivative thereof and (b) at 20 least one substituted azetidinone compound or at least one substituted ~-lactam compound, or isomers of the at least one substituted azetidinone compound or the at least one substituted ~i-lactam compound, or pharmaceutically acceptable salts or solvates of the at least one substituted azetidinone compound or the at least one substituted (3-lactam compound or of the isomers of the at least one substituted 2s azetidinone compound or the at least one substituted (3-lactam compound, or prodrugs of the at least one substituted azetidinone compound or the at least one substituted ~-lactam compound or of the isomers, salts or solvates of the at least one substituted azetidinone compound or the at least one substituted ~-lactam compound.
In another embodiment, the present invention provides a composition or 3o therapeutic combination comprising (a) at least one low-density lipoprotein receptor activator and (b) at least one substituted azetidinone compound or at least one WO 02/0a8732 PCT/US02/021109 y -79-substituted ~i-lactam compound, or isomers of the at least one substituted azetidinone compound or the at least one substituted ~i-lactam compound, or pharmaceutically acceptable salts or solvates of the at least one substituted azetidinone compound or the at least one substituted ~i-lactam compound or of the isomers of the at least one s substituted azetidinone compound or the at least one substituted (i-lactam compound, or prodrugs of the at least one substituted azetidinone compound or the at least one substituted (i-lactam compound or of the isomers, salts or solvates of the at least one substituted azetidinone compound or the at least one substituted ~-lactam compound.
In another embodiment, the present invention provides a composition or to therapeutic combination comprising (a) at least one Omega 3 fatty acid and (b) at least one substituted azetidinone compound or at least one substituted (3-lactam compound, or isomers of the at least one substituted azetidinone compound or the at least one substituted (i-lactarn compound, or pharmaceutically acceptable salts or solvates of the at least one substituted azetidinone compound or the at least one Is substituted (i-lactam compound or of the isomers of the at least one substituted azetidinone compound or the at least one substituted ~i-lactam compound, or prodrugs of the at least one substituted azetidinone compound or the at least one substituted (3-lactam compound or of the isomers, salts or solvates of the at least one substituted azetidinone compound or the at least one substituted ~3-lactam compound.
2o In another embodiment, the present invention provides a composition or therapeutic combination comprising (a) at least one natural water soluble fiber and (b) at least one substituted azetidinone compound or at least one substituted ~-lactam compound, or isomers of the at least one substituted azetidinone compound or the at least one substituted ~3-lactam compound, or pharmaceutically acceptable salts or zs solvates of the at least one substituted azetidinone compound or the at least one substituted ~-lactam compound or of the isomers of the at least one substituted azetidinone compound or the at least one substituted ~-lactam compound, or prodrugs of the at least one substituted azetidinone compound or the at least one substituted (i-lactam compound or of the isomers, salts or solvates of the at least one substituted 3o azetidinone compound or the at least one substituted ~-lactam compound.

WO 02/0S8732 PCT/US(12/(12(1(19 -$~-In another embodiment, the present invention provides a composition or therapeutic combination comprising (a) at least one of plant sterols, plant stanols or fatty acid esters of plant stanols and (b) at least one substituted azetidinone compound or at least one substituted p-lactam compound, or isomers of the at least s one substituted azetidinone compound or the at least one substituted ~-lactam compound, or pharmaceutically acceptable salts or solvates of the at least one substituted azetidinone compound or the at least one substituted ~-lactam compound or of the isomers of the at least one substituted azetidinone compound or the at least one substituted ~3-lactam compound, or prodrugs of the at least one substituted to azetidinone compound or the at least one substituted ~-lactam compound or of the isomers, salts or solvates of the at least one substituted azetidinone compound or the at least one substituted (i-lactam compound.
In another embodiment, the present invention provides a composition or therapeutic combination comprising (a) at least one antioxidant or vitamin and (b) at is least one substituted azetidinone compound or at least one substituted p-lactam compound, or isomers of the at least one substituted azetidinone compound or the at least one substituted ~-lactam compound, or pharmaceutically acceptable salts or solvates of the at least one substituted azetidinone compound or the at least one substituted ~-lactam compound or of the isomers of the at least one substituted 2o azetidinone compound or the at least one substituted (3-lactam compound, or prodrugs of the at least one substituted azetidinone compound or the at least one substituted ~-lactam compound or of the isomers, salts or solvates of the at least one substituted azetidinone compound or the at least one substituted ~-lactam compound.
Mixtures of any of the pharmacological or therapeutic agents described above 2s can be used in the compositions and therapeutic combinations of these other embodiments of the present invention.
The compositions and therapeutic combinations of the present invention can be administered to a mammal in need of such treatment in a therapeutically effective amount to treat one or more conditions, for example vascular conditions such as 3o atherosclerosis, hyperlipidaemia (including but not limited to hypercholesterolemia, hypertriglyceridaemia, sitosterolemia), vascular inflammation, stroke, diabetes, VVO (12/058732 PCT/U 502/11211119 obesity, and/or reduce the level of sterols) in the plasma. The compositions and treatments can be administered by any suitable means which produce contact of these compounds with the site of action in the body, for example in the plasma, liver or small intestine of a mammal or human.
s The daily dosage for the various compositions and therapeutic combinations described above can be administered to a patient in a single dose or in multiple subdoses, as desired. Subdoses can be administered 2 to 6 times per day, for example. Sustained release dosages can be used. Where the peroxisome proliferator-activated receptors) activator and sterol absorption inhibitors) are ~o administered in separate dosages, the number of doses of each component given per day may not necessarily be the same, e.g., one component may have a greater duration of activity and will therefore need to be administered less frequently.
The pharmaceutical treatment compositions and therapeutic combinations of the present invention can further comprise one or more pharmaceutically acceptable is carriers, one or more excipients and/or one or more additives. Non-limiting examples of pharmaceutically acceptable carriers include solids and/or liquids such as ethanol, glycerol, water and the like. The amount of carrier in the treatment composition can range from about 5 to about 99 weight percent of the total weight of the treatment composition or therapeutic combination. Non-limiting examples of suitable 2o pharmaceutically acceptable excipients and additives include non-toxic compatible fillers, binders such as starch, disintegrants, buffers, preservatives, anti-oxidants, lubricants, flavorings, thickeners, coloring agents, emulsifiers and the like.
The amount of excipient or additive can range from about 0.1 to about 90 weight percent of the total weight of the treatment composition or therapeutic combination. One skilled 2s in the art would understand that the amount of carrier(s), excipients and additives (if present) can vary.
The treatment compositions of the present invention can be administered in any conventional dosage form, preferably an oral dosage form such as a capsule, tablet, powder, cachet, suspension or solution. The formulations and pharmaceutical 3o compositions can be prepared using conventional pharmaceutically acceptable and conventional techniques. Several examples of preparation of dosage formulations are provided below.

WO 02/0,8732 PCT/US02/(12(I(19 The following formulations exemplify some of the dosage forms of this invention. In each formulation, the term "Active Compound I" designates a substituted azetidinone compound, ~-lactam compound or any of the compounds of Formulae I-XI
described herein above, or isomers of the at least one substituted azetidinone s compound or the at least one substituted ~3-lactam compound or any of the compounds of Formulae I-XI, or pharmaceutically acceptable salts or solvates of the at least one substituted azetidinone compound or the at least one substituted ~3-lactam compound or any of the compounds of Formulae I-XI or of the isomers of the at least one substituted azetidinone compound or the at least one substituted ~3-lactam io compound or any of the compounds of Formulae I-XI, or prodrugs of the at least one substituted azetidinone compound or the at least one substituted ~-lactam compound or any of the compounds of Formulae I-XI or of the isomers, salts or solvates of the at least one substituted azetidinone compound or the at least one substituted (3-lactam compound or any of the compounds of Formulae I-XI, and the term "Active Compound is II" designates a PPAR activator described herein above.
EXAMPLE
Tablets No.Ingredient m~ /tq ablet 1 Active Compound I 10 2 Lactose monohydrate NF 55 3 Microcrystalline cellulose 20 NF

4 Povidone (K29-32) USP 4 Croscarmellose sodium NF 8 6 Sodium lauryl sulfate 2 7 Magnesium stearate NF 1 Total 100 2o In the present invention, the above-described tablet can be coadministered with a tablet, capsule, etc. comprising a dosage of Active Compound II, for example a TRICOR~ capsule as described above.

Method of Manufacture Mix Item No. 4 with purified water in suitable mixer to form binder solution.
Spray the binder solution and then water over Items 1, 2, 6 and a portion of Item 5 in a fluidized bed processor to granulate the ingredients. Continue fluidization to dry the damp granules. Screen the dried granules and blend with Item No. 3 and the remainder of Item 5. Add Item No. 7 and mix. Compress the mixture to appropriate size and weight on a suitable tablet machine.
~o For coadministration in separate tablets or capsules, representative formulations comprising a cholesterol absorption inhibitor such as are discussed above are well known in the art and representative formulations comprising a peroxisome proliferator-activated receptor activator such as are discussed above are well known in the art. It is contemplated that where the two active ingredients are is administered as a single composition, the dosage forms disclosed above for substituted azetidinone or ~-lactam compounds may readily be modified using the knowledge of one skilled in the art.
Since the present invention relates to treating conditions as discussed above, such as reducing the plasma sterol (especially cholesterol) concentrations or levels by 2o treatment with a combination of active ingredients wherein the active ingredients may be administered separately, the invention also relates to combining separate pharmaceutical compositions in kit form. That is, a kit is contemplated wherein two separate units are combined: a pharmaceutical composition comprising at least one peroxisome proliferator-activated receptor activator and a separate pharmaceutical 2s composition comprising at least one sterol absorption inhibitor as described above.
The kit will preferably include directions for the administration of the separate components. The kit form is particularly advantageous when the separate components must be administered in different dosage forms (e.g., oral and parenteral) or are administered at different dosage intervals.
3o The treatment compositions and therapeutic combinations of the present invention can inhibit the intestinal absorption of cholesterol in mammals, as shown in the Example below, and can be useful in the treatment and/or prevention of V1~0 U2/t>s8732 PCT/~!S(12/llZln9 conditions, for example vascular conditions, such as atherosclerosis, hypercholesterolemia and sitosterolemia, stroke, obesity and lowering of plasma levels of cholesterol in mammals, in particular in mammals.
In another embodiment of the present invention, the compositions and s therapeutic combinations of the present invention can inhibit sterol absorption or reduce plasma concentration of at least one sterol selected from the group consisting of phytosterols (such as sitosterol, campesterol, stigmasterol and avenosterol), 5a-stanols (such as cholestanol, 5a-campestanol, 5a-sitostanol), cholesterol and mixtures thereof. The plasma concentration can be reduced by administering to a ~o mammal in need of such treatment an effective amount of at least one treatment composition or therapeutic combination comprising at least one PPAR activator and at least one sterol absorption inhibitor described above. The reduction in plasma concentration of sterols can range from about 1 to about 70 percent, and preferably about 10 to about 50 percent. Methods of measuring serum total blood cholesterol ~s and total LDL cholesterol are well known to those skilled in the art and for example include those disclosed in PCT WO 99/38498 at page 11.
Methods of determining levels of other sterols in serum are disclosed in H.
Gylling et al., "Serum Sterols During Stanol Ester Feeding in a Mildly Hypercholesterolemic Population", J. Lipid Res. 40: 593-600 (1999), Illustrating the invention are the following examples which, however, are not to be considered as limiting the invention to their details. Unless otherwise indicated, all parts and percentages in the following examples, as well as throughout the specification, are by weight.
EXAMPLES
PREPARATION OF COMPOUND OF FORMULA (II) Step 1 ): To a solution of (S)-4-phenyl-2-oxazolidinone (41 g, 0.25 mol) in 3o CH2C12 (200 ml), was added 4-dimethylaminopyridine (2.5 g, 0.02 mol) and triethylamine (84.7 ml, 0.61 mol) and the reaction mixture was cooled to OoC.
Methyl-4-(chloroformyl)butyrate (50 g, 0.3 mol) was added as a solution in CH2C12 (375 ml) WO 02/0S8732 PCT/US112/(1211119 dropwise over 1 h, and the reaction was allowed to warm to 22oC. After 17 h, water and H2S04 (2N, 100 ml), was added the layers were separated, and the organic layer was washed sequentially with NaOH (10%), NaCI (sat'd) and water. The organic layer was dried over MgS04 and concentrated to obtain a semicrystalline product.
s Step 2): To a solution of TiCl4 (18.2 ml, 0.165 mol) in CH2C12 (600 ml) at OoC, was added titanium isopropoxide (16.5 ml, 0.055 mol). After 15 min, the product of Step 1 (49.0 g, 0.17 mol) was added as a solution in CH2C12 (100 ml). After 5 min., diisopropylethylamine (DIPEA) (65.2 ml, 0.37 mol) was added and the reaction mixture was stirred at OoC for 1 h, the reaction mixture was cooled to -20oC, and 4-io benzyloxybenzylidine(4-fluoro)aniline (114.3 g, 0.37 mol) was added as a solid. The reaction mixture was stirred vigorously for 4 h at -20oC, then acetic acid was added as a solution in CH2C12 dropwise over 15 min, the reaction mixture was allowed to warm to OoC, and H2S04 (2N) was added. The reaction mixture was stirred an additional 1 h, the layers were separated, washed with water, separated and the organic layer was ~s dried. The crude product was crystallized from ethanol/water to obtain the pure intermediate.
Step 3): To a solution of the product of Step 2 (8.9 g, 14.9 mmol) in toluene (100 ml) at 50oC, was added N,O-bis(trimethylsilyl)acetamide (BSA) (7.50 ml, 30.3 mrnol). After 0.5 h, solid TBAF (0.39 g, 1.5 mmol) was added and the reaction mixture 2o stirred at 50oC for an additional 3 h. The reaction mixture was cooled to 22oC, CH30H (10 ml), was added. The reaction mixture was washed with HCI (1 N), NaHC03 (1 N) and NaCI (sat'd.), and the organic layer was dried over MgS04.
Step 4): To a solution of the product of Step 3 (0.94 g, 2.2 mmol) in CH30H (3 ml), was added water (1 ml) and LiOH-H20 (102 mg, 2.4 mmole). The reaction 2s mixture was stirred at 22oC for 1 h and then additional LiOH-H20 (54 mg, 1.3 mmole) was added. After a total of 2 h, HCI (1 N) and EtOAc was added, the layers were separated, the organic layer was dried and concentrated in vacuo. To a solution of the resultant product (0.91 g, 2.2 mmol) in CH2C12 at 22oC, was added CICOCOCI
(0.29 ml, 3.3 mmol) and the mixture stirred for 16 h. The solvent was removed in 3o vacuo.

WO 02/08732 PCT/US02/0211(19 Step 5): To an efficiently stirred suspension of 4-fluorophenylzinc chloride (4.4 mmol) prepared from 4-fluorophenylmagnesium bromide (1 M in THF, 4.4 ml, 4.4 mmol) and ZnCl2 (0.6 g, 4.4 mmol) at 4°C, was added tetrakis(triphenyl-phosphine)palladium (0.25 g, 0.21 mmol) followed by the product of Step 4 (0.94 g, s 2.2 mmol) as a solution in THF (2 ml). The reaction was stirred for 1 h at OoC and then for 0.5 h at 22oC. HCI (1 N, 5 ml) was added and the mixture was extracted with EtOAc. The organic layer was concentrated to an oil and purified by silica gel chromatography to obtain 1-(4-fluorophenyl)-4(S)-(4-hydroxyphenyl)-3(R)-(3-oxo-phenylpropyl)-2-azetidinone:
io HRMS calc'd for C24H1gF2N03 = 408.1429, found 408.1411.
Step 6): To the product of Step 5 (0.95 g, 1.91 mmol) in THF (3 ml), was added (R)-tetrahydro-1-methyl-3,3-Biphenyl-1 H,3H-pyrrolo-[1,2-c][1,3,2]
oxazaborole (120 mg, 0.43 mmol) and the mixture was cooled to -20oC. After 5 min, borohydride-dimethylsulfide complex (2M in THF, 0.85 ml, 1.7 mmol) was added dropwise over 0.5 ~s h. After a total of 1.5 h , CH30H was added followed by HCI (1 N) and the reaction mixture was extracted with EtOAc to obtain 1-(4-fluorophenyl)-3(R)-[3(S)-(4-fluorophenyl)-3-hydroxypropyl)]-4(S)-[4-(phenylmethoxy)phenyl]-2-azetidinone (compound 6A-1 ) as an oil. 1 H in CDC13 d H3 = 4.68. J = 2.3 Hz. CI (M+H) 500.
Use of (S)-tetra-hydro-1-methyl-3,3-Biphenyl-1H,3H-pyrrolo-[1,2-c][1,3,2]
20 oxazaborole gives the corresponding 3(R)-hydroxypropyl azetidinone (compound 6B-1 ). 1 H in CDCI3 d H3 = 4.69. J = 2.3 Hz. CI (M+H) 500.
To a solution of compound 6A-1 (0.4 g, 0.8 mmol) in ethanol (2 ml), was added 10% Pd/C (0.03 g) and the reaction mixture was stirred under a pressure (60 psi) of H2 gas for 16 h. The reaction mixture was filtered and the solvent was concentrated to 2s obtain compound 6A. Mp 164-166oC; CI (M+H) 410. [a]D = -28.1° (c 3, CH30H) Elemental analysis calc'd far C24H21 F2N03: C 70.41; H 5.17; N 3.42; found C
70.25; H 5.19; N 3.54.
Similarly treat compound 6B-1 to obtain compound 6B.
Mp 129.5-132.5oC; CI (M+H) 410. Elemental analysis calc'd for C24H21 F2N03:
3o C 70.41; H 5.17; N 3.42; found C 70.30; H 5.14; N 3.52.

Step 6' (Alternative): To a solution of the product of Step 5 (0.14 g, 0.3 mmol) in ethanol (2 ml), was added 10% Pd/C (0.03 g) and the reaction was stirred under a pressure (60 psi) of H2 gas for 16 h. The reaction mixture was filtered and the solvent was concentrated to afford a 1:1 mixture of compounds 6A and 6B.
s In Vivo Evaluation In a randomized, evaluator-blind, placebo-controlled, parallel-group study 32 healthy hypercholesterolemic humans (screening LDL-C > 130 mg/dL) stabilized and maintained on a NCEP Step I Diet were randomized to one of the following four treatments:
Treatment A - placebo given orally as 1 dose per day, Treatment B - 10 mg of Compound II given orally as 1 dose per day, Treatment C - 200 mg of LIPANTHYL~ micronized Fenofibrate (available from Labortoire Fournier of France) given orally as 1 dose per day, or is Treatment D - 200 mg of LIPANTHYL~ micronized Fenofibrate plus 10 mg of Compound II given orally as 1 dose per day every morning for 14 days.
Serum lipids were assessed predose (after a minimum of a 10-hour fast) on Day (Baseline), Day 7 and Day 14.
Results: The mean (S.E.) Day 14 percent (%) change from Baseline in serum lipids 2o (n=8) are shown in Table 1 below:
Table 1 Treatment LDL-C Total-C HDL-C TG
A -10.1 (4.9) -8.38 (4.0) -14.1 (2.2) 19.1 (13.9) B -22.3 (5.7) -19.6 (4.0) -13.3 (4.4) -4.57 (12.8) C -13.5 (3.1 ) -13.0 (2.4) -6.1 (3.6) 0.28 (11.4) D -36.3 (3.5) -27.8 (1.7) -1.97 (4.7) -32.4 (4.5) The coadministration of 10 mg of Compound II and 200 mg of Fenofibrate 2s (Treatment D) was well tolerated and caused a significant (p _< 0.03) reduction in LDL-C compared to either drug alone or placebo. In this inpatient study where the subjects' physical activity was restricted, in general HDL-C concentrations tended to WO 02/0,8732 PCT/US(12/(12(u19 _$$_ decrease and triglycerides tended to increase. The group receiving Treatment C
had the least decrease in HDL-C and the greatest decrease in triglyceride levels.
It will be appreciated by those skilled in the art that changes could be made to s the embodiments described above without departing from the broad inventive concept thereof. It is understood, therefore, that this invention is not limited to the particular embodiments disclosed, but it is intended to cover modifications which are within the spirit and scope of the invention, as defrned by the appended claims.

Claims (27)

1. A composition comprising (a) at least one AcylCoA:Cholesterol O-acyltransferase Inhibitor and (b) at least one substituted azetidinone compound or substituted (.beta.-lactam compound or a pharmaceutically acceptable salt or solvate of the at least one substituted azetidinone compound or the at least one substituted .beta.-lactam compound.
2. A therapeutic combination comprising (a) a first amount of at least one AcylCoA:Cholesterol O-acyltransferase Inhibitor; and (b) a second amount at least one substituted azetidinone compound or substituted .beta.-lactam compound or a pharmaceutically acceptable salt or solvate of the at least one substituted azetidinone compound or the at least one substituted .beta.-lactam compound, wherein the first amount and the second amount together comprise a therapeutically effective amount for the treatment or prevention of a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal.
3. A composition comprising (a) probucol or a derivative thereof and (b) at least one substituted azetidinone compound or substituted .beta.-lactam compound or a pharmaceutically acceptable salt or solvate of the at least one substituted azetidinone compound or the at least one substituted .beta.-lactam compound.
4. A therapeutic combination comprising (a) a first amount of probucol or a derivative thereof and (b) a second amount of at least one substituted azetidinone compound or substituted (.beta.-lactam compound or a pharmaceutically acceptable salt or solvate of the at least one substituted azetidinone compound or the at least one substituted .beta.-lactam compound, wherein the first amount and the second amount together comprise a therapeutically effective amount for the treatment or prevention of a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal.
5. A composition comprising (a) at least one low-density lipoprotein receptor activator and (b) at least one substituted azetidinone compound or substituted .beta.-lactam compound or a pharmaceutically acceptable salt or solvate of the at least one substituted azetidinone compound or the at least one substituted .beta.-lactam compound.
6. A therapeutic combination comprising (a) a first amount of at least one low-density lipoprotein receptor activator and (b) a second amount of at least one substituted azetidinone compound or substituted .beta.-lactam compound or a pharmaceutically acceptable salt or solvate of the at least one substituted azetidinone compound or the at least one substituted .beta.-lactam compound, wherein the first amount and the second amount together comprise a therapeutically effective amount for the treatment or prevention of a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal.
7. A composition comprising (a) at least one Omega 3 fatty acid and (b) at least one substituted azetidinone compound or substituted .beta.-lactam compound or a pharmaceutically acceptable salt or solvate of the at least one substituted azetidinone compound or the at least one substituted .beta.-lactam compound.
8. A therapeutic combination comprising (a) a first amount of at least one Omega 3 fatty acid and (b) a second amount of at least one substituted azetidinone compound or substituted .beta.-lactam compound or a pharmaceutically acceptable salt or solvate of the at least one substituted azetidinone compound or the at least one substituted .beta.-lactam compound, wherein the first amount and the second amount together comprise a therapeutically effective amount for the treatment or prevention of a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal.
9. A composition comprising (a) at least one natural water soluble fiber and (b) at least one substituted azetidinone compound or substituted .beta.-lactam compound or a pharmaceutically acceptable salt or solvate of the at least one substituted azetidinone compound or the at least one substituted .beta.-lactam compound.
10. A therapeutic combination comprising (a) a first amount of at least one natural water soluble fiber and (b) a second amount of at least one substituted azetidinone compound or substituted .beta.-lactam compound or a pharmaceutically acceptable salt or solvate of the at least one substituted azetidinone compound or the at least one substituted .beta.-lactam compound, wherein the first amount and the second amount together comprise a therapeutically effective amount for the treatment or prevention of a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal.
11. A composition comprising (a) at least one of plant sterols, plant stanols or fatty acid esters of plant stanols and (b) at least one substituted azetidinone compound or substituted .beta.-lactam compound or a pharmaceutically acceptable salt or solvate of the at least one substituted azetidinone compound or the at least one substituted .beta.-lactam compound.
12. A therapeutic combination comprising (a) a first amount of at least one of plant sterols, plant stanols or fatty acid esters of plant stanols and (b) a second amount of at least one substituted azetidinone compound or substituted .beta.-lactam compound or a pharmaceutically acceptable salt or solvate of the at least one substituted azetidinone compound or the at least one substituted .beta.-lactam compound, wherein the first amount and the second amount together comprise a therapeutically effective amount for the treatment or prevention of a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal.
13. A composition comprising (a) at least one antioxidant or vitamin and (b) at least one substituted azetidinone compound or substituted .beta.-lactam compound or a pharmaceutically acceptable salt or solvate of the at least one substituted azetidinone compound or the at least one substituted .beta.-lactam compound.
14. A therapeutic combination comprising (a) a first amount of at least one antioxidant or vitamin and (b) a second amount of at least one substituted azetidinone compound or substituted .beta.-lactam compound or a pharmaceutically acceptable salt or solvate of the at least one substituted azetidinone compound or the at least one substituted .beta.-lactam compound, wherein the first amount and the second amount together comprise a therapeutically effective amount for the treatment or prevention of a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal.
15. The composition or therapeutic combination according to any one of claims 1 to 14, further comprising a fabric acid derivative which is fenofibrate.
16. The composition or therapeutic combination according to any one of claims 1 to 14, further comprising a fabric acid derivative which is gemfibrozil.
17. The composition or therapeutic combination according to any one of claims 1 to 14, further comprising at least one peroxisome proliferator-activated receptor activator to provide an amount ranging from about 50 to about 3000 milligrams of peroxisome proliferator-activated receptor activator per day.
18. The composition or therapeutic combination according to any one of claims 1 to 14, further comprising at least one sterol absorption inhibitor to provide an amount ranging from about 0.1 to about 1000 milligrams of sterol absorption inhibitor per day.
19. The composition or therapeutic combination according to claim 18, further comprising at least one HMG CoA reductase inhibitor.
20. The composition according to claim 19, wherein the at least one HMG CoA reductase inhibitor is selected from the group consisting of lovastatin, pravastatin, fluvastatin, simvastatin, atorvastatin, rosuvastatin, cerivastatin and mixtures thereof.
21. The composition according to claim 20, wherein the at least one HMG CoA reductase inhibitor is simvastatin.
22. The composition according to claim 20, wherein the at least one HMG CoA reductase inhibitor is atorvastatin.
23. The composition according to claim 20, wherein the at least one HMG CoA reductase inhibitor is rosuvastatin.
24. The composition or therapeutic combination according to any one of claims 1 to 23, further comprising at least one lipid lowering agent selected from the group consisting of bile acid sequestrants, nicotinic acid or derivatives thereof, CETP inhibitors, IBAT inhibitors, AcylCoA:Cholesterol O-acyltransferase Inhibitors, probucol or derivatives thereof, low-density lipoprotein receptor activators, Omega 3 fatty acids, natural water soluble fibers, plant sterols, plant stanols and fatty acid esters of plant stanols.
25. The composition or therapeutic combination according to any one of claims 1 to 24, further comprising at least one additive selected from the group consisting of antioxidants, vitamins, hormone replacement therapy compositions, obesity control medications, blood modifiers, cardiovascular agents different from the compound of Formula II and antidiabetic medications.
26. A composition or therapeutic combination according to any one of claims 1 to 24, for use in the treatment or prevention of a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal.
27. Use of a composition or therapeutic combination according to any one of claims 1 to 24, in the manufacture of a medicament for treating or preventing a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal.
CA002563051A 2001-01-26 2002-01-25 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications Abandoned CA2563051A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26439601P 2001-01-26 2001-01-26
US60/264,396 2001-01-26
US32383901P 2001-09-21 2001-09-21
US60/323,839 2001-09-21
CA002434682A CA2434682C (en) 2001-01-26 2002-01-25 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002434682A Division CA2434682C (en) 2001-01-26 2002-01-25 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications

Publications (1)

Publication Number Publication Date
CA2563051A1 true CA2563051A1 (en) 2002-08-01

Family

ID=26950511

Family Applications (3)

Application Number Title Priority Date Filing Date
CA2562982A Expired - Fee Related CA2562982C (en) 2001-01-26 2002-01-25 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
CA002563051A Abandoned CA2563051A1 (en) 2001-01-26 2002-01-25 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
CA002434682A Expired - Lifetime CA2434682C (en) 2001-01-26 2002-01-25 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2562982A Expired - Fee Related CA2562982C (en) 2001-01-26 2002-01-25 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002434682A Expired - Lifetime CA2434682C (en) 2001-01-26 2002-01-25 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications

Country Status (33)

Country Link
US (5) US20020151536A1 (en)
EP (2) EP1413331B1 (en)
JP (4) JP4777602B2 (en)
KR (1) KR100596257B1 (en)
CN (1) CN100509058C (en)
AR (2) AR033855A1 (en)
AT (2) ATE348649T1 (en)
AU (1) AU2002247019C1 (en)
BR (1) BR0206654A (en)
CA (3) CA2562982C (en)
CL (1) CL2004001174A1 (en)
CY (2) CY1108000T1 (en)
CZ (2) CZ309209B6 (en)
DE (2) DE60216890T2 (en)
DK (2) DK1413331T3 (en)
EC (1) ECSP11004702A (en)
ES (2) ES2290562T3 (en)
HK (2) HK1063607A1 (en)
HU (2) HUP0303915A3 (en)
IL (3) IL156445A0 (en)
ME (1) MEP27808A (en)
MX (1) MXPA03006725A (en)
NO (1) NO331512B1 (en)
NZ (1) NZ525921A (en)
PL (1) PL208110B1 (en)
PT (2) PT1413331E (en)
RS (2) RS20100015A (en)
RU (1) RU2356550C2 (en)
SI (2) SI1413331T1 (en)
SK (2) SK288217B6 (en)
TW (1) TWI337083B (en)
WO (1) WO2002058732A2 (en)
ZA (1) ZA200305693B (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002240050A1 (en) * 2001-01-26 2002-08-06 Schering Corporation Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
CA2434033A1 (en) * 2001-01-26 2002-08-01 Schering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
PT1429756E (en) * 2001-09-21 2007-01-31 Schering Corp Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
CA2459926A1 (en) 2001-09-24 2003-04-03 Merck & Co., Inc. Screening and selection methods for statin drug combinations
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (en) 2002-07-26 2005-04-13 Schering Corp PHARMACEUTICAL FORMULATION INCLUDING AN INHIBITOR OF CHOLESTEROL ABSORPTION AND AN INHIBITOR OF A HMGCO TO REDUCTASE
AU2003270909A1 (en) * 2002-09-27 2004-04-19 Martek Biosciences Corporation Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
KR101077061B1 (en) * 2002-12-16 2011-10-26 깃세이 야쿠힌 고교 가부시키가이샤 Solid drug for oral use
WO2004069193A2 (en) * 2003-02-03 2004-08-19 Thomas Jefferson University Methods and compositions for inhibiting cholesterol uptake
ES2311806T3 (en) 2003-03-07 2009-02-16 Schering Corporation AZETIDINONA COMPOSITE SUBSTITUTED, FORNULATIONS AND USES OF THE SAME FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA.
US7208486B2 (en) 2003-03-07 2007-04-24 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2005015434A (en) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk Serum cholesterol-lowering agent or prophylactic or therapeutic agent for atherosclerosis
CA2544309A1 (en) * 2003-11-05 2005-05-26 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
EP1680099B1 (en) * 2003-11-07 2009-04-15 JJ Pharma, Inc. Hdl-boosting combination therapy complexes
EP1699759B1 (en) 2003-12-23 2010-10-20 AstraZeneca AB Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
WO2005069900A2 (en) * 2004-01-16 2005-08-04 Merck & Co., Inc. Npc1l1 (npc3) and methods of identifying ligands thereof
US20070116645A1 (en) * 2004-02-03 2007-05-24 Steven Farber Methods and compositions for inhibiting cholesterol uptake
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
WO2005118166A2 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
CN1759834B (en) * 2004-09-17 2010-06-23 中国医学科学院医药生物技术研究所 Application of berberine or associated with Simvastatin in preparing product for preventing or curing disease or symptom related to blood fat
US7524831B2 (en) * 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
UY29607A1 (en) 2005-06-20 2007-01-31 Astrazeneca Ab CHEMICAL COMPOUNDS
AR057072A1 (en) 2005-06-22 2007-11-14 Astrazeneca Ab CHEMICAL COMPOUNDS DERIVED FROM 2-AZETIDINONE, PHARMACEUTICAL FORMULATION AND A COMPOUND PREPARATION PROCESS
SA06270191B1 (en) 2005-06-22 2010-03-29 استرازينيكا ايه بي Novel 2-Azetidinone Derivatives as Cholesterol Absorption Inhibitors for the Treatment of Hyperlipidaemic Conditions
EP1741427A1 (en) * 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
AU2006270047A1 (en) * 2005-07-18 2007-01-25 Reliant Pharmaceuticals, Inc. Treatment with azetidinone-based cholesterol absorption inhibitors and omega-3 fatty acids and a combination product thereof
EP1986489A2 (en) 2006-02-24 2008-11-05 Schering Corporation Npc1l1 orthologues
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
US20070275052A1 (en) * 2006-05-24 2007-11-29 Glenmark Pharmaceuticals Limited Pharmaceutical compositions containing sterol inhibitors
US20070299017A1 (en) * 2006-06-23 2007-12-27 Kanter Mitchell M Compositions for lowering blood serum cholesterol and use in foods, beverages, and health supplements
US20080033019A1 (en) * 2006-08-07 2008-02-07 Duke University Cholesterol lowering drug combination
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
WO2008147807A2 (en) * 2007-05-23 2008-12-04 Amcol International Corporation Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal
UA103179C2 (en) 2007-12-10 2013-09-25 Ратиофарм Гмбх Pharmaceutical composition comprising ezetimibe
EP2168573A1 (en) 2008-09-30 2010-03-31 LEK Pharmaceuticals D.D. Formulations comprising ezetimibe
TWI522109B (en) * 2009-01-26 2016-02-21 臺北醫學大學 Use of pterosin compounds for treating diabetes and obesity
ATE536172T1 (en) 2009-03-13 2011-12-15 Sanovel Ilac Sanayi Ve Ticaret As EZETIMIBE COMPOSITIONS
US9388440B2 (en) 2009-04-01 2016-07-12 Mylan Laboratories Limited Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of Ezetimibe and further conversion to Ezetimibe
TR200904500A2 (en) 2009-06-10 2009-10-21 Öner Levent Methods and pharmaceutical formulations for the preparation of ezetimibe nanocrystals.
AU2013321918B2 (en) 2012-09-27 2018-05-10 Kowa Company, Ltd. Therapeutic agent for dyslipidemia
KR20150079373A (en) 2013-12-30 2015-07-08 한미약품 주식회사 Composite formulation for oral administration comprising ezetimibe and rosuvastatin
CN104337785A (en) * 2014-11-04 2015-02-11 万全万特制药江苏有限公司 Orally disintegrating tablet containing ezetimibe and preparation method of orally disintegrating tablet
CN105213340A (en) * 2015-10-29 2016-01-06 无锡福祈制药有限公司 A kind of Ezetimibe sheet and preparation method thereof
JP2017210455A (en) * 2016-05-27 2017-11-30 ニプロ株式会社 Ezetimibe-containing pharmaceutical composition
CN106310173A (en) * 2016-08-24 2017-01-11 厦门三川利生物科技有限公司 Multi-vitamin acidity alcohol containing peroxisome proliferator activated receptor and preparing method thereof
EP3437636A1 (en) 2017-08-02 2019-02-06 Adamed sp. z o.o. Pharmaceutical composition comprising ezetimibe
CN109718215A (en) * 2017-10-30 2019-05-07 海南皇隆制药股份有限公司 A kind of Ezetimibe piece
KR101983298B1 (en) * 2018-06-11 2019-05-29 연세대학교 산학협력단 Pharmaceutical coomposition for preventing or treating inflammasome mediated inflammatory disease

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809194A (en) * 1957-10-08 Thiadiazine type natriuretic agents
US3108097A (en) * 1963-10-22 Ehnojs
US1286A (en) * 1839-08-13 Richard else
BE578515A (en) * 1958-05-07
NL127065C (en) * 1964-04-22
NL137318C (en) * 1964-06-09
FI52570C (en) * 1969-04-16 1977-10-10 Sumitomo Chemical Co Process for producing the cholesterol or lipoid content of the blood using phenoxyaliphatic carboxylic acid compounds and ester compounds.
US3692895A (en) * 1970-09-08 1972-09-19 Norman A Nelson Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
DE2230383C3 (en) * 1971-10-01 1981-12-03 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarboxylic acid derivatives and processes for making the same
US4148923A (en) * 1972-05-31 1979-04-10 Synthelabo 1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity
US3948973A (en) * 1972-08-29 1976-04-06 Sterling Drug Inc. Halocyclopropyl substituted phenoxyalkanoic acids
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
US4235896A (en) * 1975-02-12 1980-11-25 Orchimed S.A. Benzyl-phenoxy acid esters and hyperlipaemia compositions containing the same
US4179515A (en) * 1975-02-12 1979-12-18 Orchimed S. A. Benzoylphenoxy propionic acid, esters thereof and pharmaceutical composition
JPS5195049A (en) * 1975-02-12 1976-08-20 * **********so*****no***tsu*****************************************ni*no
US4075000A (en) * 1975-05-27 1978-02-21 Eli Lilly And Company Herbicidal use of 4-amino-3,3-dimethyl-1-phenyl-2-azetidinones
US4576753A (en) * 1975-10-06 1986-03-18 Fujisawa Pharmaceutical Co., Ltd. Azetidinone compounds and processes for preparation thereof
US4472309A (en) * 1975-10-06 1984-09-18 Fujisawa Pharmaceutical Co., Ltd. 2-Azetidinone compounds and processes for preparation thereof
US4304718A (en) * 1975-10-06 1981-12-08 Fujisawa Pharmaceutical Co., Ltd. 2-Azetidinone compounds and processes for preparation thereof
US4166907A (en) * 1976-11-01 1979-09-04 E. R. Squibb & Sons, Inc. 3,3-Dichloro-2-azetidinone derivatives having antiinflammatory activity
US4144232A (en) * 1976-12-23 1979-03-13 Eli Lilly And Company Substituted azetidin-2-one antibiotics
FR2403078A1 (en) * 1977-09-19 1979-04-13 Lafon Labor NEW PROCESS FOR THE PREPARATION OF PHARMACEUTICAL, COSMETIC OR DIAGNOSIS FORMS
IT1157365B (en) * 1977-10-24 1987-02-11 Sandoz Ag MEDICATIONS TO TREAT OBESITY OR REDUCE BODY WEIGHT
US4250191A (en) * 1978-11-30 1981-02-10 Edwards K David Preventing renal failure
US4375475A (en) * 1979-08-17 1983-03-01 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
US4260743A (en) * 1979-12-31 1981-04-07 Gist-Brocades N.V. Preparation of β-lactams and intermediates therefor
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DE3107100A1 (en) * 1981-02-20 1982-09-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen AZAPROSTACYCLINE, METHOD FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE
US4500456A (en) * 1981-03-09 1985-02-19 Eli Lilly And Company Preparation of 4-fluoroazetidinones using FClO3
US4784734A (en) * 1981-04-10 1988-11-15 Otsuka Kagaku Yakuhin Kabushiki Kaisha Azetidinone derivatives and process for the preparation of the same
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4443372A (en) * 1982-06-23 1984-04-17 Chevron Research Company 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
US4534786A (en) * 1982-06-23 1985-08-13 Chevron Research Company 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
US4595532A (en) * 1983-02-02 1986-06-17 University Of Notre Dame Du Lac N-(substituted-methyl)-azetidin-2-ones
CA1256650A (en) * 1983-03-25 1989-06-27 Toshinari Tamura Process of producing 2-azetidinone-4-substituted compounds, and medicaments containing the compounds
EP0126709B1 (en) * 1983-03-28 1991-04-03 Ciba-Geigy Ag Process for the preparation of optically active azetidinones
US4675399A (en) * 1983-03-28 1987-06-23 Notre Dame University Cyclization process for β-lactams
WO1985004876A1 (en) * 1984-04-24 1985-11-07 Takeda Chemical Industries, Ltd. 2-azetidinone derivatives and process for their preparation
US4576749A (en) * 1983-10-03 1986-03-18 E. R. Squibb & Sons, Inc. 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5229381A (en) * 1983-12-01 1993-07-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5229510A (en) * 1983-12-01 1993-07-20 Merck & Co., Inc. β-lactams useful in determining the amount of elastase in a clinical sample
US4654362A (en) * 1983-12-05 1987-03-31 Janssen Pharmaceutica, N.V. Derivatives of 2,2'-iminobisethanol
FR2561916B1 (en) * 1984-03-30 1987-12-11 Lafon Labor GALENIC FORM FOR ORAL ADMINISTRATION AND METHOD FOR PREPARING IT BY LYOPHILIZATION OF AN OIL-TO-WATER EMISSION
US4581170A (en) * 1984-08-03 1986-04-08 E. R. Squibb & Sons, Inc. N-hydroxyl protecting groups and process and intermediates for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4633017A (en) * 1984-08-03 1986-12-30 E. R. Squibb & Sons, Inc. N-hydroxy protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4576748A (en) * 1984-09-17 1986-03-18 Merck & Co., Inc. 3-Hydroxy-3-aminoethyl β-lactams
US4620867A (en) * 1984-09-28 1986-11-04 Chevron Research Company 1-carbalkoxyalkyl-3-aryloxy-4-(substituted-2'-carboxyphenyl)-azet-2-ones as plant growth regulators and herbicides
AR240698A1 (en) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Process for the preparation of 5-(4-(2-(5-ethyl-2-pyridil)-ethoxy)benzyl)-2,4-thiazolodinedione and their salts
US4642903A (en) * 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
DE3787815T2 (en) * 1986-02-19 1994-03-24 Sanraku Inc Azetidinone derivatives.
GB8607312D0 (en) * 1986-03-25 1986-04-30 Ici Plc Therapeutic agents
FR2598146B1 (en) * 1986-04-30 1989-01-20 Rech Ind NEW PROCESS FOR THE PREPARATION OF FIBRATES.
DE3621861A1 (en) * 1986-06-30 1988-01-14 Laszlo Dr Med Ilg USE OF ARYLOXYCARBONIC ACID DERIVATIVES AGAINST DERMATOLOGICAL DISEASES
FR2602423B1 (en) * 1986-08-08 1989-05-05 Ethypharm Sa PROCESS FOR THE PREPARATION OF A FENOFIBRATE-BASED MEDICINAL PRODUCT, OBTAINED BY THIS PROCESS
US4814354A (en) * 1986-09-26 1989-03-21 Warner-Lambert Company Lipid regulating agents
US4803266A (en) * 1986-10-17 1989-02-07 Taisho Pharmaceutical Co., Ltd. 3-Oxoalkylidene-2-azetidinone derivatives
ZA879415B (en) 1986-12-15 1989-08-30 Lilly Co Eli Antibiotic a10255 complex and factors,microorganisms,process and production therefor
US5229362A (en) * 1986-12-15 1993-07-20 Eli Lilly And Company Antibiotic A10255 complex and factors, and process and production therefor
JPS63156788A (en) * 1986-12-22 1988-06-29 Sanraku Inc Optically active azetidinones
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
EP0288973B1 (en) * 1987-04-28 1993-01-13 Fujisawa Astra Ltd. Benzothiazolinone derivatives, their production and pharmaceutical composition
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US5091525A (en) * 1987-10-07 1992-02-25 Eli Lilly And Company Monohydrate and DMF solvates of a new carbacephem antibiotic
US4834846A (en) * 1987-12-07 1989-05-30 Merck & Co., Inc. Process for deblocking N-substituted β-lactams
US5385885A (en) * 1988-01-15 1995-01-31 Gasic; Gregory P. Inhibition of smooth muscle cell proliferation by antistasin and tick anticoagulant peptide
FR2627696B1 (en) * 1988-02-26 1991-09-13 Fournier Innovation Synergie NEW GALENIC FORM OF FENOFIBRATE
DE3807895A1 (en) * 1988-03-10 1989-09-21 Knoll Ag PRODUCTS CONTAINING A CALCIUM ANTAGONIST AND A LIPID DOWNER
GB8813012D0 (en) * 1988-06-02 1988-07-06 Norsk Hydro As Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals
FR2634376B1 (en) * 1988-07-21 1992-04-17 Farmalyoc NOVEL SOLID AND POROUS UNIT FORM COMPRISING MICROPARTICLES AND / OR NANOPARTICLES, AS WELL AS ITS PREPARATION
US4952689A (en) * 1988-10-20 1990-08-28 Taisho Pharmaceutical Co., Ltd. 3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation
CA1340977C (en) * 1988-11-15 2000-04-25 Monty Krieger Scavenger receptor protein and antibody thereto
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
US4876365A (en) * 1988-12-05 1989-10-24 Schering Corporation Intermediate compounds for preparing penems and carbapenems
US5260305A (en) 1988-12-12 1993-11-09 E. R. Squibb & Sons, Inc. Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
FR2640621B1 (en) * 1988-12-19 1992-10-30 Centre Nat Rech Scient N-ARYL-AZETIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ELASTASE INHIBITORS
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
CA2016467A1 (en) 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
JPH03108490A (en) * 1989-06-30 1991-05-08 Shionogi & Co Ltd Phospholipase a2 inhibitor
US5021461A (en) * 1989-07-26 1991-06-04 Merrell Dow Pharmaceuticals Inc. Method of treating diabetes mellitus with bisphenol derivatives
US4983597A (en) * 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5219574A (en) * 1989-09-15 1993-06-15 Cima Labs. Inc. Magnesium carbonate and oil tableting aid and flavoring additive
US5223264A (en) * 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US5120729A (en) * 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
US5120713A (en) * 1990-09-10 1992-06-09 Applied Research Systems Ars Holding N.V. Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
JP2640986B2 (en) * 1990-11-08 1997-08-13 高砂香料工業株式会社 Process for producing (1'R, 3S) -3- (1'-hydroxyethyl) -azetidin-2-one or a derivative thereof
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
AU642066B2 (en) 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
EP0596015B1 (en) 1991-07-23 1997-10-01 Schering Corporation Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
US5278176A (en) 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5503846A (en) * 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
US5412092A (en) * 1993-04-23 1995-05-02 Bristol-Myers Squibb Company N-substituted 2-azetidinones
AU681419B2 (en) * 1993-07-09 1997-08-28 Schering Corporation Process for the synthesis of azetidinones
ATE208615T1 (en) * 1993-07-09 2001-11-15 Scherer Corp R P METHOD FOR PRODUCING FREEZE-DRIED MEDICINAL DOSAGE FORMS
US5622719A (en) * 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5595761A (en) * 1994-01-27 1997-01-21 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving tablet
US5627176A (en) * 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
TW384224B (en) * 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
MX9606319A (en) * 1994-06-20 1997-05-31 Schering Corp Substituted azetidinone compounds useful as hypocholesterolemic agents.
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
FR2730231B1 (en) * 1995-02-02 1997-04-04 Fournier Sca Lab COMBINATION OF FENOFIBRATE AND VITAMIN E, USE IN THERAPEUTICS
US5639475A (en) * 1995-02-03 1997-06-17 Eurand America, Incorporated Effervescent microcapsules
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
JP3144624B2 (en) * 1995-06-02 2001-03-12 杏林製薬株式会社 N-benzyldioxothiazolidylbenzamide derivative and method for producing the same
US5612378A (en) * 1995-06-06 1997-03-18 3-Dimensional Pharmaceuticals, Inc. Bis-arylsulfonylaminobenzamide derivatives and the use thereof as factor Xa inhibitors
US5612353A (en) * 1995-06-07 1997-03-18 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
US5607697A (en) * 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
FR2738817B1 (en) * 1995-09-14 1997-10-17 Adir NOVEL SUBSTITUTED ALKANOIC 2,2-DIMETHYL-OMEGA-PHENOXY ACIDS AND ESTERS, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5618707A (en) * 1996-01-04 1997-04-08 Schering Corporation Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof
AU7472896A (en) * 1995-11-02 1997-05-22 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-({phenyl or 4-fluorophenyl})-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinon
GB9600464D0 (en) * 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
GB9606805D0 (en) * 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
CA2251972A1 (en) * 1996-04-17 1997-10-23 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US5858409A (en) * 1996-04-17 1999-01-12 Fmc Corporation Hydrolyzed cellulose granulations for pharmaceuticals
PE68898A1 (en) * 1996-05-24 1998-11-10 Schering Corp ANTI-FUNGAL COMPOSITIONS WITH IMPROVED BIOAVAILABILITY
US5739321A (en) * 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5886171A (en) * 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
EP0852117A4 (en) * 1996-06-12 1999-02-03 Kyowa Hakko Kogyo Kk Lipid metabolism ameliorants
US5883109A (en) * 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
FR2761266B1 (en) * 1997-03-28 1999-07-02 Sanofi Sa PHARMACEUTICAL COMPOSITION FORMED BY WET GRANULATION FOR THE ORAL ADMINISTRATION OF A DERIVATIVE OF N-PIPERIDINO-3- PYRAZOLECARBOXAMIDE, ITS SALTS AND THEIR SOLVATES
DE69829293T2 (en) * 1997-04-02 2006-04-13 The Brigham And Women's Hospital Inc., Boston USE OF A MEANS TO REDUCE THE RISK OF CARDIOVASCULAR DISEASES
ES2125198B1 (en) * 1997-05-13 1999-11-16 Vita Invest Sa FIXED-DOSE ASSOCIATION OF AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR AND AN ANTAGONIST OF THE CALCIUM CHANNELS, PROCEDURE FOR ITS PREPARATION AND USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES.
US5886191A (en) * 1997-08-18 1999-03-23 Dupont Pharmaceuticals Company Amidinoindoles, amidinoazoles, and analogs thereof
US5869098A (en) * 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
AR016827A1 (en) * 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL TABLET
US6180660B1 (en) * 1997-08-26 2001-01-30 Merck & Co., Inc. Cholesterol-lowering therapy
ES2216309T3 (en) * 1997-09-09 2004-10-16 Bristol-Myers Squibb Pharma Company BENCIMIDAZOLINONAS, BENZOXAZOLINONAS, BENZOPIPERAZINONAS, INDANONAS AND THEIR DERIVATIVES AS INHIBITORS OF THE XA FACTOR.
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
US6027747A (en) * 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
US6008237A (en) * 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives
US6180625B1 (en) * 1998-03-24 2001-01-30 Novo Nordisk A/S Heterocyclic compounds regulating clotting
EP1064270B1 (en) * 1998-03-27 2004-10-06 Bristol-Myers Squibb Pharma Company Disubstituted pyrazolines and triazolines as factor xa inhibitors
DE69828445D1 (en) * 1998-04-23 2005-02-03 Reddys Lab Ltd Dr HETEROCYCLIC COMPOUNDS, AND THEIR USE IN MEDICAMENTS, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF
US6207822B1 (en) * 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
EP1140187B1 (en) * 1998-12-23 2003-09-03 G.D. Searle LLC. Combinations of an ibat inhibitor and a mtp inhibitor for cardiovascular indications
US6180138B1 (en) * 1999-01-29 2001-01-30 Abbott Laboratories Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
US6033656A (en) * 1999-05-04 2000-03-07 Sumitomo Chemical Company, Limited Method of preventing or alleviating mammalian obesity
US6207699B1 (en) * 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
US6174665B1 (en) * 1999-09-10 2001-01-16 Biex, Inc. Hormone replacement therapy monitoring
DE60019741T2 (en) * 1999-12-08 2006-03-02 Pharmacia Corp., Chicago NANOPARTICLE COMPOSITIONS CONTAINING EPLERENONE
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
US20020132855A1 (en) * 2000-08-03 2002-09-19 Nelson Edward B. Use of acetaminophen to prevent and treat arteriosclerosis
DE10042447A1 (en) * 2000-08-29 2002-03-28 Aventis Pharma Gmbh Vertebrate intestinal protein that absorbs cholesterol and use of this protein to identify inhibitors of intestinal cholesterol transport
AU9287401A (en) * 2000-09-27 2002-04-08 Merck & Co Inc Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
NZ526594A (en) * 2000-12-21 2004-08-27 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
AU2002216097B2 (en) * 2000-12-21 2006-09-07 Sanofi-Aventis Deutschland Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
CA2434033A1 (en) * 2001-01-26 2002-08-01 Schering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
KR20080077033A (en) * 2001-01-26 2008-08-20 쉐링 코포레이션 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
US7091230B2 (en) * 2001-02-09 2006-08-15 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
WO2002072104A2 (en) * 2001-03-08 2002-09-19 Merck & Co., Inc. Antihypertensive agent and cholesterol absorption inhibitor combination therapy
WO2002081454A1 (en) * 2001-04-09 2002-10-17 Dr. Reddy's Laboratories Ltd. Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them
US7348334B2 (en) * 2001-04-09 2008-03-25 Dr. Reddy's Laboratories Limited Monocyclic derivatives of aryl alkanoic acids and their use in medicine: process for their preparation and pharmaceutical compositions containing them
AU2002308778A1 (en) * 2001-05-25 2002-12-09 Schering Corporation Use of azetidinone substituted derivatives in the treatment of alzheimer's disease

Also Published As

Publication number Publication date
HUP0303915A3 (en) 2012-12-28
HK1063607A1 (en) 2005-01-07
JP2004521893A (en) 2004-07-22
ZA200305693B (en) 2005-04-26
HUP0303915A2 (en) 2004-03-01
RU2003126184A (en) 2005-03-10
CY1108000T1 (en) 2013-09-04
RS20100015A (en) 2010-12-31
EP1413331B1 (en) 2007-10-03
AU2002247019B2 (en) 2006-08-03
PL368653A1 (en) 2005-04-04
MXPA03006725A (en) 2003-10-24
ECSP11004702A (en) 2011-03-31
US20060199793A1 (en) 2006-09-07
WO2002058732A2 (en) 2002-08-01
US20050153952A1 (en) 2005-07-14
EP1353696B1 (en) 2006-12-20
SK9482003A3 (en) 2003-12-02
CZ20032030A3 (en) 2004-01-14
NO331512B1 (en) 2012-01-16
RU2008144912A (en) 2010-05-20
IL156445A (en) 2010-11-30
JP2008088184A (en) 2008-04-17
US20020151536A1 (en) 2002-10-17
AR064012A2 (en) 2009-03-04
DE60222773T2 (en) 2008-07-17
ES2274013T3 (en) 2007-05-16
ATE348649T1 (en) 2007-01-15
NZ525921A (en) 2005-06-24
CN100509058C (en) 2009-07-08
PT1413331E (en) 2007-12-18
CA2434682C (en) 2008-11-18
KR20040025887A (en) 2004-03-26
HK1056696A1 (en) 2004-02-27
JP4777602B2 (en) 2011-09-21
SK288217B6 (en) 2014-08-05
HU230253B1 (en) 2015-11-30
RS51449B (en) 2011-04-30
AR033855A1 (en) 2004-01-07
US20020192203A1 (en) 2002-12-19
CZ309209B6 (en) 2022-05-25
DE60222773D1 (en) 2007-11-15
DK1353696T3 (en) 2007-04-10
EP1413331A2 (en) 2004-04-28
JP2007211031A (en) 2007-08-23
SI1413331T1 (en) 2008-02-29
JP4937836B2 (en) 2012-05-23
CZ2010307A3 (en) 2004-01-14
WO2002058732B1 (en) 2003-09-12
RU2356550C2 (en) 2009-05-27
CL2004001174A1 (en) 2005-05-06
IL156445A0 (en) 2004-01-04
SK287988B6 (en) 2012-09-03
CA2562982A1 (en) 2002-08-01
CZ301871B6 (en) 2010-07-14
CA2434682A1 (en) 2002-08-01
NO20033355D0 (en) 2003-07-25
WO2002058732A3 (en) 2003-07-03
EP1353696A2 (en) 2003-10-22
YU58603A (en) 2006-05-25
ES2290562T3 (en) 2008-02-16
JP2012087149A (en) 2012-05-10
US20080058306A1 (en) 2008-03-06
US7612058B2 (en) 2009-11-03
DE60216890T2 (en) 2007-08-30
DK1413331T3 (en) 2007-12-10
AU2002247019C1 (en) 2017-05-11
CA2562982C (en) 2011-03-15
CN1646165A (en) 2005-07-27
IL191417A (en) 2011-12-29
PL208110B1 (en) 2011-03-31
NO20033355L (en) 2003-07-25
BR0206654A (en) 2004-02-25
EP1413331A3 (en) 2004-06-30
TWI337083B (en) 2011-02-11
CY1107045T1 (en) 2012-09-26
PT1353696E (en) 2007-02-28
ATE374641T1 (en) 2007-10-15
DE60216890D1 (en) 2007-02-01
KR100596257B1 (en) 2006-07-03
US7030106B2 (en) 2006-04-18
SI1353696T1 (en) 2007-04-30
MEP27808A (en) 2010-10-10

Similar Documents

Publication Publication Date Title
CA2562982C (en) Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
AU2002247019B9 (en) Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US20080261942A1 (en) Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
AU2002247019A1 (en) Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
CA2434430A1 (en) The use of substituted azetidinone compounds for the treatment of sitosterolemia
CA2460340C (en) Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
CA2460344A1 (en) Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
US20030119796A1 (en) Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
AU2002335770A1 (en) Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
US20020183305A1 (en) Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
AU2008201609B2 (en) Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitors(s) and treatments for vascular indications
AU2006202618B2 (en) Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
AU2007201970B2 (en) Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
EP1911462A2 (en) Compositions comprising a sterol absorption inhibitor
NZ539190A (en) Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
EP1864680A2 (en) Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued